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CHAPTER 1 
GENERAL INTRODUCTION AND OBJECTIVES OF THE 
THESIS 
1 GENERAL INTRODUCTION 
1.1 Current management of arthritic diseases 
Arthritic diseases are considered as one of the leading causes for progressive and 
irreversible joint degeneration resulting in reduced quality of life and/or disability [1]. 
Osteoarthrits (OA) and rheumatoid arthritis (RA) are the most common forms, affecting 
predominantly weight bearing joints such as knees, hips and ankles [1, 2]. The main 
symptoms are joint inflammation, pain and cartilage destruction. Due to a high prevalence in 
the elderly population, the number of affected patients in the US is expected to reach 
60 millions by the year 2020, thus presenting an enormous social and economical burden [3]. 
As no curative therapy has been developed so far, the medical disease management is 
focused on the reduction of pain and inflammation in order to maintain mobility and prevent 
joint degeneration [4, 5]. According to the guidelines of the American College of 
Rheumatology and Osteoarthritis Research Society International, the current treatment of OA 
includes the systemic and intra-articular (IA) application of non-biologic drugs such as 
corticosteroids, analgetic and anti-inflammatory agents. The treatment of RA includes 
additional systemic administration of disease-modifying anti-rheumatic drugs (DMARDs), 
such as methotrexate, sulfasalazine, cyclosporine, hydroxychloroquine, penicillamine or 
azathioprine, and biologic agents like interleukine-1 receptor antagonists or TNF-α 
antagonists [5-7]. The long-term systemic application of these therapeutics frequently results 
in substantial side-effects [8]. Moreover, oftentimes high doses are required to achieve 
adequate therapeutic drug levels in the affected joint which makes therapies with e.g. 
biologic agents highly expensive [9]. The local direct targeting of the affected site by IA 
application of the drug presents an attractive approach from both the economic and the 
patient´s perspective. It offers the possibility to achieve high drug concentrations at the site of 
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application with limited systemic exposure leading to overall dose reduction and therefore 
minimization of side-effects and costs. Furthermore, drugs with low bioavailability can be 
administered [10]. However, the IA route of application is accompanied by pain for the patient 
and bears the risk of joint infections and cartilage damage. Therefore, the IA injection 
frequency should be limited (see section 1.3) [11]. 
1.2 Anatomy and physiology of the joint 
Joints can be classified into amphiathroses, synarthroses and diarthroses (synovial joints). 
Synovial joints, most often affected by OA and RA, are enclosed by a fibrous capsule and 
ligaments providing joint stability and mobility. The surfaces of the bone endings are covered 
by hyaline cartilage contributing to an almost frictionless mobility of the joint. The cartilage is 
an avascular tissue, composed of chondrocytes embedded in a matrix of collagen, 
proteoglycans and water [12]. It is supplied with nutritiens by the synovial fluid (SF), a 
viscous liquid with similar composition to plasma. In comparison to plasma, SF comprises 
additional amounts of hyaluronic acid and lubricin, both providing lubricating functions [13]. 
Moreover, lower total protein concentrations, e.g. albumin, are found in SF [13, 14]. In normal 
joints, the SF volume is approximately 0.5-2 mL whereas in RA affected joints, it can be 
increased up to 100 mL [13, 15]. The inner layer of the joint capsule is lined by the 
vascularized synovial membrane (synovium) consisting of type A and B synoviocytes and 
capillaries. Type A synoviocytes have macrophage-like properties whereas type B cells 
secrete hyaluronic acid and lubricin [15]. Both the synovial membrane and the capillary 
endothelium are highly fenestrated. Due to the little diffusion barrier provided by the synovial 
membrane, a high synovial turnover is observed with a complete SF replacement within 2 hrs 
[13]. Small molecules with a molecular weight (MW) below 10 kDa are in equilibrium between 
SF and plasma as diffusion through the intercellular gaps of the synovial membrane and 
across the capillary walls is enabled. The synovial entrance of higher MW molecules, such 
as proteins, is limited by the endothelial fenestration and presents therefore a size dependent 
process. In comparison, clearance of higher MW species is reported to occur via lymph 
drainage in the subsynovial tissue [15]. Rodnan et al. investigated the clearance of IA 
injected molecules of different size and albumin (67 kDa) and γ-globulin (150 kDa) left the 
joint space within the same time of 72 hrs [16]. These data indicate that the synovial 
clearance presents a size-independent mechanism for molecules within the size range of 
plasma molecules. Instead of diffusion, clearance via passive bulk flow of the lymphatic 
drainage presents the predominant mechanism [17]. Upon joint inflammation, permeability of 
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the capillary walls is enhanced leading to an increase of volume and protein concentration in 
SF, but also to an accelerated synovial clearance rate.  
1.3 The intra-articular route of application 
The IA route of application offers the possibility to target the localized affected tissue of the 
joint while circumventing high systemic drug exposure that it is typically observed upon 
systemic dosing. The IA adminstration is characterized by direct injection of the drug into the 
joint cavity. Due to the risk of serious infections and cartilage damage induced by incorrect 
needle placement, sterile conditions and application from experienced physicians are of 
utmost importance [18]. The number of injections per joint and year should be limited to 3-4 
[11]. According to clinical studies, a post-injection rest of 24 hrs is recommended in order to 
increase the residence time of the drug at the site of application [11]. Aspiration of SF prior to 
administration of the drug is suggested as it reduces dilution of the injected drug and 
oftentimes relieves pain [11, 18]. Because of the rapid clearance from the synovial space, the 
IA delivery of therapeutic drugs presents a challenging approach with respect to the 
maintenance of therapeutic concentrations for prolonged periods of time. For paracetamol 
and diclofenac mean terminal half-lives of 1.1 and 5.2 hrs were reported respectively [19]. IA 
application of anakinra, a recombinant interleukine-1 receptor antagonist, in patients 
suffering of OA, revealed a slight improvement of the symptoms until day 4 in comparison to 
placebo. Afterwards, no significant difference was detectable suggesting that IA injection 
does no lead to depot formation in the joint [20]. These examples emphasize the need for 
injectable depot systems that facilitate prolonged therapeutic action at the site of application.  
1.4 Requirements on formulations for intra-articular administration 
The IA route of application presents a special form of the parenteral way of administration. 
Therefore, the pH of the formulation should be isohydric or exhibit a pH close to 7.4. 
Isotonicity is desirable to provide high physiological compatibility. In order to avoid joint 
infection and further inflammation, sterility is of major importance [13]. Therefore, the use of 
pre-filled syringes is advantageous since critical preparation steps, such as formulation 
transfer from vial into syringe, entails the risk of contamination [11, 13]. In order to allow a 
rapid and easy application through thin syringe needles, an adequate formulation viscosity 
needs to be provided. It is known from literature that the maximal injection force should not 
exceed 25 N [21]. The syringe needle size is reported to differ depending on the affected 
4 CHAPTER 1 
 
joint and the patient´s constitution. Commonly recommended needle sizes for knee or 
shoulder treatment are in the range of 18 G to 25 G. Smaller joints, e.g. interphalangeal 
joints, require smaller needle sizes in the range of 25-30 G [22]. Compatibility of the 
formulation components with both the injection site and the incorporated drug has to be 
assured as activation of unwanted immune responses may amplify the inflammatory 
conditions [13]. After injection, the formulation should allow preservation of the entire joint 
mobility. Therefore, a semi-solid consistency is beneficial in order to avoid joint blockage or 
cartilage friction. On account of the limited injection frequency, the restricted injection volume 
and the rapid clearance of injected drugs, a high drug load and a prolonged residence time at 
the injection site present central formulation aspects. 
1.5 Intra-articular drug delivery systems 
Several attempts were made with respect to prolongation of the drug residence time at the 
site of application. On the German market, mainly glucocorticoid products can be found that 
are formulated as (crystal-) suspensions (table 1-1). As they show poor aqueous solubility 
continuous dissolution occurs upon IA administration, leading to prolonged drug 
concentrations over several days [13, 23]. Also an emulsion formulation, containing 
dexamethasone-21-palmitate, has received approval for IA administration. This formulation 
provides a mean residence time in the joint of 8 days [24]. Besides the drug containing 
formulations, several hyaluronic acid formulations can be found on the market. The use of 
hyaluronic acid gels for the treatment of arthritic diseases can be attributed to its 
viscosupplemementative effect, as the lubricating properties of SF are typically reduced in 
arthritic joints [25]. Moreover, anti-inflammatory properties of HA are discussed in literature 
[26].  
Besides the formulations available on the market, intensive research has been focused on 
the development of other drug delivery systems for sustained drug release. Most of the drug 
delivery systems in literature are based on microparticles or microspheres. The use of semi-
solid formulations is also reported. The group of Liang analyzed the pharmacokinetic profile 
of 30-100 µm polylactide microparticles containing methotrexate after IA administration in 
healthy rabbits. In comparison to the free drug, significantly higher methotrexate levels were 
found in the SF 6 hrs after injection and in the synovial tissue after 24 hrs [27]. Thakkar et al. 
investigated the effect of chitosan microparticles containing celecoxib in arthritic rats over an 
observation period of 18 days. A continuous anti-inflammatory effect was demonstrated. In 
comparison, after IA administration of the free drug, an initial reduction of the joint 
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inflammation was observed that increased again until the end of the study [28]. Mierisch et 
al. proposed calcium alginate beads as carrier system for the IA delivery of transforming 
growth factor-β (TGF-β). In vitro experiments revealed a slow release rate of 0.25 % per 
hour. The results were underlined by in vivo experiments in rabbits where an improved effect 
on osteochondral defects was demonstrated [29]. The studies mentioned above emphasize 
the potential of drug-loaded microparticles to prolong the therapeutic effect after IA 
administration. In patent literature, the use of HA based injectable microparticles for the 
sustained release of proteins or peptides is described. Even though the IA application is not 
described by the authors, the IA use of this drug delivery system would present an interesting 
approach due to the physiological presence of HA in the SF [30, 31].  
Table 1-1 IA formulations on the German market, derived from [13] and [32]. 
Active pharmaceutical ingredient Exemplary product name Formulation 
Betamethasone hydrogenphosphate disodium/ 
Betamethasone acetate 
Celestan Depot®  
 
 
 
Solution 
Dexamethasone hydrogenphosphate disodium Dexabene®,  
Fortecortin® Inject 
Gadopentic acid  Magnevist® 
Gadoteric acid  Artirem® 
Hyaluronic acid Curavisc® 
Hyaluronic acid, cross-linked Synvisc® 
Hyaluronate sodium   Viscoseal® 
Prednisolone acetate Prednigalen® 
Betamethasone hydrogenphosphate disodium / 
Betamethasone dipropionate 
Diprosone® Depot  
 
 
Suspension 
Dexamethasone acetate / lidocaine-HCl Supertendin® 
Prednisolone acetate Predni H injekt® 
Triamcinolone acetonide Volon A® 
Triamcinolone-16, 21-diacetate  Delphicort® 
Triamcinolone hexacetonide Lederlon® 
Dexamethasone-21-palmitate Lipotalon® Emulsion 
Besides the use of polymer-based formulations, numerous studies can be found dealing with 
the liposomal drug encapsulation. The concept of IA administration of drug-loaded liposomes 
for the treatment of inflammatory joint diseases was first described by Shaw et al. in 1976 
[33]. Dingle et al. reported a significant reduction of joint inflammation, temperature and 
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diameter in arthritic rabbits during an observation period of 6 days after IA injection of cortisol 
containing liposomes. Upon administration of the free drug an anti-inflammatory response 
was only detectable at higher concentrations during the first 24 hrs [34]. Comparable studies 
can be found on the IA administration of liposomally encapsulated drugs, such as 
dexamethasone palmitate [35], methotrexate [36], lidocaine [37], lactoferrin [38], iohexol [39], 
triamcinolone acetonide [40] or the radionuclide [99mTc]pertechnetate [41]. The successful IA 
injection of liposomal Verteporfin® for the photodynamic therapy of RA as an alternative to 
surgical or radiation synvectomy was demonstrated by Chowdhary et al. in arthritic rabbits. 
High accumulation of the liposomes in the synovial tissue without recovery in plasma was 
observed 3 hrs after IA injection. Upon intravenous (IV) application, liposomes were 
recovered both in the synovial tissue and in plasma [42]. Tanaka et al. presented an 
interesting approach to extend IA drug residence time using magnetic liposomes containing 
TGF-β. Prior to injection of the liposomal formulation, magnetic implants were inserted into 
the articular cartilage of rabbits. Upon administration of the TGF-β liposomes containing 
Fe3O4 as magnetic agent, cartilage defects were continuously reduced within the observation 
period of 12 weeks. This effect was attributed to the magnetic induced accumulation of the 
liposomes at the target site [43]. Instead of magnet implantation, Butoescu et al. reported 
about the use of a local external magnetic field leading to IA retention of dexamethasone 
acetate-loaded PLGA microparticles that contain superparamagnetic iron oxide nanoparticles 
(SPIONs) [44].  
1.6 Drug delivery systems for therapeutic proteins 
Despite the numerous promising studies found in literature, IA delivery approaches for 
therapeutic proteins are rare at present. Concomitantly with the tremendous advances in 
biotechnology, which have revolutionized the therapies of chronic and life-threatening 
diseases, the demand for the development of injectable protein delivery systems has 
increased in recent years [45] due to the oftentimes short drug plasma half-lives and thus 
high injection frequencies [46]. Numerous research groups have been focused on this topic, 
however, no sustained release formulation for a therapeutic protein can be found on the 
market which emphasizes the challenge of this approach [47]. Delivery strategies for proteins 
have been extensively reviewed in literature [9, 48-52]. The protein stability within the 
delivery system and upon release presents an important aspect as the native three-
dimensional macromolecular structure strongly correlates with biological activity [53] and 
protein denaturation is known to provoke immunological repsonses in the body [54].  
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In literature, microparticles, solid or in situ forming implants, liposomes or hydrogels are 
mainly reported as potential carrier systems for the sustained release of proteins. These 
systems primarily consist of synthetic or natural polymers or lipids. The most frequently used 
synthetic polymers in this context are polylactide (PLA) and poly(lactide-co-glycolide) 
(PLGA), formulated as microparticles or in situ forming implants [55-58]. The extensive use 
can be attributed to the high biocompatibility and safety which led to approval by the Food 
and Drug Administration [59]. But also natural polymers such as gelatin [60], chitosan [61], 
alginate [62] or hyaluronic acid [30], formulated as microparticles or hydrogels, were 
demonstrated to present suitable carrier materials. Microparticle systems suffer from the 
major disadvantage that only low amounts of drug can be loaded [48]. Moreover, in case of 
PLGA-based microparticles, harsh preparation conditions are required. The formation of 
organic/water interfaces is reported to bear the risk of protein unfolding and thus presents a 
major drawback for the incorporation of susceptible proteins [48, 63]. In contrast, the in situ 
depot formation based on e.g. PLGA is an attractive alternative. Although protein instability 
related to PLA and PLGA degradation has been discussed [64, 65], promising release 
studies can be found in literature [57, 58]. Hydrogels reveal a highly protein-compatible 
environment due to the hydrophilic character of the matrix. The drug release velocity can be 
tailored by variation of the concentration and MW of the polymer. Chemical or physical cross-
linkage of hydrogels is a frequently applied method to decelerate drug release due to the 
formation of a dense hydrogel network [49, 66]. However, cross-linkage of hydrogels might 
compromise protein stability [66]. Apart from the above mentioned formulation approaches, 
lipid derived protein delivery systems have been in the focus of several research groups [67-
69]. Besides the development of solid lipid implants [70] or solid lipid particles [71], drug 
encapsulation into lipid vesicles was demonstrated to provide protein release over prolonged 
periods of time [68, 69] and high protein stability [68, 72].  
As the IA route of application presents a special form of the parenteral route of 
administration, the current knowledge concerning the controlled parenteral release strategies 
for therapeutic proteins can be adopted and form the basis of the present project. However, 
the prevailing physiologic conditions in the joint, such as clearance mechanism and velocity, 
pH and composition of SF have to be taken into consideration. Moreover, formulation 
aspects, like injectable volume, release window, type and viscosity of the formulation are 
important parameters that have to be included.  
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2 OBJECTIVES OF THE THESIS 
The aim of the present project was the development of sustained release formulations for the 
IA application of a therapeutic monoclonal antibody (mAb). Within this scope, four 
formulations were to be developed which should provide different release profiles and depot 
forming mechanisms. On account of the characteristics of the IA route of application and the 
physiological conditions in the joint, the formulations to be developed were intended to fulfill a 
variety of requirements. In order to avoid critical preparation steps that might introduce the 
risk of contamination, the formulations were envisaged to show a convenient and easy 
handling. An adequate viscosity was required to allow injectability through thin syringe 
needles. The syringe needle size commonly used for IA injection depends on the joint to be 
treated. In order to assure adequate injection even into small joints, injectability was primarily 
evaluated by using 26 G syringe needles. This needle size is representative for the lower 
needle size limit. With regards to the formulation consistency after injection, the focus was on 
the development of a semi-solid depot enabeling entire mobility of the joint and providing 
prolonged residence time in the joint cavity. Due to the restricted injection volume and the 
limited injection frequency, a high drug load was desirable. The mAb-loaded formulation was 
intended to provide a constant drug release over a prolonged period of time. Besides the 
physical characterization of the carrier systems, a detailed understanding concerning the 
protein´s conformational stability upon incorporation into the formulation and release was 
within the focus of this project. In vitro mAb release from the formulations was to be 
investigated by using adequate release models that simulate well the physiological 
conditions present in the joint. Based on the most promising in vitro release profiles, the 
pharmacokinetic characteristics should be evaluated in vivo by making use of a rat model.  
The first objective of this work was the development of an in situ forming PLGA formulation, 
suitable for the IA administration of mAb (Chapter 2). Into a non-aqueous PLGA solution, 
mAb was to be suspended as spray-dried powder. Upon contact with aqueous body fluid, 
PLGA precipitation occurs on account of the solvent exchange which leads to entrapment of 
the mAb particles. As PLGA is a hydrolytically unstable polymer, sustained mAb release 
occurs simultaneously with polymer degradation. A suitable formulation composition was to 
be evaluated with respect to mAb stability and in vitro mAb release. Therefore, the PLGA 
type and content as well as the choice, type and concentration of the non-aqueous organic 
PLGA solvents were to be varied. Based on in vitro and in vivo data, the efficiency of this 
formulation for the IA delivery of mAb was to be assessed.  
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The suitability of polysaccharides as carrier for the local IA delivery of mAb was investigated 
in Chapter 3. Hyaluronic acid (HA) was used as gel forming agent for the preparation of a 
highly-concentrated mAb-containing gel. Besides the detailed formulation characterization, it 
was an additional aim to investigate the presence of electrostatic interactions between 
negatively charged HA and slightly positively charged mAb at physiological pH. Within this 
scope, sodium alginate, a polysaccharide with a higher charge density than HA, was 
additionally used to study the conditions at which insoluble charge complexes with mAb are 
formed that could contribute to enhanced mAb retention within the joint cavity.  
In Chapter 4 the development of phospholipid (PL)-based mAb containing formulations is 
presented. Two different formulations were within the scope of this study. In a first approach, 
an in situ forming PL-mAb formulation was to be developed, consisting of spray-dried mAb 
particles suspended within a non-aqueous PL solution. Upon contact with SF, the formulation 
was envisaged to spontaneously transfer into a vesicular formulation, causing the dissolution 
of the incorporated mAb particles and mAb entrapment into the vesicles. The second 
approach comprised the development of a vesicular PL-mAb formulation that was intended 
to be prepared ex vivo by mixing of a non-aqueous PL solution with a highly-concentrated 
mAb solution. After being administered into the joint cavity, both formulations were expected 
to provide prolonged residence time and thus sustained synovial mAb concentration and 
therapeutic effects. 
10  
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CHAPTER 2 
DEVELOPMENT OF AN IN SITU FORMING POLY(LACTIDE-
CO-GLYCOLIDE)-BASED FORMULATION FOR THE INTRA-
ARTICULAR DELIVERY OF A THERAPEUTIC ANTIBODY 
1 INTRODUCTION 
Since the first approval by the FDA as carrier material for the application of therapeutic drugs 
in humans, poly(lactide-co-glycolide) (PLGA) has received enormous interest because this 
polymer shows complete biodegradability, high biocompatibility and the potential to release 
incorporated drugs in a controlled manner over a period of days to months [59, 73, 74]. 
PLGA is a co-polymer of lactic and glycolic acid and belongs to the group of hydrolysable 
synthetic polyesters. In aqueous environment, its ester bonds are cleaved into shorter chains 
and ultimately into α-hydroxy acids which makes surgery for removal of PLGA carriers 
unnecessary [59]. PLGA degradation has been studied intensively and is reported to be 
influenced by the polymer properties (molecular weight (MW) [75], co-polymer ratio [59], 
esterification of the end-group functionality [76]), formulation components (organic solvents 
[77], pH regulating excipients [78]), sterilization techniques [79, 80] as well as by the 
properties of the release medium (temperature [81], pH, solvent [82]). PLGA has been mainly 
used as carrier material for the preparation of drug loaded solid implants and microparticles. 
Despite the presence on the market, solid implants suffer from low patient acceptance due to 
painful administration as large trochars are required [83]. Drug loaded microparticles present 
a more attractive way for the delivery of small molecules and peptides. The microparticle-
based delivery of high MW drugs such as proteins, however, is reported to be challenging 
due to manufacturing related instabilities comprising the emulsification and the exposure to 
water-organic phase interfaces that might induces protein aggregation [47, 63, 84]. Dunn and 
co-workers introduced in situ forming PLGA implants as attractive option [85]. This approach 
encompasses the dissolution of the polymer in a biocompatible water-miscible solvent in 
which the drug is dispersed or dissolved. Upon contact with aqueous body fluid, polymer 
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precipitation takes place on account of the solvent exchange, leading to entrapment of the 
drug and depot formation at the injection site. Based on this so called Atrigel® technology, 
several products can be found on the market, such as Eligard® (Medigene), Atridox® (Atrix 
Laboratories) and Atrisorb®-D Free FlowTM (Zila). Among the used solvents, N-methyl-2-
pyrrolidone (NMP), 2-pyrrolidone and dimethylsulfoxide (DMSO) were preferred due to their 
rather good compatibility [86]. However, as shown by several research groups, the use of 
hydrophilic solvents leads to a higher drug burst which can be attributed to the rapid solvent 
exchange accompanied by the formation of a highly porous matrix [58, 82, 87]. In contrast, 
the Alzamer® DepotTM technology by ALZA Corp. is based on the use of poorly water-
miscible solvents such as benzyl benzoate, in order to minimize drug burst and modify 
formulation morphology [88]. These product examples indicate that, besides the factors 
mentioned above, the choice of the organic solvents has a major impact on the overall drug 
release and therefore has to be carefully selected with respect to the intended purpose.  
Concomitantly to the expansion of therapeutic proteins, the interest in in situ forming depot 
systems has emerged [45]. The main requirements for these systems are that the burst upon 
injection is limited and the drug is continuously released over a longer period of time in native 
conformation [58]. Eliaz and co-workers found out that with increasing protein load the 
release rate from in situ hardening PLGA/glycofurol systems increased due to rapid 
dissolution of the protein particles situated at the surface of the matrix followed by the 
formation of a porous network that enables drug diffusion out of the matrix. Moreover, with 
increasing PLGA content a significant burst reduction was achieved [59]. A reduction in burst 
and release rate was also found in other studies where the impact of polymer MW on the 
release of the model peptide leuprolide acetate was studied [75, 89]. The influence of a 
variation in solvent, testing NMP, triacetin and ethyl benzoate, on the in vitro release of 
lysozyme was investigated by Brodbeck et al.. The use of triacetin and ethyl benzoate, both 
showing low water-miscibility, revealed a slow phase inversion and thus low burst intensity. 
Moreover, after contact with aqueous medium the formulation exhibited a semi-solid 
consistency [82].  
Due to the potential to form a local depot system at the site of injection, PLGA-based in situ 
forming systems present a promising vehicle for the intra-articular (IA) sustained delivery of 
therapeutic proteins. With respect to IA administered PLGA-based drug delivery systems, 
microspheres are the most studied vehicles [90]. However, the in vivo release tests were 
typically performed with small molecules such as diclofenac sodium [91], ibuprofen [92], 
methotrexate [93], paclitaxel [94] or dexamethasone [95]. Only a few studies report about the 
successful release of peptides or proteins [55, 56]. As mentioned previously, the use of 
CHAPTER 2  13 
 
PLGA-based microparticles for the delivery of proteins faces some drawbacks. The 
application of an in situ forming PLGA-based system for the delivery of proteins could be 
advantageous with respect to protein stability. A semi-solid consistency might be beneficial 
for the administration into the joint cavity. 
The aim of this part of the thesis was the development of a PLGA-based in situ forming 
formulation for the IA delivery of a therapeutic monoclonal antibody (mAb). With respect to 
the rapid clearance of drugs from the synovial cavity, a continuous drug release over a 
prolonged period of time was envisaged. Based on prior knowledge about spray drying of 
proteins, the mAb was used as spray-dried powder to be suspended in an injectable 
PLGA/organic solvent mixture. In a next step, it was the aim to evaluate a suitable 
formulation composition with regards to PLGA type and content, protein drug load, type and 
concentration of organic solvents. Moreover, the formulation consistency upon injection into 
aqueous medium, the injectability, the protein stability and the in vitro drug release were to 
be evaluated. After having identified a suitable formulation composition, the in vivo 
pharmacokinetic profile upon IA injection into healthy rats was intended to be analyzed. 
Based on these results, a final formulation for a larger preclinical trial was to be selected. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Monoclonal antibody (mAb) 
The mAb (IgG1) with a MW of 148 kDa was formulated at 100 mg/mL, pH of 5.4 with 
trehalose (201.6 mM), histidine (15 mM) and polysorbate 80 (0.01 %). The bulk solution was 
stored at -80 °C until use. Prior to use, protein solutions were filtered through an Acrodisc® 
0.2 µm PVDF syringe filter (Pall, Dreieich, Germany). For in vivo experiments, instead of the 
human mAb, the murine variant was used, which was formulated in histidine buffer (15 mM) 
at pH 6.0 and a concentration of 24.5 mg/mL.  
2.1.2 Biodegradable polymers 
All polymers listed in table 2-1 were purchased from Boehringer Ingelheim (Ingelheim, 
Germany) and were stored at 2-8 °C in a desiccator under exclusion of light. 
Table 2-1 List of PLGA 50:50 qualities used. 
Name of polymer End-group functionality Inherent viscosity 
(0.1% in CHCl3, 25°C) 
[dL/g] 
Article number/ 
batch number 
Resomer® RG 502H Free carboxylic acid 0.16-0.24 60640802/1040446 
Resomer® RG 503H Free carboxylic acid 0.32-0.44 60640660/RES-0281 
Resomer® RG 502 Endcapped 0.16-0.24 60640667/1039274 
Resomer® RG 503 Endcapped 0.32-0.44 60640661/1002249 
2.1.3 Excipients, reagents and chemicals 
Table 2-2 lists the excipients, reagents and chemicals used throughout this chapter. All 
substances were of analytical grade. Ultrapure water for all buffers was used from a PureLab 
UV/UF system (Elga LabWater, Celle, Germany). 
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Table 2-2 List of excipients, reagents and chemicals.  
Excipients, reagents, chemicals Source 
Calcium chloride Merck, Darmstadt, Germany 
Citric acid monohydrate Carl Roth, Karlsruhe, Germany 
Cobalt nitrate hexahydrate Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
Dibasic potassium phosphate AnalaR Normapur, VWR international, 
Leuven, Belgium 
Dibasic sodium phosphate dihydrate Merck, Darmstadt, Germany 
Ethanolamine Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
Ethyl acetate Merck, Darmstadt, Germany 
Glycine Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
L-histidine Merck, Darmstadt, Germany 
Hydroxyethyl cellulose 400 Merck, Darmstadt, Germany 
L-isoleucine Fluka Chemie, Buchs, Switzerland 
Mannitol Riedel-de Haen, Seelze, Germany 
Monobasic sodium phosphate dihydrate Merck, Darmstadt, Germany 
N-ethyl-N9-(dimethylaminopropyl) carbodiimide Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
N-hydroxy succinimide Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
ortho-phosphoric acid Zentrale Versorgung LMU München, 
Germany 
Polyethylene glycol 300 Sasol, Marl, Germany 
Polysorbate 80 Merck, Darmstadt, Germany 
Potassium chloride Caelo, Hilden, Germany 
Potassium thiocyanate Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
Sodium alginate, viscosity 350-550 mPas  
(1 %, 20 °C) 
AppliChem, Darmstadt, Germany 
Sodium azide Acros organics, Geel, Belgium 
Sodium citrate Caelo, Hilden, Germany 
Sodium chloride AnalaR Normapur, VWR international, 
Leuven, Belgium 
Sodium hydroxide, 1M Merck, Darmstadt, Germany 
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Trehalose Merck, Darmstadt, Germany 
Triacetin Fluka Chemie, Buchs, Switzerland 
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2.2 Methods 
2.2.1 Spray drying with the Mini Spray Dryer B-290 
Spray drying experiments with the mAb were performed on a Mini Spray Dryer B-290 (Büchi 
Labortechnik, Flawil, Switzerland). The instrument consisted of a heating system with inlet 
temperature (Tin) sensor for the drying air, a spray nozzle, a drying chamber with outlet 
temperature (Tout) sensor, a high efficiency cyclone for separation of the dried powder, a 
collection vessel and an aspirator with particle filter. For atomization of the spray drying 
solution, a two fluid nozzle (tip Ø 0.7 mm, cap Ø 1.5 mm) or a three fluid nozzle (inner tip 
Ø 0.7 mm, outer tip Ø 2.0 mm, cap Ø 2.8 mm) were used with compressed air from an in-
house supply. The use of a LT Mini dehumidifier (Deltatherm® Hirmer, Much, Germany) 
ensured a constant low residual moisture (RM) within the system. Cooling water was 
circulated through a jacket around the nozzle. The Tin/Tout was 130 °C/64 °C, the aspirator 
flow rate was 38 m3/hr or 100 % and the atomizing air flow rate was 667 L/hr. The spray 
drying solution was pumped with a liquid feed rate of 3 mL/min by means of an internal 
pump. In case that the three fluid nozzle was employed, an external pump was used 
(Minipuls 3, Gilson, Middleton, USA). All liquid samples were filtered through an Acrodisc® 
0.2 µm PVDF syringe filter (Pall, Dreieich, Germany) prior to spray drying. After the process, 
the resulting powder was collected in glass vials, closed and stored in a desiccator at 
ambient atmosphere. The yield was calculated from the amount of powder recovered in the 
collection vessel in relation to the solid content of the used spray drying solution.  
2.2.2 Spray drying with the Nano Spray Dryer B-90 
Spray drying experiments with the murine mAb were performed on a Nano Spray Dryer B-90 
(Büchi Labortechnik, Flawil, Switzerland), comprising a heating system with Tin sensor for the 
drying air, an inbuilt peristaltic pump for the drying solution, a spray head with vibrating mesh 
for generation of small droplets, a spray tower where a laminar air flow is generated, an 
electric particle collector for efficient separation of the dried particles and an particle filter with 
Tout sensor. The Tin/Tout was 55 °C/28 °C, the drying air was used from an in-house supply at 
a flow rate of 115 L/min and a mesh size of 5.5 µm was employed for droplet generation. 
Spray solutions were filtered through an Acrodisc® 0.2 µm PVDF syringe filter prior to spray 
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drying. During the spray drying process, spray solutions were kept on ice. Dried particles 
were collected in glass vials, closed and stored in a desiccator at ambient temperature. 
2.2.3 Karl-Fischer analysis 
The RM content of the spray-dried (sd) powder was determined by coulometric Karl-Fischer 
titration using an Aqua 40,00 titrator with headspace module (Analytik Jena, Jena, Germany). 
Therefore, 10-20 mg of the respective powder were accurately weighed into a 2 R glass vial, 
sealed with rubber stopper and heated up to 100 °C. For determination of the RM content, 
the evaporated water was transferred into the titration solution. As reference, a standard with 
defined RM was used (apura® water standard oven 1 %, Merck, Darmstadt, Germany). 
2.2.4 Scanning electron microscopy (SEM) 
Scanning electron microscopy was performed on a JSM-6500F JEOL scanning electron 
microscope (JEOL, Eching, Germany). Samples were attached on a sample holder by 
means of double-sided tape and sputtered with carbon. SEM was used for morphology 
analysis of sd particles and vacuum dried PLGA specimens. 
2.2.5 Preparation of formulations 
The respective amount of PLGA was accurately weighed into a glass vial. After addition of 
the respective volumes of the organic solvents, the vials were closed by a rubber stopper 
and shortly vortexed in order to disperse the PLGA powder. Samples were heated up to 
40 °C in a beaker until complete dissolution of PLGA was achieved. After cooling down to 
room temperature, the respective amount of sd mAb powder was added and dispersed in the 
PLGA solution by means of a spatula. Directly prior to injection, the PLGA-mAb suspensions 
were transferred into syringes. 
2.2.6 Injectability 
The maximal injection force, required for injection of 0.4 mL of the formulation into air, was 
determined by means of a TA.XTplus texture analyzer (Stable Micro Systems, Surrey, UK) at 
ambient temperature. This value was defined as the highest force measured before the 
plunger reached the end of the syringe after having overcome the plunger-stopper 
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breakloose force. Therefore, 1 mL Luer-Lock syringes (VWR International, Ismaning, 
Germany) connected to 23 G syringe needles (Terumo, Leuven, Belgium) were clamped in a 
tripod underneath the punching tool of the instrument. The crosshead velocity was set to 
1 mm/s, a representative velocity for the manual syringe delivery [96]. After 30 s, the 
measurement stopped automatically. 
2.2.7 Mechanical testing 
For determination of the mechanical properties of in situ hardened PLGA specimens, 
approximately 100 µL of the respective formulation were placed into a 96-well plate (Nunc®, 
Sigma-Aldrich Laborchemikalien, Seelze, Germany). The well plate was submersed for 
24 hrs in PBS in order to allow solvent exchange and PLGA precipitation. The buffer medium 
was heated-up to 37 °C and agitated by means of a magnetic stirrer. After incubation, the 
hardness of the samples was investigated using a TA.XTplus texture analyzer (Stable Micro 
Systems, Surrey, UK) at ambient temperature. Therefore, a cylindrical stainless steel 
punching tool (Ø 4 mm) penetrated into the specimens with a velocity of 0.05 mm/s. The 
required maximal forces to achieve a penetration depth of 1 mm were recorded and used for 
comparison.   
2.2.8 Rheometry 
The viscosity of in situ hardened PLGA formulations was studied on a plate-cone rheometer 
(Physica MCR 100, Anton Paar, Ostfildern, Germany) with logarithmically increasing shear 
rate (10-3-500 s-1, 500-10-3 s-1) at a gap position of 0.042 mm. A cone with a diameter of 
50 mm and an angle of 1 ° was used and measurements were performed at 20 °C. 
Approximately 600 mg of the sample were used. For formulation comparison the viscosity at 
500 s-1 was utilized. 
2.2.9 Protein extraction from non-aqueous PLGA formulations 
In order to analyze the structural integrity of mAb after dispersion in non-aqueous PLGA 
solutions, approximately 250 mg of freshly prepared non-aqueous PLGA-mAb formulation 
were accurately weighed into a 2 mL Eppendorf cup. Ethyl acetate was added up to the 2 mL 
mark and the sample was incubated for 15 min. As reference, approximately 44 mg sd mAb 
were accurately weighed into an Eppendorf cup and treated in the same way. Samples were 
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centrifuged for 10 min at 12,000 rpm. Afterwards, approximately 1.5 mL ethyl acetate was 
replaced and the pellet was resuspended. This washing step was repeated twice. After the 
last centrifugation step the supernatant was removed and the residual sediment was dried in 
a vacuum chamber at ambient temperature. After one hour, the dried protein was 
reconstituted with 1 mL water. The obtained solutions were used for HP-SEC and HP-IEC 
analysis. 
2.2.10 Protein extraction from PLGA matrices after release experiments 
Protein extraction from hardened PLGA matrices was performed after lyophilzation of the 
PLGA matrices in an Epsilon 2-6 D freeze dryer (Christ, Osterode, Germany) in the vials 
used for the in vitro release experiments. The vials were frozen to -50 °C at 0.45 °C/min and 
held for 2 hrs. Primary drying was performed at a shelf-temperature of -15 °C and 
0.045 mbar within 20 hrs. Secondary drying was carried out at a shelf-temperature of 40 °C 
within 10 hrs and 0.045 mbar. Lyophilized vials were closed manually. After drying, protein 
extraction was performed according to 2.2.9. 
2.2.11 In vitro mAb release tests 
2.2.11.1 Vial model 
In vitro mAb release experiments from in situ hardened PLGA formulations were performed 
by injection of approximately 400 mg of the non-aqueous PLGA-mAb suspensions into 6 R 
glass vials (Schott, Mainz, Germany) filled with 6 mL PBS containing 0.01 % NaN3. If 
possible, formulations were manually injected. At higher formulation viscosities, injection 
through syringe needles was carried out with the help of a custom made manual injection aid 
consisting of a syringe holder and a screw as syringe plunger substitute. After injection, the 
vials were sealed with rubber stopper, stored at 37 °C in a convection oven and agitated at 
40 rpm on a shaker. At predefined time points the complete release medium was carefully 
replaced by fresh buffer and analyzed for protein concentration via UV spectroscopy or 
fluorimetry. 
2.2.11.2 Mechanical stress model 
In order to simulate the mechanical conditions present in the joint, in situ hardening 
formulations were subjected to mechanical treatment during in vitro release experiments. 
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Therefore, approximately 50 mg of non-aqueous PLGA-mAb formulations were injected into 
HPLC vials (VWR international, Ismaning, Germany) filled with 750 µL PBS containing 
0.01 % NaN3. Directly after injection, the in situ hardening PLGA formulations were kneaded 
with 20 penetration cycles of a plane stainless steel punching tool (Ø 4 mm) by means of a 
TA.XTplus texture analyzer (Stable Micro Systems, Surrey, UK) at ambient temperature 
(figure 2-1). Meanwhile, the vial was manually rotated in order to avoid indentation at the 
same position. After mechanical stressing, the vials were tightly sealed and incubated at 
37 °C. At predefined time points, the complete release medium was carefully replaced by 
fresh buffer and the mechanical treatment of the remaining PLGA matrix was repeated. 
Protein release was determined via UV spectroscopy or fluorimetry. 
 
Figure 2-1 Mechanical stress model for simulation of IA conditions during mAb release. 
After injection of 50 mg of the PLGA formulation a punching tool penetrates 
into the in situ formed matrix with 20 indentation cycles.  
2.2.12 UV spectroscopy (OD 280, second derivative, absorbance at 350 nm) 
Protein concentrations were determined photometrically on an Agilent 8453 UV-Vis 
spectrometer (Agilent Technologies Deutschland, Böblingen, Germany) equipped with a 
Peltier temperature controller (Agilent Technologies Deutschland, Böblingen, Germany) at 
λ=280 nm and 25 °C in quartz UV cuvettes with a path length of 1 cm. An extinction 
coefficient of either 1.39 mL·mg-1·cm-1 (mAb) or 1.40 mL·mg-1·cm-1 (murine mAb) was 
applied. Samples were diluted to a concentration ranging from 0.1 to 0.7 mg/mL prior to 
analysis. Corresponding blank spectra were subtracted from the protein spectra. Second 
derivative protein spectra were calculated between 240 and 350 nm by means of the 
ChemStation software. Turbidity of undiluted protein containing samples was determined at 
350 nm and 25 °C. Concentrations of smaller sample volumes were analyzed undiluted with 
a NanoDrop ND-2000 spectrometer (PEQLAB Biotechnologie, Erlangen, Germany). 
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2.2.13 Fluorimetry 
Protein concentrations below 0.1 mg/mL were determined with a Varian Carry Eclipse 
fluorimeter (Varian, Darmstadt, Germany). Solutions were measured at 20 °C either in 
3.0 mL (Sarstedt, Nümbrecht, Germany) or 0.5 mL (Brand, Wertheim, Germany) cuvettes, 
depending on the available volume. Excitation occurred at a wavelength of 280 nm with an 
excitation slit of 5 nm. The emission spectrum was recorded from 280 nm to 600 nm. For 
protein quantification a calibration curve, ranging from 0.002 to 0.1 mg/mL at the emission 
maximum at 334 nm, was used. 
2.2.14 Fourier transform infrared spectroscopy (FTIR) 
FTIR spectra were recorded with a Tensor 27 FTIR spectrometer (Bruker Optics, Ettlingen, 
Germany) using a Bio-ATR unit (attenuated total reflection) connected to a thermostat 
tempered to 20 °C (DC30-K20, Thermo Haake, Dreieich, Germany). Corresponding blank 
spectra were subtracted from the protein spectra. After a 120-scan measurement, the 
second derivative spectra were generated (OPUS, Bruker Optics, Ettlingen, Germany). For 
investigation of changes in secondary protein structure, the vector normalized second 
derivative spectra between the wavenumbers of 1720 and 1580 cm-1 were compared with the 
spectra of the native, untreated protein. 
2.2.15 High performance size exclusion chromatography (HP-SEC) 
HP-SEC was used for quantification of soluble aggregates, monomer and fragments of the 
mAb. The measurement was performed on a HPLC 1100 chromatograph (Agilent 
Technologies Deutschland, Böblingen, Germany) using a Superose® 6 10/300 GL column 
(GE Healthcare, Uppsala, Sweden) with UV detection at 214 and 280 nm. The mobile phase 
consisted of 0.15 M sodium chloride in 0.02 M sodium phosphate, adjusted to pH 7.5 with 
ortho-phosphoric acid. The flow rate was 0.5 mL/min. Samples were diluted with mobile 
phase to a target concentration of 1 mg/mL and centrifuged for 10 min at 12,000 rpm (Sigma 
1-15, Sigma Laborzentrifugen, Osterode am Harz, Germany) in order to remove insoluble 
aggregates. Chromatograms were integrated manually by means of the ChemStation 
software Rev. B.02.01 (Agilent Technologies Deutschland, Böblingen, Germany). For 
quantification, the area under the curve was used. Protein concentrations were calculated 
based on a calibration curve.  
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2.2.16 High performance ion exchange chromatography (HP-IEC) 
HP-IEC was performed for detection of oxidized protein species after protein extraction from 
non-aqueous PLGA formulations. The experiment was performed on a HPLC 1200 
chromatograph (Agilent Technologies Deutschland, Böblingen, Germany) with a ProPac-
WCX-10 column and a ProPac-WCX-10G-precolumn (Dionex, Sunnyvale, USA). Mobile 
phase A consisted of 0.01 M sodium phosphate, pH 7.5, mobile phase B of 0.01 M sodium 
phosphate and 0.5 M sodium chloride at pH 5.5. The binary gradient listed in table 2-3 was 
applied with a flow rate of 1.0 mL/min. Protein detection occurred at 280 nm. 
Table 2-3 Binary gradient used for HP-IEC measurements. 
Time Solvent 
0 min 94 % A, 9 % B 
20 min 84 % A, 16 % B 
22 min 0 % A, 100 % B 
28 min 94 % A, 6 % B 
2.2.17 Bright-field microscopy 
In order to visualize large insoluble protein aggregates, protein samples were filtered through 
a 0.2 µm polypropylene membrane filter (Pall, Dreieich, Germany). Protein on the filter 
surface was stained with 1 mL of a protein detection kit as described by the supplier (Sigma-
Aldrich Laborchemikalien, Seelze, Germany). After 5 min, protein aggregates were washed 
with 10 mL PBS. The filter membrane was analyzed on a Keyence digital VHX-500F bright-
field microscope (Keyence Deutschland, Neu-Isenburg, Germany). 
2.2.18 Surface plasmon resonance (SPR) measurements  
Analysis of the binding capacity of in vitro released mAb was performed at the Abbott 
Bioresearch Center, Worcester, USA using a BIACORE T100 instrument (GE Healthcare, 
Uppsala, Sweden) connected to the BIAevaluation® software. Release experiments were 
performed with the murine mAb. Goat anti-murine mAb antibody was immobilized on a 
carboxy methylated (CM5®) chip according to the standard immobilization procedures 
described by Biacore Life Science. The sensor chip surfaces of sample and reference cells 
were first activated by a 6-min injection of a solution containing 0.4 M N-ethyl-N9-
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(dimethylaminopropyl) carbodiimide and 0.1 M N-hydroxy-succinimide. After anti-murine mAb 
antibody immobilization in the sample cell via amine linkage of lysine residues, residual 
activated carboxymethyl groups of both sample and reference cell were deactivated with 
ethanolamine. In order to verify that the immobilized mAb was still intact, the binding capacity 
was determined with a murine mAb antigen solution, carried through the sample cell. MAb 
containing samples obtained from in vitro release experiments were diluted with the running 
buffer to a concentration of 0.5 µg/mL. The experiment was performed at 25 °C with a flow 
rate of 50 µL/min. After injection of the mAb samples and capture by the covalently bound 
goat anti-murine mAb antibody, murine TNFα solution was carried through the cell in order to 
determine the binding capacity of murine mAb. As reference a mAb standard solution at 
same concentration was used. Dissociation of captured murine mAb was performed with 
10 mM glycine (pH=1.5) in order to regenerate the sensor surface for the next experiment. 
2.2.19 In vivo experiments  
An in vivo study was performed at the Abbott Bioresearch Center in Worcester, USA 
according to the granted animal test proposal in order to assess the pharmacokinetic profile 
of PLGA-mAb formulations upon IA injection. The study was performed with healthy male 
Lewis rats weighing approximately 275 – 300 g at the start of the study. Instead of the human 
mAb, the murine variant was used. For generation of protein particles, the mAb solution, 
formulated in 15 mM histidine, was admixed with excipients (201.6 mM trehalose, 0.01 % 
polysorbate 80) and spray-dried as described in section 2.2.2. Selection of PLGA formulation 
composition was based on in vitro release data. In order to cover a broad release window, 
three formulations showing “long”, “intermediate” and “short” in vitro mAb release profiles 
were selected. Besides the IA administration, the PLGA-mAb formulation with the “long” in 
vitro release profile was additionally administered subcutaneously (SC) in order to assess the 
impact of the mechanical exposure in the knee joint on the in vivo release. 
Prior to injection, animals were anaesthetized in an anesthesia chamber using isoflurane 
(5 %) and oxygen. Once the rats were completely anesthetized, the right knee was shaved. 
Animals were dosed either IA or SC with 50 µL of the respective PLGA-mAb formulation. IA 
injection was carried out by injection through the patella into the knee joint using a 21 G 
needle. At predefined time points (1 hr, 2 hrs, 4 hrs, 6 hrs, 12 hrs, 1 d, 2 d, 3 d, 7 d) blood 
samples were collected from the tail nick of the animals and stored at -80 °C until analysis. At 
day 7, animals were sacrificed in an anesthesia chamber using CO2. Blood samples were 
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analyzed in regard to mAb concentration via ELISA according to the Abbott standard 
protocol. 
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3 RESULTS AND DISCUSSION 
3.1 Spray drying of mAb and powder characterization 
At first, sd mAb particles had to be generated for preparation of the non-aqueous PLGA-mAb 
suspension. The recovery of the sd mAb powder prepared on a Mini Spray Dryer B-290 was 
between 60 and 74 % and the RM ranged from 3.4 to 4.9 %. SEM analysis revealed a broad 
particle size distribution in the low µm-range and the presence of particles of round and 
doughnut-like shape (figure 2-2 A). Reconstitution with water resulted in clear solutions and 
HP-SEC showed that the monomer recovery was unchanged compared to prior to spray 
drying (99.5 ± 0.03 % (sd mAb), vs. 99.6 ± 0.1 % (mAb before spray drying)). 
Generation of sd murine mAb particles for in vivo experiments was carried out on a Nano 
Spray Dryer B-90 on account of the possibility to dry the minute volumes of restricted murine 
mAb solutions while achieving high yields [97]. Dried particles were prepared with a recovery 
of 86 % and a RM content of 7.3 %. In order to reduce the RM content, the powder was 
subjected to an additional vacuum drying step by incubation of the powder at 100 mbar and 
32 °C for 40 hrs. This led to a slight reduction of RM to 6.4 %. SEM images revealed the 
presence of spherical particles in the size range of 0.5 µm to 6 µm (figure 2-2 B). Again, HP-
SEC analysis after reconstitution showed an unchanged monomer recovery (98.4 % ± 0.7 % 
(sd murine mAb), vs. 98.6 % ± 0.5 % (murine mAb before spray drying)). Thus it was 
possible to generate the mAb powder necessary for formulation preparation at high quality 
and adequate yields. 
  
Figure 2-2 SEM images of sd mAb particles generated on a Mini Spray Dryer B-290 (A) 
and of sd murine mAb particles prepared on a Nano Spray Dryer B-90 (B).  
A B 
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3.2 Pre-screening experiments 
3.2.1 Initial screening of different PLGA and organic solvent concentrations 
PLGA-based drug containing formulations intended for IA administration have to meet 
several requirements including injectability through thin syringe needles and drug release in 
the desired time frame. In order to guarantee the preservation of the entire joint mobility, a 
semi-solid consistency after contact with synovial fluid (SF) and subsequent hardening needs 
to be provided as joint blockage or cartilage friction have to be avoided. In general, the 
polymer content plays an important role in controlling the release window. But it also needs 
to be considered that high polymer content leads to an increase in viscosity of the 
formulations which limits injectability. Besides the polymer content, also the PLGA MW and 
the end-group functionality have a major influence on solvent exchange after contact with 
aqueous medium and initial hardening. Furthermore, the choice of the organic solvents used 
for preparation of PLGA solutions plays a crucial role: the use of hydrophilic solvents 
accelerates water influx and subsequent PLGA precipitation but commonly ends up in a rapid 
drug burst. In contrast, the addition of hydrophobic solvents is reported to decelerate solvent 
exchange accompanied with a significant reduction of drug burst. As hydrophobic solvents 
are known to act as plasticizer, the resulting in situ formed matrix exhibits a mellow 
consistency. Various organic solvents such as PEG 400, NMP, DMSO, triacetin, triethyl 
citrate, 2-pyrrolidone and benzyl alcohol have been investigated as solvents for in situ 
forming PLGA systems [77, 98]. Strickley reviewed organic solvents that are commonly used 
in commercially available injectable products [99]. According to that, the water-miscible 
solvents PEG 300 and PEG 400 are considered as safe and highly compatible. The 
hydrophobic solvent triacetin is affirmed as generally recognized as safe (GRAS) by the FDA 
[77]. It can be used as parenteral nutrient [100] and is employed in oral dosage forms. In 
order to evaluate a suitable formulation composition with adequate consistency after 
incubation in aqueous medium, different PLGA-organic solvent placebo mixtures were 
prepared. As PLGA component for the initial evaluation Resomer® RG 503H was chosen 
based on prior knowledge about precipitation and degradation behavior. PEG 300 was used 
as hydrophilic solvent for PLGA and triacetin served as hydrophobic solvent and formulation 
plasticizer. The placebo samples were tested with respect to injectability through a 23 G 
needle and consistency after incubation for one day at 37 °C in PBS. PLGA was employed at 
5 to 25 % (w/w) and triacetin concentrations ranged from 10-30 % (w/w). 
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In the preliminary study, only formulations with polymer content up to 10 % were easily 
injectable through a 23 G syringe needle. A polymer content above 10 % led to such a high 
formulation viscosity that manual injection through the 23 G syringe needle was hardly 
possible. Formulations comprising triacetin contents of 20-30 % revealed a semi-solid 
consistency after incubation which was in accordance to the initial idea about the formulation 
consistency. Consequently, a formulation composition with 10 % PLGA, a triacetin content of 
20-30 % and 60-70 % PEG 300 were determined as suitable starting point for further 
investigations with respect to injectability and formulation consistency. 
3.2.2 Investigation of the influence of PEG 300 and triacetin on mAb 
conformational stability 
One basic requirement concerning the selection of formulation components is the 
compatibility with the incorporated protein. In the following the influence of PEG 300 and 
triacetin at the aforementioned concentration ranges on mAb conformational stability were 
analyzed via turbidity measurements, second derivative UV and FTIR spectroscopy and HP-
SEC. Therefore, the sd mAb was incubated for 1 hr in 1 mL PEG 300 as well as in 1 mL of a 
mixture of PEG 300 and triacetin (PEG 300/triacetin (P/T) ratio 80 %/20 % and 70 %/30 %). 
After incubation, 3 mL PBS were added to the suspensions, respectively, in order to 
redissolve the sd mAb.  
Turbidity measurements after redissolution of sd mAb revealed a slight increase of turbidity 
with raising triacetin content (figure 2-3). The tertiary protein structure was studied by 
analysis of the second derivative UV spectra. This method allows the detection of changes in 
the microenvironment polarity of the aromatic amino acids phenylalanine (Phe), tyrosine (Tyr) 
and tryptophane (Trp) [101, 102]. The native mAb showed five characteristic peaks that can 
be attributed to the aromatic amino acids as follows: 249 nm (Phe), 259 nm (Phe), 276 nm 
(Tyr/Trp), 284 nm (Tyr/Trp) and 292 nm (Trp) [103]. Since no peak shifts were detectable in 
the samples compared to the reference, it was assumed that the organic solvents in the used 
concentration ranges have no detrimental impact on the tertiary protein structure (figure 2-4 
A). In order gain futher insight into the impact of the organic solvents on the secondary mAb 
structure, FTIR measurements were performed. The results shown in figure 2-4 B underline 
the findings of the UV measurements as also no effects on the secondary protein structure 
by the addition of the organic solvents were seen. Additional HP-SEC analysis demonstrated 
that the monomer recovery was not reduced significantly by the incubation of the protein 
particles in the solvent systems (P/T 100 %/0 % 99.8 ± 3.2 %, P/T 80 %/20 % 99.2 ± 3.4 %, 
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P/T 70 %/30 % 96.7 ± 1.7 %, reference 96.5 ± 2.1 %). According to these results, it was 
concluded that PEG 300 and triacetin present suitable solvents for the preparation of a mAb 
containing PLGA formulation since at the analyzed concentration ranges no destabilizing 
effects on the protein were detectable. 
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Figure 2-3 Blank corrected results of turbidity measurements at 350 nm of sd mAb 
incubated in different PEG 300/triacetin (P/T) mixtures (P/T 100 %/0 %, 
80 %/20 % and 70 %/30 %) for 1 hr and redissolution in 3 mL PBS in 
comparison to sd mAb in PBS. 
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Figure 2-4 Second derivative UV (A) and FTIR (B) spectra of sd mAb incubated in 
different PEG 300/triacetin (P/T) mixtures (P/T 100 %/0 % (gray, thick), 
80 %/20 % (black, thick) and 70 %/30 % (gray, thin) for 1 hr and subsequent 
addition of 3 mL PBS in comparison to untreated mAb (black, thin). Artificial 
offset for clarity. 
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3.2.3 Evaluation of a suitable drug load 
Subsequently, a suitable drug load was to be found which has to balance the high protein 
load necessary for pharmacological reasons, a potential effect on burst release as well as a 
potential increase in viscosity with high particle concentration. At first, the viscosity and the 
injectability of the formulation were studied. In order to evaluate the highest drug load 
possible, the required maximal injection force using a 23 G syringe needle was determined. 
Moreover, the viscosity prior to injection was studied. As basic formulation composition a 
PLGA content of 10 % (Resomer® RG 503H) in P/T 70 %/30 % was chosen to evaluate a 
protein content of 5 %, 7 % and 10 %. 
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Figure 2-5 Injection force-plunger displacement diagram of injectability measurements 
using a 23 G needle and formulations with 10 % Resomer® RG 503H, a P/T 
ratio of 70 %/30 % and a mAb content of 0 % (black, thin line), 5 % (black, 
thick line), 7 % (gray, thin line) and 10 % (gray, thick line). 
Figure 2-5 shows the results of the injectability measurements using a 23 G syringe needle. 
With increasing drug load, the injection force increased from 27 N (mAb 5 %) up to 47 N 
(mAb 10 %). In literature, formulations which require injection forces up to 25 N in vivo are 
declared as easy to inject [21]. As the experiment was performed by injection into air, a slight 
increase of the forces after injection in vivo is expected due to a higher resistance and the 
limited physiological space [21]. To overcome high injection forces, the use of syringe 
needles with bigger inner diameter could be used. According to the law of Hagen-Poiseuille, 
the use of a 21 G syringe needle would lead to an injection force of 15 N for the formulation 
with 10 % drug load which is easy to handle. However, an increase in needle size is known 
to influence the patient compliance due to injection pain [96]. Therefore, thin needle sizes 
should always be aspired. Rheometry measurements confirmed that with increasing drug 
load also the viscosity increases (1.5 ± 0.1 Pa·s (0 % drug load), 2.7 ± 0.1 Pa·s (5 % drug 
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load), 3.4 ± 0.2 Pa·s (7 % drug load), 4.9 ± 0.2 Pa·s (10 % drug load) at a shear rate of  
500 s-1). In order to keep both the injection forces and the viscosity of the formulations as low 
as possible, a drug load of 5 % was chosen for further experiments. At this drug load, the 
amount of formulation to be administered to the joint would be 280 mg, presuming a release 
period of 28 days with a complete drug release and an envisaged daily mAb release of 
500 µg.  
3.2.4 Studies on the in vitro release of mAb from PLGA formulations and 
characterization of the formulations 
In situ forming PLGA-based drug containing formulations are generally described to show a 
triphasic release pattern. The first phase is characterized by a burst release of the drug due 
to the lag between injection and solidification. Drug particles that are deposited on or close to 
the surface are easily accessible by the incubation medium, leading to rapid dissolution and 
diffusion out of the matrix [87]. The second phase is governed by a diffusion controlled 
sustained release of the drug that is entrapped in the solidified PLGA matrix. In the third 
phase, drug release occurs concomitantly with PLGA erosion [104]. For orientation, mAb in 
vitro release experiments were performed by injection of approximately 0.4 g of a formulation 
composed of 10 % Resomer® RG 503H, a P/T ratio of 70 %/30 % and a mAb content of 5 % 
into 6 R glass vials filled with 6 mL release medium at 37 °C. For this preliminary experiment 
20 G needles were employed in order to allow easy manual injection. A strong burst effect of 
85 ± 11 % during the first 5 hrs was observed with no further release within the next 40 hrs 
(figure 2-6). This almost complete burst release can be ascribed to the rapid PEG 300 
exchange accompanied by an influx of the surrounding aqueous medium into the 
formulation.  
The role of solvent exchange in this context was investigated by Brodbeck et al. who 
reported a strong initial burst release from in situ forming PLGA formulations when solvents 
with a high hydrophilicity were used. The burst effect was reduced when using solvents with 
a lower water affinity due to slower solvent exchange causing the formation of a less porous 
structure with hampered water influx and subsequent protein dissolution [82]. Besides by the 
use of less hydrophilic solvents, the burst intensity can be reduced by increasing the polymer 
MW as longer polymer chains induce the formation of a more entangled network that hinders 
protein release [89]. Shively et al. pointed out that with increasing polymer content the drug 
release from in situ forming implants can be significantly reduced [105]. This effect might be 
explained by the fact that both the hydrophobicity and the density of the system increase, 
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leading to a decreased water influx rate and the formation of a less porous structure [106]. 
Moreover, the polymer type is reported to influence the drug release. In the present study, a 
polymer type with free carboxylic acid end-group was employed. The use of an end-capped 
polymer variant is known to increase the hydrophobicity [107] and therefore the water influx 
into the in situ forming system is reduced. 
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Figure 2-6 Cumulative mAb release from a formulation composed of 10 % 
Resomer® RG 503H, a P/T ratio of 70 %/30 % and a mAb content of 5 %; 
injection of approximately 0.4 g through a 20 G needle into PBS at 37 °C. 
To study whether the burst release could be suppressed by the use of significantly higher 
polymer content, the formulations with the highest polymer content possible were to be 
tested independent of injectability of the formulation and consistency of the formed matrices. 
Resomer® RG 503H showed a maximal solubility of 33 % (w/w) in both pure PEG 300 and 
triacetin. In order to test if a polymer with lower MW than Resomer® RG 503H shows a higher 
solubility, Resomer® RG 502H was also dissolved at various concentrations in both solvents 
(MW range Resomer® RG 503H 24-38 kDa vs. Resomer® RG 502H 7-17 kDa). It became 
obvious that Resomer® RG 502H has a maximal solubility of 50 % (w/w) in both solvents. 
Consequently, this polymer was used for following in vitro release experiments as higher 
polymer content was achieved. As the handling of the formulation after addition of 5 % sd 
mAb was hardly possible, the polymer content was slightly reduced from 50 % to 45 % for 
further in vitro mAb release experiments. 
Even at a PLGA content of 45 % the PEG 300 containing formulation still exhibited a burst of 
70 ± 10 %. A phase of continuous drug release of 0.1 % per day followed. Beginning on 
day 9 the release was slightly enhanced and the incubation medium turned slightly turbid 
with the presence of white flakes pointing towards enhanced PLGA degradation and erosion. 
Opposite to that, the triacetin containing formulation did not show any burst. Until day 6 only 
1.3 % of mAb were released. After day 6, a significant increase in mAb release up to 30 % at 
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day 26 in a sigmoidal release pattern was identified (figure 2-7). The observed differences in 
mAb release rate confirm the findings of Brodbeck et al. [82]. The impact of the hydrophilic 
solvent on the formation of an interconnecting highly porous structure was clearly underlined 
by SEM analysis of the vacuum dried PEG 300 containing PLGA matrix (figure 2-8). The 
triacetin containing formulation could not be analyzed via SEM analysis as this formulation 
showed a mellow consistency indicating that PLGA was not completely precipitated. In 
contrast to triacetin, the PEG 300 containing formulation was of hard consistency after 
incubation that enabled vacuum drying and SEM analysis. 
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Figure 2-7 Cumulative mAb release from formulations composed of 45 % 
Resomer® RG 502H, 5 % mAb and either PEG 300 (filled square) or triacetin 
(opened square). Approximately 0.4 g of the formulations was injected without 
syringe needle into 6 R vials filled with PBS at 37 °C. 
  
Figure 2-8 SEM images of side view (A) and cross section (B) of a formulation composed 
of 45 % Resomer® RG 502H, 5 % mAb and PEG 300 after incubation for 
1 day. 
The above findings indicate that the used solvent has a major influence on both the 
consistency of the in situ formed matrix and the in vitro mAb release. Concerning the 
formulation consistency, the PEG containing formulation is expected be too hard for IA 
A B 
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application as it might lead to friction in the joint and restricted joint mobility, whereas the 
consistency of the triacetin containing formulation seems to be applicable. However, 
regarding the mAb release behavior, the release rate from the triacetin formulation might be 
too low for the intended purpose. In order identify a formulation showing a release profile in 
between the two formulations analyzed, the impact of various P/T ratios on the in vitro mAb 
release as well as on the formulation consistency was studied. MAb containing formulations 
based on 45 % Resomer® RG 502H and different P/T ratios were prepared. As the viscosity 
of the prepared formulations was too high for an injection through syringe needles, injection 
into the release medium was carried out without syringe needle. 
The visual inspection of the formulations one day after incubation revealed that with more 
than 15 % triacetin, the in situ formed matrices exhibited a mellow consistency and flowed 
down to the bottom of the vial (figure 2-9). With PEG 300 contents of equal or more than 
95 %, the implant solidified immediately upon contact with release medium due to the rapid 
solvent exchange and the injected matrix shape was maintained. 
   
   
Figure 2-9 Visual appearance of mAb containing formulations consisting of 45 % 
Resomer® RG 502H and P/T ratios as indicated after one day of incubation in 
PBS at 37 °C. Injection occurred without syringe needle. 
In vitro release experiments demonstrated that a triacetin content of only 5 % leads to a 3-
fold reduction of the burst from 67.9 ± 10.3 % to 23.8 ± 1.8 % (figure 2-10). A further increase 
in triacetin content did not change the initial release profiles drastically. All formulations 
revealed the same release pattern as described above. Thus, after one day the release 
profile in the triacetin containing formulations was identified to be independent of the P/T 
ratio. 
P/T 0 %/100 % P/T 33.3 %/66.6 % 
P/T 85 %/15 % P/T 95 %/5 % P/T 100 %/0 % 
P/T 66.6 %/33.3 % 
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Mechanical strength measurements of the incubated matrices after 24 hrs confirmed that the 
mechanical strength decreased with increasing triacetin content (figure 2-11). The addition of 
only 5 % triacetin led to a reduction of the mechanical strength by factor 3. A further increase 
in triacetin content altered the mechanical strength only slightly.  
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Figure 2-10 In vitro release profiles of mAb from formulations composed of 45 % 
Resomer® RG 502H, 5 % mAb and P/T ratios as indicated. Approximately 
0.4 g of the formulations was injected without syringe needle into 6 R vials 
filled with PBS at 37 °C. 
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Figure 2-11 Mechanical characteristics of mAb containing formulations based on 
Resomer® RG 502H, a mAb content of 5 % and P/T ratios as indicated after 
one day of incubation in PBS at 37 °C.  
The results of these pre-screening experiments demonstrate that mAb entrapment into an in 
situ forming PLGA-based matrix at high polymer content in general is possible. The initial 
burst can be controlled by the P/T ratio employed. So far, formulations were not injectable. In 
a further step the formulations were intended to be modified with respect to injectability. 
Moreover, the protein stability after release was to be investigated.  
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3.3 Investigation of mAb stability in non-aqueous PLGA formulations and 
after in vitro release 
So far, formulation development was performed with the focus on the impact of the P/T ratio 
on the mAb release behavior and the mechanical characteristics of the formulation after 
incubation. Another aspect of major importance is the preservation of the mAb stability upon 
formulation preparation and subsequent release. In literature, several degradation reactions 
and mechanisms are described that might occur when proteins are incorporated into PLGA, 
such as deamidation, amide bond hydrolysis or acylation induced by the polymer itself or its 
acidic degradation products. Moreover, protein aggregation is described as a consequence 
of pH drop during polymer hydrolysis or adsorption on the hydrophobic polymer surface [65]. 
At first, the physical and chemical stability of mAb dispersed in the non-aqueous PLGA 
formulation was intended to be analyzed. As PLGA is non-miscible with water, extraction 
necessitates the use of organic solvents. There are three major requirements on the used 
solvent for this purpose: (i) it should present a solvent for PLGA but a non-solvent for mAb, 
(ii) it should be volatile for easy removal after extraction of the protein and (iii) the solvent 
should be compatible with the mAb. Körber et al. successfully used ethyl acetate for 
extraction of lysozyme from non-aqueous PLGA solutions [108]. Based on this study, the 
suitability of ethyl acetate for the present purpose was evaluated. In a second step, mAb 
stability after extraction was assessed via HP-SEC and HP-IEC. In order to exclude any 
detrimental impact of ethyl acetate on mAb conformational stability, sd mAb was dispersed in 
ethyl acetate and incubated for 20 min. For separation of sd particles, samples were 
centrifuged. The supernatant was removed and the sediment was dried under vacuum 
atmosphere. The dried sediment was reconstituted in water, leading to a clear solution which 
was analyzed by HP-SEC and HP-IEC measurements.  
Dispersion of sd mAb particles in ethyl acetate did not lead to any increase in HP-SEC 
aggregate or fragment formation (99.2 ± 0.7 % monomer recovery (sd mAb + ethyl acetate) 
vs. 99.4 ± 0.1 % monomer recovery (sd mAb)). Also HP-IEC measurements did not show 
any changes induced by ethyl acetate. Thus, ethyl acetate was selected for mAb extraction 
from the PLGA formulations. For this purpose, an exemplary PLGA formulation composed of 
30 % Resomer® RG 502H, 5 % mAb and a P/T ratio of 85 %/15 % was used. Upon mAb 
separation, drying and reconstitution, a clear solution was obtained that was used for further 
analysis. HP-SEC monomer recovery after extraction of mAb from the PLGA formulation did 
not significantly differ from the reference (figure 2-12 A). Similar to HP-SEC, HP-IEC did not 
show any indications of protein degradation (figure 2-12 B). Based on these results it was 
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concluded that mAb is initially unaffected by the incorporation into a non-aqueous PLGA 
solution. 
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Figure 2-12 (A) HP-SEC recovery of monomer, aggregates and fragments and (B) HP-IEC 
recovery of acidic, main and basic species of reconstituted mAb extracted 
from a non-aqueous PLGA formulation (30 % Resomer® RG 502H, 5 % mAb 
and a P/T ratio of 85 %/15 %) using ethyl acetate (EA), compared to equally 
treated sd mAb. 
In a further step, mAb stability after release from in situ formed PLGA matrices was 
investigated. Therefore, the release fractions were analyzed in regard to monomer content 
and the presence of soluble aggregates or fragments via HP-SEC. Tertiary protein structure 
was elucidated via secondary UV spectroscopy. Moreover, large insoluble protein 
aggregates were intended to be identified via bright-field microscopy after protein staining on 
a filter membrane.  
Due to the low mAb release rate and therefore the low mAb concentration in the release 
medium after day 1, release fractions could only be analyzed during the burst phase. At 
these time points, PLGA degradation had not started yet and a pH drop that might induce 
protein degradation is therefore not expected. However, protein aggregation induced by e.g. 
interaction with the precipitated polymer could be identified. HP-SEC analysis revealed that 
additional soluble aggregates or fragments were not present in the release fractions and the 
total AUC was not reduced. Figure 2-13 shows an exemplary second derivative UV spectrum 
of released mAb at day 1 in comparison to native mAb. As no peak shifts were detectable, it 
was concluded, that the tertiary protein structure was essentially preserved upon release 
from the PLGA matrix. 
As mentioned in section 3.2.4, release fractions after day 9 turned slightly turbid with the 
presence of white flakes. This turbidity was observed in both mAb containing and placebo 
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samples. In order to tell whether this turbidity is accompanied by protein aggregation, release 
fractions were filtered through a 0.2 µm membrane filter and stained with a protein detection 
kit. In presence of protein that is retained by the membrane, purple colorization can be 
detected by bright-field microscopy. The analysis of the release fractions revealed that the 
slight turbidity was not exclusively related to PLGA degradation as protein particles or protein 
carrying PLGA particles in the lower µm range were detected (figure 2-14).  
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Figure 2-13 Second derivative concentration normalized UV spectrum of mAb containing 
release fractions at day 1 (thick line) in comparison to native mAb (thin line). 
Artificial offset for clarity. 
  
Figure 2-14 Bright-field microscopy images after staining with protein detection kit of 
release fractions at day 14 from a formulation composed of 45 % 
Resomer® RG 502H, a P/T ratio of 100 %/0 % and a mAb content of 5 % (A) in 
comparison to the corresponding placebo sample (B).  
The exact mechanism for the detected protein instability is difficult to identify. On the one 
hand, protein aggregates could be formed already at earlier time points but they initially 
remain entrapped in the dense PLGA matrix. Release and subsequent detection of these 
aggregates might occur during PLGA degradation and matrix erosion. On the other hand, it 
could be the case that protein is adsorbed on the matrix surface during or after release which 
can be detected upon PLGA degradation and erosion.  
A B 
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The findings of the above study indicate that mAb prior to incubation as well as initially 
released mAb shows excellent stability. However, the stability of mAb that remains in the 
degrading PLGA matrix might be a critical aspect. 
3.4 Modification of PLGA formulation in regard to injectability and 
analysis of the resulting release profile 
The formulations containing 45 % Resomer® RG 502H had to be tested without syringe 
needle due to their high viscosity so far. In a next step, the formulations with 5 % mAb and 
P/T ratios ranging from 85 %/15 % to 33.3 %/66.6 % were intended to be modified in regard 
to injectability by reducing the polymer content to 30-35 % and the impact of the use of 26 G 
syringe needles on mAb release was studied. As the viscosity of the formulations was still 
too high for a manual injection, an injection aid was applied.  
The addition of only 15 % triacetin to the formulation still led to a high burst effect of 96 % 
(figure 2-15). The burst suppression by small amounts of triacetin that was detected at 45 % 
polymer and injection without needle could not be shown upon injection of a 30 % polymer 
containing formulation through a 26 G needle. Hence, both the reduction of PLGA content 
and the use of syringe needles apparently have a tremendous impact on the release profile. 
However, an increase in triacetin content up to 66 % led to a suppression of the burst effect 
and incorporation of the mAb in the precipitated matrix could be achieved. Due to high 
standard deviations, a significant difference between formulations with a P/T ratio between 
66.6 %/33.3 % and 33.3 %/66.6 % at a Resomer® RG 502H content of 30 % could not be 
identified. An increase of the PLGA content from 30 % to 35 % significantly reduced the 
initially released mAb amount from approximately 50 % to 8 % at a P/T ratio of 
33.3 %/66.6 %. The formulation with PLGA content of 35 % revealed the slowest mAb 
release profile with overall total mAb release of only 28 % after day 16. The effect of the 
polymer content on the release rate was also reported by Shively et al. and Eliaz et al. who 
found out that an increase in PLGA content reduces the overall drug release which might be 
attributed to an enhanced hydrophobicity and therefore reduced water uptake [59, 105]. A 
change in formulation consistency could also be hypothesized. Furthermore, it is expected 
that higher polymer content leads to the formation of a highly dense matrix and thus more 
efficient mAb incorporation. The high standard deviations can be attributed to differences in 
shape upon injection induced by the consistency of the formulations causing different initial 
release rates. Similar to experiments in section 3.2.4, the addition of high amounts of 
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triacetin led to a moldable formulation consistency (figure 2-16). Triacetin content of 15 % 
induced the formation of matrices that maintained the structure after injection. The results of 
the present study demonstrate that formulations based on Resomer® RG 502H were 
successfully modified with regards to injectability and the burst can be controlled by the 
addition of triacetin.  
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Figure 2-15 In vitro release profiles of mAb from formulations composed of 30 % to 35 % 
Resomer® RG 502H, a mAb content of 5 % and P/T ratios as indicated; 
injection through 26 G needles. 
    
Figure 2-16 Visual appearance of formulations with 30 % Resomer® RG 502H, a mAb 
content of 5 % and P/T ratios as indicated; injection through 26 G needles. 
3.5 In vitro release experiments of murine mAb from PLGA formulations 
and characterization of released mAb 
In order to gain insight into the pharmacokinetic profile of selected formulations, an in vivo 
study in rats was envisaged. As this study was intended to be performed with the murine 
mAb variant, the in vitro mAb release experiments performed with the human mAb were to 
be confirmed with the murine mAb first. Three formulations showing “long” (35 % 
Resomer® RG 502H and P/T ratio of 33.3 %/66.6 %), “intermediate” (30 % 
Resomer® RG 502H and a P/T ratio of 66.6 %/33.3 %) and “short release” (30 % 
Resomer® RG 502H and a P/T ratio of 85 %/15 %) were selected. The murine mAb content 
was reduced to 2.5 % due to pharmacological reasons. Injection occurred by means of 21 G 
P/T 33.3 %/66.6 % P/T 50 %/50 % P/T 66.6 %/33.3 % P/T 85 %/15% 
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syringe needles. This needle size was the largest possible needle size allowing IA injection in 
rats.  
Murine mAb release was studied during one week. A high burst of 62 % was observed in the 
“short release” formulation but not for the “intermediate” and “long release” formulations 
(figure 2-17). The obtained release profiles are overall comparable to the release profiles 
achieved with the human mAb. Slight differences concerning the total mAb release can be 
seen: while the “short release” formulation revealed a murine mAb release of 66 ± 4 % after 
7 days, complete release of the human mAb was observed in foregoing experiments. 
Regarding the “intermediate” and “long release” formulations, an overall significant slower 
murine mAb release was identified. After 7 days, only 5.2 ± 1.6 % (“intermediate”) and 2.1 ± 
1.9 % (“long”) were recovered in the release fractions. The observed differences can be 
ascribed to the use of different needle size in both experiments: while the experiment with 
the human mAb was performed with 26 G needles, the murine mAb formulations were 
injected through 21 G needles. Moreover, differently produced sd powders were employed 
and the drug load in the murine mAb formulations was reduced by factor 2 which might 
contribute to the observed release differences. However, overall three different release 
profiles were seen with both the human and the murine mAb variant which presents an 
essential aspect for the intended in vivo study. 
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Figure 2-17 In vitro release profiles of murine mAb (2.5 %) from “short release” (30 % 
Resomer® RG 502H, P/T 85 %/15 %, filled square), “intermediate release” 
(30 % Resomer® RG 502H, P/T 66.6 %/33.3 %, opened square) and “long 
release” formulations (35 % Resomer® RG 502H, P/T 33.3 %/66.6 %, triangle). 
Injected through 21 G syringe needles. 
HP-SEC analysis of release fractions revealed that the monomer content of murine mAb 
slightly decreased during the release experiment (figure 2-18). After 3 days, a reduction of 
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the monomer recovery to 86 ± 1.7 % (“short release” formulation) was detected. Incubation of 
murine mAb at 37 °C in PBS for the same period of time also led to a slight reduction in 
monomer recovery from 97 ± 0.4 % to 94 ± 0.4 % after 7 days. Only samples from “short” 
and “intermediate release” formulations up to day 3 could be analyzed. In all other samples 
the protein content was too low. 
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Figure 2-18 Monomer recovery of murine mAb (mu mAb) upon release from “short 
release” (black) and “intermediate release” formulation (white) at different time 
points compared to mu mAb standard solution and mu mAb solution incubated 
for 7 days at 37 °C in PBS / NaN3 (striped). 
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Figure 2-19 KD as determined by SPR of murine mAb (mu mAb) released from “short 
release” (black), “intermediate release” (white) and “long release” formulation 
(gray) at different time points compared to mu mAb standard solution (striped). 
Additionally, SPR analysis of the released murine mAb was performed in order to investigate 
its binding activity by determination of the dissociation constant (KD) of bound murine mAb 
antigen upon binding to the murine mAb. This value reflects the binding strength between 
two binding partners and is calculated by the quotient of association rate constant and 
dissociation rate constant of the complex. A strong binding is reflected by a low KD value. 
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Changes in KD values indicate structural and thus functional disorder of one of the reaction 
partners [109]. Released murine mAb fractions showed comparable KD values compared to 
murine mAb standard solution (figure 2-19) thus indicating that the binding activity of the 
murine mAb released from different PLGA formulations was preserved.  
3.6 In vivo study of mAb release from PLGA formulations after IA 
application 
In order to study the pharmacokinetic profile of the PLGA formulations upon IA administration 
in vivo, an animal study was performed. The previously characterized murine mAb containing 
PLGA formulations showing “long”, “intermediate” and “short release” profiles were analyzed. 
Moreover, the release of murine mAb from “long release” PLGA formulation and a murine 
mAb solution upon SC administration was tested in order to highlight the difference between 
the two application sites IA and SC.  
Serum analysis upon IA administration of the formulations at predefined time points revealed 
an increase in mAb concentration during the first 72 hrs (figure 2-20). During the time 
between 72 hrs and 168 hrs, a significant decrease in mAb concentration was observed. 
However, no significant difference in serum mAb concentration between “long”, 
“intermediate” and “short release” formulation could be seen.  
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Figure 2-20 Mean serum concentrations of murine mAb after IA administration of 50 µL of 
“short release” (30 % Resomer® RG 502H, P/T ratio 85 %/15 %, black), 
“intermediate release” (30 % Resomer® RG 502H, P/T ratio 66.6 %/33.3 %, 
white) and “long release” formulation (35 % Resomer® RG 502H, P/T ratio 
33.3 %/66.6 %, gray) determined via ELISA. 
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In table 2-4 the cmax and tmax values of the formulations are summarized. The PLGA 
formulations reached similar cmax values. While the “long release” and “short release” 
formulation showed a tmax of 72 hrs, the “intermediate release” formulation reached the 
highest serum level already after 48 hrs. In contrast, IA injected murine mAb solution 
revealed an approximately 50 % higher cmax which was reached already after 12 hrs. 
However, it has to be taken into account that the results of the mAb solution were obtained 
with a slightly higher dose. From other studies performed by the Abbott Bioresearch Center, 
it is known that a lower dosing leads to lower cmax but same tmax values. Therefore, it is 
expected that cmax of mAb solution after IA administration should be rather similar to the ones 
of the PLGA formulations at same dose. 
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Figure 2-21 Mean serum concentrations of murine mAb after SC administration of 50 µL of 
“long release” formulation (35 % Resomer® RG 502H, P/T ratio 
33.3 %/66.6 %, 2.5 % murine mAb, black) compared to murine mAb solution 
at same concentration (white). 
Different results were obtained after SC administration. As shown in figure 2-21, the “long 
release” PLGA formulation revealed significantly lower serum mAb concentrations compared 
to the mAb solution at same concentration. Both formulations showed the same tmax of 
72 hrs. The formation of anti-drug antibodies was observed in some animals that were dosed 
with the PLGA formulation. These animals were removed from the calculation. Concerning 
the impact of the application site, a significant influence on the mAb release rate was 
identified (table 2-4). The cmax of the “long release” formulation after IA administration was by 
a factor of 2.2 higher compared to the cmax after SC application. This effect might be ascribed 
to the exposure of the formulation to stronger mechanical manipulation in the knee joint 
compared to the subcutaneous space leading to enhanced mAb release. The mechanical 
influence would also explain the fact that no differences in serum levels between “short”,  
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Table 2-4 Dose, cmax and tmax of different formulations upon IA and SC administration.  
 
Dose [mg/kg] cmax [µg/mL] tmax [hr] 
“long release”, IA 4.5 27.9 ± 10.6 72 
“intermediate release”, IA 4.5 32.8 ± 9.1 48 
“short release”, IA 4.5 24.9 ± 9.8 72 
mAb solution, IA 6.5 46.5 ± 12.0 12 
“long release”, SC 4.5 12.6 ± 4.8 72 
mAb solution, SC 4.5 35.8 ± 6.0 72 
 
“intermediate” and “long release” formulation were seen. Besides the mechanical exposure it 
has to be taken into account that the absorption half-life of SC administered drugs is 
described to be longer than that of IA injected drugs. For the SC administration an absorption 
half-life of 1.4 day is reported for mAbs in general [110] while the synovial half-life of mAb 
upon IA injection was determined to be 0.5 days (data generated by Abbott). The 
physiological differences of the application sites might contribute to the detected higher mAb 
serum concentrations upon IA administration of the “long release” formulation compared to 
the SC application. The main reason for the short residence time of IA administered drugs in 
general is the rapid turnover of the SF within few hours. This effect is known to be even more 
accelerated in patients suffering from rheumatoid arthritis [13]. Due to this fact, the 
incorporation of the drug into a depot system for prolongation of the residence time at the site 
of application presents a promising approach. In vitro release experiments clearly revealed 
differences in mAb release profile between the different PLGA formulations tested. But these 
differences could not be seen in vivo. Even in comparison to a non-retarded mAb solution, no 
significant difference in cmax was observed. This poor in vitro – in vivo correlation might be 
ascribed to the high mechanical stress within the knee joint. This leads to spreading and 
kneading of the formulation with animal movement and consequently changes in shape, 
reduced diffusion path lengths of incorporated mAb and exposure of otherwise internal 
structures. These effects are strongly related to an increase in mAb release rate. Based on 
these findings, it can be concluded that the observed formulation differences in vitro are not 
sufficient to result in differences in vivo upon IA administration. Upon SC administration, 
however, the retardation effect was more pronounced which points to the impact of the 
mechanical conditions at the application site on the pharmacokinetic. From these findings it 
was concluded that the in vitro release model needs to be modified with respect to simulation 
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of the joint conditions in order to be able to predict the in vivo mAb release from PLGA 
formulations. 
3.7 PLGA formulation screening with the mechanical stress model 
The use of an in vitro release model that simulates well the physiological conditions is 
essential to predict in vivo drug release behavior. Up to now, no regulatory approved 
standard methods are available for in vitro release testing of sustained release parenteral 
formulations [111, 112]. In general, besides the presence of sink conditions, the appropriate 
in vitro model should induce the same drug release mechanism as in vivo [111]. This 
includes in the present case the simulation of the mechanical conditions in the joint that lead 
to spreading and kneading of the in situ forming matrix. This mechanical effect was to be 
implemented by the use of a punching tool that repeatedly penetrates into the incubated 
PLGA matrix. In order to assess the suitability of the model, the three formulations tested in 
vivo were analyzed. The injected volume of the formulations was reduced to 50 mg in 
analogy to the in vivo study. Directly after injection through a 21 G needle into PBS, the 
formulations were subjected to 20 penetration cycles by the punching tool. After 24 hrs of 
incubation at 37 °C the released mAb amount was quantified.  
All formulations revealed a high mAb release of equal or more than ~50 % (“short release” 
formulation 74.9 ± 4.1 %, “intermediate release” formulation 49.3 ± 7.7 %, “long release” 
formulation 54.4 ± 12.0 %). Comparing these results with the burst intensities of foregoing in 
vitro release experiments (section 3.4, “short release” formulation 96.8 ± 4.4 %, “intermediate 
release” formulation 37.5 ± 9.9 %, “long release” formulation 8.4 ± 8.9 %), the impact of 
mechanical treatment becomes obvious. Based on these results this model was applied in 
the following for further formulation screening.  
In order to identify a PLGA formulation that provides sufficient mAb retention, the PLGA 
content was increased up to 50 % irrespectively to injectability and the P/T ratio was varied 
from 40 %/60 % to 100 %/0 % at 5 % mAb content. Injection into the incubation medium was 
performed without syringe needle. After each sample draw, the formulations were subjected 
to mechanical manipulation with the punching tool. Significant differences in the release rates 
between the formulations were only observed at day 1 (figure 2-22). Until day 3, an intensive 
mAb release of more than 55 % was observed for all formulations. Subsequently, the release 
rate decreased for all formulations leading to a plateau formation. 
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Figure 2-22 In vitro release profiles of mAb from formulations composed of 40 % to 50 % 
Resomer® RG 502H, a mAb content of 5 % and P/T ratios as indicated; 
injection without syringe needle. 
A clear relation between burst intensity and P/T content and/or polymer content could not be 
identified as indicated by previous experiments. Compared to the experiments performed 
without mechanical treatment (section 3.4) the mAb release rate in all formulations was 
significantly accelerated at day 1 and 2 which can be explained by a substantially enhanced 
matrix swelling due to water uptake which was visually detectable by an increase in matrix 
volume. The water uptake led to dissolution of sd mAb particles incorporated in the matrix. 
During the second mechanical treatment, after the first sample draw at day 1, the swollen 
matrices were compressed and the dissolved mAb solution was squeezed out. The 
experiment was terminated after 22 days as no further mAb release was noticed despite 
visually detectable PLGA degradation. Analysis of the non-released mAb amount after 
lyophilization, extraction of PLGA with ethyl acetate and redissolution indicated that large 
protein particles had formed (see figure 2-23).  
  
Figure 2-23 Bright-field microscopy images after staining with protein detection kit of mAb 
extracted from PLGA matrices (42 % Resomer® RG 502H, P/T 66.6 %/33.3 %, 
mAb 5 %) at day 22. (A) placebo formulation, (B) active formulation. 
A B 
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Besides the incomplete release, fractions at day 1 and 2 exhibited a high turbidity. This was 
most pronounced in formulations with a P/T ratio of 100 %/0 % and these fractions were 
investigated for monomer recovery by HP-SEC. It could be shown that the relative monomer 
recovery was unchanged (figure 2-24). However, the total AUC was reduced from 90 % to 
70 % at day 2 indicating the presence of insoluble aggregates reflected by the sample 
turbidity. In conclusion, with the help of the mechanical treatment model a rapid mAb release 
and strong protein aggregate formation was observed which leads to the fact that after the 
initial burst, no further mAb release could be seen. 
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Figure 2-24 Results of HP-SEC analysis of release fractions at day 1 (d1) and day 2 (d2) 
of selected formulations composed of 40-50 % Resomer® RG 502H, a P/T 
ratio of 100 %/0 % and a mAb content of 5 %.  
Despite the successful incorporation of proteins in PLGA systems, the occurrence of protein 
instabilities and incomplete protein drug release is recognized as challenging [47, 64, 65, 84]. 
Protein instabilities include deamidation, chain cleavage and acylation by the polymer as well 
as protein aggregation induced by the acidic microclimate pH occurring during polymer 
degradation, the use of organic solvent in formulation preparation or protein adsorption 
phenomena to hydrophobic polymer surfaces or water/organic solvent interfaces [64, 65]. On 
the one hand, instabilities occurring at the beginning of a release experiment can be ascribed 
to formulation preparation and/or storage as well as to unfolding induced by water/organic 
phase interfaces. On the other hand, instabilities detected after the burst release are likely 
induced by polymer degradation, interactions between protein and polymer or protein 
adsorption to the solid PLGA matrix [64]. In the present study, both instabilities at the 
beginning and upon extraction at the end of the release experiment were identified. As mAb 
stability upon formulation preparation (see paragraph 3.3) and incubation in the organic 
solvents (see paragraph 3.2.2) has been demonstrated, the aggregate formation can be 
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attributed to mAb-polymer interactions such as adsorption on the hydrophobic surface and 
unfolding on water/organic phase interfaces after incubation in aqueous medium. As 
foregoing release experiments, performed with the vial model, rendered clear release 
fractions but incomplete overall release, it can be presumed that insoluble aggregates were 
retained inside the PLGA matrix. In opposite to that, application of the mechanical stress 
model led to release of both soluble and partly aggregated protein. These protein instabilities 
may be prevented by the addition of excipients such as surfactants, HSA, cyclodextrins, L-
arginine and/or pH modifying additives [65, 84]. However, the addition of excipients could 
have an impact on the protein release kinetic and complete suppression of aggregate 
formation due to stabilizing excipients might be challenging, as demonstrated by Morlock et 
al. [84]. Irrespective of protein instability, the experiments also demonstrate that the burst 
release could not be controlled by the formulation components.  
3.8 Modification of the reconstitution time of mAb powder and analysis of 
the impact on mAb release from PLGA formulations 
Previous experiments demonstrated that the burst release could not be controlled by 
formulation components when applying the mechanical stress model as in vitro release 
system. In order to achieve drug release over an extended period of time, a high mAb 
incorporation and thus low burst release is mandatory. To avoid rapid dissolution of mAb 
particles during the lag between formulation injection and PLGA hardening, the sd mAb 
powder was to be modified. This was to be achieved by adding either gel forming excipients 
or hydrophobic additives to the mAb solution which is dried. The gel forming excipient 
hydroxyethyl cellulose 400 (HEC) was expected to decelerate mAb dissolution by formation 
of a gel matrix. The addition of the hydrophobic amino acid isoleucine (ile) was presumed to 
reduce the particle hydrophilicity and prolong particle dissolution. 
Addition of 4 % HEC to the 10 % mAb spray drying solution and subsequent lyophilization of 
the highly viscous gel, milling on dry ice under nitrogen atmosphere and sieving of the 
powder through a 90 µm mesh led to prolongation of the reconstitution time to 62.1 ± 2 min 
vs. 3.2 ± 0.1 min (sd mAb without HEC). Ile at a concentration of 3 % (w/v) was added to the 
10 % mAb spray drying solution in a volumetric ratio of 1:2.3. After spray drying, the resulting 
powder showed a reconstitution time of 23.1 ± 13.4 min. 
In order to study whether the addition of dissolution modifying excipients could reduce the 
mAb burst release from PLGA formulations, HEC-mAb particles generated by lyophilization 
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as well as ile-mAb particles obtained by spray drying were dispersed in a PLGA formulation 
(40% Resomer® RG 502H, P/T ratio 40 %/60 %, 5% mAb content) respectively and the 
release was tested. Compared to a formulation without dissolution modifying agent, the use 
of HEC led to a more rapid and complete mAb release (figure 2-25). Instead of delaying the 
release by a gel matrix formation, the presence of HEC seemed to induce enhanced water 
influx into the system and swelling due to the hygroscopic character of the excipient. The 
overall release profile of the ile containing formulation was similar to the reference 
formulation with an even higher burst at day 1. In conclusion, it was not possible to achieve 
higher mAb retention in the solidifying PLGA matrix by modifying the dissolution rate of the 
mAb particles using HEC or ile.  
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Figure 2-25 In vitro release profiles of mAb from PLGA formulations (40 % 
Resomer® RG 502H, P/T ratio 40 %/60 %, mAb content 5 %) using HEC or ile 
as dissolution modifying excipients of the incorporated mAb particles in 
comparison to a formulation with non-modified sd mAb. 
In conclusion, the present study revealed that the development of an in situ forming PLGA-
based depot system for the sustained release of mAb is particularly challenging. This can be 
primarily ascribed to the high mechanical exposure of the formulation in the joint cavity that 
induces high mAb release during the lag between injection and PLGA hardening. As no 
promising formulation with the use of PEG 300 and triacetin could be indentified and protein 
aggregation during formulation incubation was observed, this formulation approach has 
limited suitability for the IA administration of mAb.  
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4 SUMMARY AND CONCLUSIONS 
The aim of this part of the thesis was the development and characterization of a PLGA-based 
formulation for the IA delivery of a therapeutic antibody. This concept encompassed the 
dispersion of the sd mAb in a non-aqueous PLGA solution that precipitates in situ upon 
contact with SF leading to a solidified matrix with entrapped mAb particles. Drug release was 
intended to take place concomitantly to polymer degradation. The formulation to be 
developed was meant to provide adequate injectability through thin syringe needles and mAb 
release over a prolonged time in order to reduce injection frequency. Moreover, the 
formulation was intended to provide a semi-solid consistency with adequate mechanical 
strength in order to resist the high mechanical impact present in the knee joint but avoid 
friction and restricted joint mobility. Additionally, the formulation components had to be highly 
compatible with the incorporated mAb and the application site. As these formulation 
characteristics are strongly dependent on the formulation components and the used 
concentrations, it was the first task to evaluate a suitable formulation composition and drug 
load with respect to the aforementioned prerequisites. Therefore, Resomer® RG 503H was 
used as polymer component. PEG 300 and triacetin were identified as suitable biocompatible 
polymer solvents. Analysis of the compatibility of the chosen solvents with the sd mAb did 
not show any instabilities detectable via turbidity measurements, HP-SEC, second derivative 
UV and FTIR spectroscopy. However, in vitro release experiments that were performed by 
injection of the formulations into PBS filled vials showed a nearly complete mAb release 
during the first 5 hrs indicating that mAb was not retained by the precipitating polymer. As a 
proof of principle, the polymer content was increased to 45 % and dissolved in either 
PEG 300, triacetin or in mixtures of both solvents. Instead of Resomer® RG 503H, 
Resomer® RG 502H, a polymer with lower MW and intrinsic viscosity was employed as 
higher concentrated polymer solutions were achieved. This experiment pointed out that mAb 
retention in the solidifying matrix in general is possible and that the initial burst und 
subsequent drug release are strongly reduced when higher concentrations of the 
hydrophobic polymer solvent triacetin are used. The reduced burst effect was explained by 
the high hydrophobicity of triacetin and therefore high affinity to the polymer leading to 
reduced water influx and mAb dissolution as well as by the change in formulation 
consistency. However, the addition of small amounts of triacetin drastically reduced the 
mechanical strength of the in situ formed matrix and therefore a balance between initial drug 
release and formulation consistency had to be found. In a further step, the formulation was 
52 CHAPTER 2 
 
modified with respect to injectability. Therefore, the PLGA content was reduced and 
formulations were injected through 26 G syringe needles into the release medium. It could be 
shown that these modifications had a significant impact on the mAb release pattern. Due to 
injection through the syringe needle, the surface area of the solidifying formulations 
increased drastically leading to an overall enhanced burst effect. However, it was clearly 
detectable, that with increasing triacetin as well as polymer content, the burst intensity was 
reduced. Based on these data, three formulations showing “long”, “intermediate” and “short” 
release profiles were selected for an in vivo study with rats using a murine mAb variant. 
Murine mAb analysis of the in vitro release fractions revealed a slight decrease in monomer 
recovery, detected via HP-SEC but unchanged binding affinity as identified by SPR. In 
accordance to these findings, unchanged tertiary protein structure as well as monomer 
recovery were observed for the human mAb upon release. Results of in vivo experiments 
clearly displayed that IA mAb retention was only marginal. No differences in serum mAb 
concentrations between “long”, “intermediate” and “short” release formulation were observed 
indicating that the mechanical impact induced by movement of the animals leads to 
unexpected high mAb release rates. In comparison to that, SC application of the “long 
release” formulation showed drastically lower serum mAb concentrations compared to SC 
administered mAb solution and to IA injected “long release” formulation which emphasizes 
the mechanical impact on mAb release. Based on these findings, the in vitro release model 
was modified by incorporation of mechanical manipulation at each sampling time point 
performed by formulation kneading with a punching tool. Formulations with various polymer 
contents and P/T ratios were investigated, but insufficient mAb retention resulted using this 
modified in vitro release model. This suggested that mAb dissolution occurs more rapidly 
than polymer precipitation. Finally, in an effort to reduce the burst release, HEC 400 and the 
hydrophobic amino acid ile were added to the mAb particle formulation respectively, in order 
to prolong the particle dissolution. Both modifications led to prolonged reconstitution times of 
the powders, but the mAb release from the PLGA formulation was not significantly delayed 
by the additives. Besides the insufficient mAb retention in the PLGA matrix, protein 
containing release fractions obtained during in vitro release experiments with the mechanical 
stress model were turbid. MAb analysis via HP-SEC did not show a reduction in monomer 
recovery but a significant decline of the total AUC. From these results it could be concluded, 
that substantial amounts of insoluble protein aggregates were formed already early during 
drug release in the course of solvent exchange, PLGA precipitation and formation of 
hydrophilic-hydrophobic interfaces. These instabilities were not detected in earlier studies as 
the insoluble aggregates were entrapped within the PLGA matrix and release of insoluble 
aggregates was only possible upon squeezing of the matrix by applying a punching tool.  
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The present study clearly demonstrates that the IA administration of in situ forming PLGA-
based mAb depots is particularly challenging due to the exposure to mechanical load and the 
rapid SF exchange that makes drug retention at the site of application difficult. Due to 
movement of the joints, the injected formulation is subjected to kneading effects that lead to 
increase of the formulation surface accompanied by a reduction of the diffusion path length 
of incorporated mAb followed by release. In order to avoid enhanced mAb release during 
joint movement, form-stable matrices with short lag phase between injection and hardening 
appear necessary that resist the high mechanical exposure. The development of a 
formulation with high mechanical strength and low burst effect was shown to be highly 
challenging as the use of high amounts of PEG 300 led to form-stable matrices but was 
accompanied by a high burst. In contrast, the addition of small amounts of triacetin reduced 
the burst but simultaneously drastically reduced the mechanical strength. A compromise 
between consistency and drug release might be possible by using the dispersion or solution 
of the drug in a polymer solution which is subsequently dispersed in a second oil phase 
[113]. Upon SC or intra muscular injection, microparticles are reported to be formed due to 
influx of aqueous body fluids and/or diffusion of the solvent out of the polymer droplets 
leading to polymer precipitation and thus incorporation of the drug that can be released in a 
controlled manner. Moreover, preformed drug-loaded small size PLGA implants could be 
used to overcome the burst release. 
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CHAPTER 3 
THE USE OF POLYSACCHARIDES AS CARRIERS FOR THE 
INTRA-ARTICULAR DELIVERY OF A THERAPEUTIC 
ANTIBODY 
1 INTRODUCTION 
Natural polymers, such as polysaccharides, are considered as attractive carrier materials for 
the delivery of drugs due to their excellent biocompatibility, biodegradability, abundant 
availability in nature and low costs [114, 115]. They provide unique physico-chemical 
properties as well as gelation characteristics that can be beneficial when drugs are 
envisaged to be released in a controlled way [116]. Depending on their functional groups, 
polysaccharides are divided into non-polyelectrolytes and polyelectrolytes at physiological 
pH. The group of polyelectrolytes can be further categorized into positively charged (e.g. 
chitosan) and negatively charged polysaccharides, such as alginate, hyaluronic acid (HA), 
heparin or chondroitin sulphate [114]. Some of the functional groups are able to be 
derivatized by e.g. esterification [117] or acrylation [118]. This is of advantage if improved 
viscoelastic properties, enhanced resistance towards enzymatic degradation, reduced 
solubility or prolonged residence time upon injection are desired. Apart from that, these 
functional groups are reported to interact ionically with charged drug substances, such as 
proteins [119, 120], to affect drug delivery.  
Remarkable attention has been drawn to the use of HA as carrier material in drug delivery. 
Besides its biocompatibility and biodegradability, it exhibits excellent viscoelastic properties 
and the ability to create a dense network in which a drug can be incorporated. Especially, the 
development of HA based formulations for therapeutic proteins and peptides has been in the 
focus of various research groups. Due to the hydrophilic nature, HA based drug delivery 
systems provide a protein- and peptide-compatible environment [121]. Concerning non-
parenteral drug delivery, studies can be found dealing with the enhanced nasal bioavailability 
of insulin, released from HA ester microspheres in sheep [122]. More intensively, the 
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parenteral protein delivery from HA based systems was investigated. Prisell et al. analyzed 
the release of human recombinant insulin-like growth factor-I from HA gels (0.5 – 2 %) in 
rats. Upon subcutaneous (SC) injection, a significantly slower release was demonstrated 
compared to the HA-free formulation [123]. Meyer et al. investigated the in vitro stability and 
in vivo release profile of recombinant human granulocyte colony stimulating factor (rHG-CSF) 
from viscous HA solutions (2 %) after SC injection in hamsters. No significant protein 
aggregation upon storage for 6 weeks at 37 °C was detected. In vivo, prolonged elevated 
rHG-CSF plasma levels were observed [124]. In another study, the release of growth 
hormone (GH) from HA-poly(acrylic acid) sponges was monitored in vitro. It could be shown 
that this delivery system appears to be highly suitable to achieve a sustained drug release 
[125]. Tian et al. investigated the release of an IgG antibody from a HA based gel that was 
covalently linked with the antibody via a hydrolytically unstable hydrazine linker. Upon 
hydrolysis the antibody was continuously released over a period of 400 hrs [126]. Despite the 
numerous in vitro and in vivo drug release studies found in literature, only little emphasis has 
been placed on the input in detailed analysis of protein conformational stability after 
incorporation into the carrier matrix [47]. The preservation of the protein´s conformational 
stability presents a crucial aspect as its bioactivity largely depends on the native folding. 
Moreover, protein denaturation is known to induce immunologic reactions [127] and presents 
therefore a critical parameter.  
Especially in the local treatment of joint diseases the use of HA as a carrier for disease 
modifying drugs presents a promising approach. It combines the beneficial 
viscosupplementative properties of HA with the pharmacologic effects of the incorporated 
drug. Various studies are reported in literature dealing with the concept of local intra-articular 
(IA) delivery. Lyons et al. combined a viscous HA gel with triamcinolone crystals that are 
discussed to dissolve slowly in presence of HA and thus provide a sustained release effect. 
Moreover, the risk for crystal induced joint inflammation is reported to be reduced by the 
protective gel [128]. Another patent deals with the incorporation of an antimicrobial agent into 
a HA gel intended for the treatment or prevention of joint infections upon IA injection [129]. 
Furthermore, studies about the IA application of HA gels containing a hyaluronidase inhibitor, 
such as xylose sulphate, dextran sulphate or heparin sulphate, are reported. The 
incorporated enzyme inhibitor is meant to prevent HA degradation by hyaluronidase and 
therefore provides a long-lasting therapeutic effect [130]. These studies, however, were only 
performed with low molecular weight drugs. The applicability of this concept to high 
molecular weight drugs like therapeutic proteins, however, is not highlighted in literature and 
is therefore the basis for the present project. 
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In this study the suitability of HA as a carrier for the local IA delivery of a therapeutic 
monoclonal antibody (mAb) was investigated. Local IA delivery of a drug presents an 
attractive approach to generate high drug concentrations at the site of application while 
reducing the systemic exposure. Especially for expensive drugs with low oral bioavailability, 
such as therapeutic proteins, this way of application is of enormous interest. However, 
because of the potentially rapid clearance from the joint cavity, the need for drug delivery 
systems with prolonged residence time arises [90]. As the IA injection is accompanied by a 
certain risk of joint infections, the injection frequency has to be limited. Therefore, a high drug 
load per injection is aspired. In the present study, a highly-concentrated HA-based mAb 
formulation was to be developed first. In order to achieve a high residence time upon 
injection, the formulation was meant to provide a high viscosity but acceptable injectability. 
Different HA materials with various molecular weights and concentrations were to be 
evaluated. In a subsequent step, the compatibility with the used mAb was assessed by a 
bundle of analytical methods. This should provide a detailed understanding concerning the 
protein´s stability upon incorporation into the HA matrix. Additionally, the presence of 
interactions between HA and mAb as well as the in vitro and in vivo release behavior were 
investigated.  
Another promising approach for prolongation of the residence time of a therapeutic protein at 
the site of injection is the use of polysaccharides with a high charge density that induce the 
formation of insoluble complexes with the protein via charge interactions. The tendency to 
interact electrostatically with positively charged proteins at physiological pH is described to 
be enhanced with increasing negative charge density of the polysaccharide [131]. As sodium 
alginate is known to possess a higher charge density than e.g. HA, it was used in this study. 
The conditions at which mAb precipitation occurs were intended to be indentified. 
Interestingly, sodium alginate is used in food industry for purification of whey solutions via 
precipitation of proteins and subsequent separation [132]. The use of freeze-dried collagen-
alginate complexes, cross-linked via multivalent cations, presents a medical application of 
protein-alginate precipitates. In this context, the precipitates are used as soft tissue implants, 
wound dressings or prosthesis [133]. The concept of protein precipitation by sodium alginate 
in the field of drug delivery, however, has not been reported in literature and was to be tested 
for the IA delivery of mAb. 
58 CHAPTER 3 
 
2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Monoclonal antibody (mAb) 
The mAb (IgG1) with a molecular weight (MW) of 148 kDa was formulated at 70 mg/mL, pH 
5.2 with sodium chloride (105.5 mM), monobasic sodium phosphate dihydrate (5.5 mM), 
dibasic sodium phosphate dihydrate (8.6 mM), sodium citrate (1.16 mM), citric acid 
monohydrate (6.19 mM), mannitol (65.9 mM) and polysorbate 80 (0.1 %). The bulk solution 
was stored at -80 °C until use. Prior to use, protein solutions were filtered through an 
Acrodisc® 0.2 µm PVDF syringe filter (Pall, Dreieich, Germany). For in vivo experiments, 
instead of the human mAb, the murine variant was used, which was formulated in histidine 
buffer (15 mM) at pH 6.0 and a concentration of 24.5 mg/mL. 
2.1.2 Hyaluronic acid (HA) 
For gel preparation, four different HA qualities were used, as summarized in table 3-1. 
Table 3-1 Description of HA powders used. 
HA batch No. Source MW [MDa] Residual moisture content [% w/w] 
006 
Shiseido 
(Japan) 
~1.07 7.4 
A07A ~1.50 4.5 
TP0711-1 ~2.19 6.1 
PHI 923 HTL Bio (France) ~1.2 10.4 
2.1.3 Excipients, reagents and chemicals 
Table 3-2 lists the excipients, reagents and chemicals used throughout this chapter. All 
substances were of analytical grade. Ultrapure water for all buffers was used from a PureLab 
UV/UF system (Elga LabWater, Celle, Germany). 
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Table 3-2 List of excipients, reagents and chemicals used in this chapter. 
Excipients, chemicals, reagents Source 
Calcium chloride Merck, Darmstadt, Germany 
Citric acid monohydrate Carl Roth, Karlsruhe, Germany 
Dibasic potassium phosphate AnalaR Normapur, VWR international, 
Leuven, Belgium 
Dibasic sodium phosphate dihydrate Merck, Darmstadt, Germany 
Ethanolamine Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
Glycine Merck, Darmstadt, Germany 
L-histidine Merck, Darmstadt, Germany 
Mannitol Riedel-de Haen, Seelze, Germany 
Monobasic sodium phosphate dihydrate Merck, Darmstadt, Germany 
N-ethyl-N9-(dimethylaminopropyl) carbodiimide Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
N-hydroxy succinimide Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
ortho-phosphoric acid Zentrale Versorgung LMU München, 
Germany 
Polysorbate 80 Merck, Darmstadt, Germany 
Potassium chloride Caelo, Hilden, Germany 
Sodium alginate, viscosity 4-12 mPas  
(1 %, 25 °C) 
Sigma-Aldrich Chemie, Steinheim,  
Germany 
Sodium alginate, viscosity 350-550 mPas  
(1%, 20 °C) 
AppliChem, Darmstadt, Germany 
Sodium azide Acros organics, Geel, Belgium 
Sodium citrate Caelo, Hilden, Germany 
Sodium chloride AnalaR Normapur, VWR international, 
Leuven, Belgium 
Sodium hydroxide, 1M Merck, Darmstadt, Germany 
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2.2 Methods 
2.2.1 Preparation of formulations 
HA powder was filled into a Luer-Lock syringe (VWR International, Ismaning, Germany). Into 
a second syringe the appropriate amount of mAb buffer, pH 5.2, was filled. The two syringes 
were connected by a syringe adapter (Braun, Melsungen, Germany). Both components were 
mixed by moving the syringe plungers back and forth until a homogeneous gel was obtained. 
The received HA gel with a concentration of 3.5 % was filled into one of the two syringes and 
was allowed to swell overnight at low temperature (storage at 2-8 °C). For final formulation 
preparation, the HA gel was further mixed with the 2.5-fold amount of either mAb solution, 
70 mg/mL (active), or mAb buffer (placebo) by means of the previously described dual-
syringe system. This aimed at a HA-mAb gel with a HA concentration of 1 % and a mAb 
concentration of 50 mg/mL (active).  
2.2.2 Characterization of HA bulk material by Karl-Fischer analysis 
The residual moisture (RM) content of the HA bulk material was determined by coulometric 
Karl-Fischer titration using an Aqua 40,00 titrator with headspace module (Analytik Jena, 
Jena, Germany). Therefore, 10-20 mg of the respective HA powder were accurately weighed 
into a 2 R glass vial, sealed with rubber stopper and heated up to 100 °C. For determination 
of the RM content, the evaporated water was transferred into the titration solution. As 
reference, a standard with defined RM was employed (apura® water standard oven 1 %, 
Merck, Darmstadt, Germany). 
2.2.3 Characterization of HA gels 
2.2.3.1 Rheometry 
The rheological properties of prepared gels were studied on a plate-cone rheometer (Physica 
MCR 100, Anton Paar, Ostfildern, Germany) with exponentially in- and decreasing shear rate 
(0.01-500 s-1, 500-0.01 s-1) at a gap position of 0.042 mm. The applied cone exhibited a 
diameter of 50 mm and an angle of 1 °. Analysis was performed at 6, 20 and/or 35 °C using 
600 mg of the respective gel. The viscosity at 1 s-1 was used for comparison. 
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2.2.3.2 Turbidity 
The turbidity of diluted HA gels in formazine nephelometric units (FNU) was determined with 
a NEPHLA turbidimeter (Dr. Lange, Düsseldorf, Germany), based on light scattering in an 
90 ° angle at λ=860 nm. The system was calibrated with a formazine standard. Prior to 
analysis, the gels were diluted 1:5 with mAb buffer and centrifuged in order to remove air 
bubbles (10 min, 10,000 rpm). Approximately 2 mL of each sample were used for analysis. 
2.2.3.3 Injectability 
The maximal force, required for injection of 0.4 mL of the gel into air, was determined by 
means of a TA.XTplus texture analyzer (Stable Micro Systems, Surrey, UK) at ambient 
temperature. This value was defined as the highest force measured before the plunger 
reached the end of the syringe after having overcome the plunger-stopper breakloose force. 
For this purpose, 1 mL Luer-Lock syringes (VWR International, Ismaning, Germany) 
connected to 26 G or 23 G syringe needles (Terumo, Leuven, Belgium) were clamped in a 
tripod underneath the punching tool. The crosshead velocity was set to 1 mm/s, a 
representative velocity for the manual injection [96]. After 20 s, the measurement stopped 
automatically.  
2.2.4 Characterization of mAb  
2.2.4.1 UV spectroscopy (OD 280, second derivative, absorbance at 350 nm) 
Protein concentrations were determined photometrically on an Agilent 8453 UV-Vis 
spectrometer (Agilent Technologies Deutschland, Böblingen, Germany) equipped with a 
Peltier temperature controller (Agilent Technologies, Böblingen, Germany) at λ=280 nm and 
25 °C. Quartz UV cuvettes with a path length of 1 cm were employed. An extinction 
coefficient of either 1.39 mL·mg-1·cm-1 (mAb) or 1.4 mL·mg-1·cm-1 (murine mAb) was used. 
Samples were diluted to a concentration of 0.1 to 0.7 mg/mL prior to analysis. Corresponding 
blank spectra were subtracted. Smaller sample volumes were analyzed undiluted with a 
NanoDrop ND-2000 spectrometer (PEQLAB Biotechnologie, Erlangen, Germany). Second 
derivative protein spectra were calculated between 240 and 350 nm by means of the 
ChemStation software. Determination of turbidity of protein containing samples was 
performed with a UV plate reader (FLUOstar Omega, BMG LABTECH, Ortenberg, Germany) 
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in 96-well plates (Nunc®, Sigma-Aldrich Laborchemikalien, Seelze, Germany) at a filling 
volume of 300 µL. 
2.2.4.2 Fourier transform infrared spectroscopy (FTIR) 
FTIR spectra were recorded with the Tensor 27 FTIR spectrometer (Bruker Optics, Ettlingen, 
Germany) using a Bio-ATR unit (attenuated total reflection) connected to a thermostat at 
20 °C (DC30-K20, Thermo Haake, Dreieich, Germany). Corresponding blank spectra were 
subtracted from the protein spectra. After a 120-scan measurement, the second derivative 
spectrum was generated (OPUS, Bruker Optics, Ettlingen, Germany). For investigation of 
changes in secondary protein structure, the vector normalized second derivative spectra 
between the wavenumbers of 1720 and 1580 cm-1 were compared with the spectra of the 
native, untreated protein. 
2.2.4.3 Differential scanning calorimetry (DSC) 
A DSC 821e (Mettler Toledo, Giessen, Germany) was used for determination of the melting 
temperature (Tm) of the protein in presence and absence of HA. Approximately 60 mg of the 
respective sample was weighed into a 100 µL aluminium crucible and sealed with caps. 
Analysis was performed with a heating rate of 1.0 °C/min from 25-90 °C. Tm was calculated 
by evaluating the midpoint of the endothermic transition peak of the protein.  
2.2.4.4 High performance size exclusion chromatography (HP-SEC) 
Size exclusion chromatography was applied for quantification of soluble aggregates, 
monomer and fragments of the mAb. The measurement was performed on a HPLC 1100 
chromatograph (Agilent Technologies Deutschland, Böblingen, Germany) using a 
Superose® 6 10/300 GL column (GE Healthcare, Uppsala, Sweden) with UV detection at 214 
and 280 nm. The mobile phase consisted of 0.15 M sodium chloride and 0.02 M sodium 
phosphate, adjusted to pH 7.5 with ortho-phosphoric acid. The flow rate was 0.5 mL/min. 
Samples were diluted with mobile phase to a target concentration of 1 mg/mL and 
centrifuged for 10 min at 12,000 rpm (Sigma 1-15, Sigma Laborzentrifugen, Osterode am 
Harz, Germany) in order to remove insoluble aggregates. Chromatograms were integrated 
manually by means of the ChemStation software Rev. B.02.01 (Agilent Technologies 
Deutschland, Böblingen, Germany). For quantification, the area under the curve was used. 
Protein concentrations were calculated based on a calibration curve.  
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2.2.4.5 MAb bioassay 
The biological activity of the mAb after incorporation into the HA formulation was assessed 
by a cell based bioassay performed at Abbott, Ludwigshafen according to the Abbott 
standard protocol. This assay is based on the determination of cell viability upon 
neutralization of cytotoxic recombinant human TNF (rhTNF) by the mAb. Mouse L-929 cells 
were incubated with defined amounts of rhTNF and various concentrations of mAb. After 
incubation for 48 hrs at 37 °C the survived cells were stained with crystal violet and their 
color intensity was determined photometrically at 620 nm. The relative bioactivity [%] was 
then calculated in comparison to a reference mAb solution. HA-mAb samples were diluted to 
a mAb concentration of 1 mg/mL with formulation buffer. As reference, a mAb solution at 
same concentration was employed. A placebo sample (HA solution, 0.02 %) was used as 
negative control. Samples were analyzed in duplicate. 
2.2.4.6 Surface plasmon resonance (SPR) measurements  
Binding between HA and mAb was monitored by SPR on a BIACORE-3000 instrument (GE 
Healthcare, Uppsala, Sweden) using BIAevaluation® software. The experiments were 
performed at the Abbott Bioresearch Center in Worcester, USA. The mAb was immobilized 
on a carboxy methylated (CM3®) chip according to the standard immobilization procedures 
described by Biacore Life Science. The sensor chip surfaces of sample and reference cells 
were first activated by a 6-min injection of a solution containing 0.4 M N-ethyl-N9-
(dimethylaminopropyl) carbodiimide and 0.1 M N-hydroxy-succinimide. After mAb 
immobilization in the sample cell via amine linkage of lysine residues, residual activated 
carboxymethyl groups of both sample and reference cell were deactivated with 
ethanolamine. In order to verify that the immobilized mAb is still intact, the binding capacity 
was determined with a TNFα solution, carried through the sample cell. As running buffer, 
10 mM phosphate buffer, pH 7.4 with an ionic strength of 125 mM was used, representative 
for the ionic strength (I) of the mAb formulation. Furthermore, in a second experiment, a 
buffer, consisting of 15 mM histidine (I<1 mM, pH 7.4) was used in order to exclude shielding 
effects induced by the running buffer. HA gels (3.5 %) were diluted with running buffer to a 
concentration of 0.05 %. This dilution step was necessary as the viscosity of undiluted 
samples was too high for injection into the highly sensitive cells. After a 100 µL injection, HA 
samples were carried through the cell with a flow rate of 10 µL/min. The experiment was 
performed at 25 °C.  
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To distinguish between electrostatic interactions and binding events related to the specific 
binding site of mAb, a TNF-unspecific human IgG1 (pI=7.2) was immobilized in a third flow-
cell. Regeneration of the sensor surface for the next experiment was performed using a 
10 mM glycine solution at a pH of 1.5. 
2.2.5 In vitro mAb release tests 
In vitro mAb release experiments were carried out using flow-through cells, illustrated on 
figure 3-1. Approximately 1 g of HA-mAb gel was accurately weighed into the lower donor 
compartment. The donor compartment was separated from the upper acceptor compartment 
by a 0.2 µm pore size polyethersulfone membrane (Supor®-200, Pall Corporation, Michigan, 
USA) in order to avoid rapid dissolution of the gel and simulate the mAb release from the 
synovial cavity. The contact area between both compartments was 240 mm2. The tightly 
closed cells were placed in a water bath, heated up to 37 °C (Thermomix 1441, B. Braun 
Biotech International, Melsungen, Germany). PBS containing 0.01 % sodium azide was 
pumped through the acceptor compartment of the cell with a flow rate of 1.5 mL/hr by means 
of silicon tubes and 60 mL syringes (Terumo, Leuven, Belgium), clamped into a syringe 
pump (Kd Scientific, Holliston, USA). The flow rate was chosen in accordance to the synovial 
turnover within a healthy knee joint [13]. At predefined time points, the released fraction were 
collected in 50 mL-centrifuge tubes (VWR International, Ismaning, Germany) and analyzed 
photometrically for protein concentration. 
 
Figure 3-1 Opened diffusion flow-through cell used for mAb in vitro release experiments 
consisting of upper acceptor compartment (A) and lower donor compartment 
(B). 
A 
B 
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2.2.6 In vivo experiments with HA-mAb gel  
An in vivo study was performed at the Abbott Bioresearch Center in Worcester, USA for 
assessment of the pharmacokinetic profile of the HA-mAb formulation upon IA injection. The 
study was carried out according to a granted animal test proposal in healthy Lewis rats. 
Instead of the human mAb, the murine mAb variant was used. As the murine mAb was 
formulated in histidine buffer (15 mM) at a concentration of 24.5 mg/mL, buffer exchange and 
up-concentration to 50 mg/mL was performed using Vivaspin® centrifugation tubes with a 
MW cutoff of 30 kDa (Satorius Stedim, Göttingen, Germany). Prior to administration, animals 
were anaesthetized in an anesthesia chamber using isoflurane (5 %) and oxygen. Once the 
rat was completely anesthetized, the right knee was shaved. Animals were dosed IA with 
50 µL of a HA-mAb formulation (1 %, 35.7 mg/mL) via injection through the patella into the 
knee joint. For injection, 26 G syringe needles were employed. A HA-free mAb solution 
served as reference. The study was performed during 48 hrs. At predefined time points 
(2 hrs, 4 hrs, 12 hrs, 24 hrs and 48 hrs) animals were sacrificed in an anaesthesia chamber 
using CO2. Synovial fluid (SF) samples were obtained from each animal via synovial wash. 
Therefore, a small volume of PBS was injected into the joint cavity and subsequently 
removed. Moreover, blood samples were taken at each time point. Both, SF and blood 
samples were analyzed for mAb concentration via ELISA according to the Abbott standard 
protocol.  
2.2.7 Lyophilization of mAb-alginate mixtures 
Lyophilization of mAb-alginate mixtures was performed in 6 R glass vials (Schott, Mainz, 
Germany) on an Epsilon 2-6 D freeze-drier (Christ, Osterode, Germany). 2 mL per vial were 
frozen to -50 °C at 0.5 °C/min and held for 2 hrs. Primary drying was carried out at a shelf-
temperature of -25 °C and 0.045 mbar within 30 hrs. Secondary drying was conducted at a 
shelf-temperature of 40 °C within 10 hrs at 0.045 mbar. Lyophilized vials were stoppered at 
800 mbar under nitrogen atmosphere.  
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3 RESULTS AND DISCUSSION 
3.1 Screening of HA materials and identification of suitable HA gel 
concentrations 
For selection of the most suitable HA material, four HA qualities were evaluated. In order to 
provide a long residence time of the formulation at the site of application, the main focus was 
to develop a highly viscous gel. Besides viscosity, the injectability presents a basic 
requirement in formulation development also considering that thin needles are desired. 
Within this scope, the injection forces using 26 G needles were determined. Viscosity 
measurements were performed at 6 °C and 35 °C. The lower temperature was meant to 
resemble refrigerated product storage temperature, whereas the temperature of 35 °C 
presents the mean temperature in healthy knee joints [134]. HA gels were prepared and 
analyzed at 1 % and 1.5 %. 
All gels showed a reversible shear thinning behavior as exemplarily illustrated in figure 3-2. 
The enormous decrease in viscosity with increasing shear rate presents a special property of 
HA. Various scientists studied this characteristic which can be explained by the ordering of 
the coiled HA molecules with the streamline of the flow [135-137]. This phenomenon is 
advantageous since it allows the injection through thin syringe needles, where high shear 
rates are applied. At the site of application, where the shear rates are small, it leads to the 
spontaneous formation of a viscous gel [138].  
To be able to compare the results, the viscosity values at a shear rate of 1 s-1 were used 
(figure 3-3). By increasing the MW from 1.07 to 2.19 MDa the viscosity was raised by factor 4 
to 5. This is consistent with literature where a non-linear relation between viscosity and MW 
of HA is described [139]. As expected, also the augmentation of the HA concentration 
induced a viscosity increase. This effect was shown to be non-proportional to the employed 
HA concentration. The 1 % HA gel with a MW of 2.19 MDa (TP0711-1) exhibited a viscosity 
of 53.2 Pa·s whereas at a concentration of 1.5 % the viscosity was elevated to 132 Pa·s. A 
similar trend was observed by Krause et al. [140] who analyzed HA gels (MW 1.6 MDa) at 
various concentrations. Comparing these results with the viscosity values of the present 
study, it becomes evident that at comparable concentrations, MW and shear rate the gels of 
the present study showed higher viscosity values. These differences can be explained by the 
fact that the source of HA has a great influence on the material properties which makes 
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direct comparison difficult [140]. Besides the influence of MW and concentration, the impact 
of the temperature on viscosity decrease was clearly visible (figure 3-3).  
0.01 0.1 1 10 100
0.01
0.1
1
10
100
1000
v
is
co
si
ty
 
[P
a*
s]
shear rate [s-1]
 
Figure 3-2  Viscogram of a HA gel 1 % (TP0711-1) at 20 °C with increasing (filled square) 
and decreasing (open square) shear rate.  
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Figure 3-3  Viscosity at 1 s-1 of different HA gels (batch name as indicated) at a 
concentration of 1 % (A) and 1.5 % (B) at 6 °C (black) and 35 °C (white).  
Injectability measurements were performed with the HA gels of batch TP0711-1 as this 
material provided the highest viscosity. Elevated injection forces were demonstrated for 
increasing HA content. However, a force of 4 N was not exceeded (HA gel 1 %: 1.9 ± 0.2 N, 
HA gel 1.5 %: 3.1 ± 0.5 N). In the following, the required injection force for higher 
concentrated HA gels was tested. The maximal injection force increased from 4 ± 0.4 N to 
5.7 ± 0.7 N if the HA concentration changed from 2 % to 3 %, indicating that elevated HA 
concentrations could be used. In order to keep the injection forces as low as possible, HA 
material of batch TP0711-1 in a concentration of 1 % was chosen for following experiments.  
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3.2 Compatibility of mAb with HA 
3.2.1 Impact of mAb on HA gel characteristics 
One of the major requirements in formulation development is the compatibility of the carrier 
material with the incorporated drug. The compatibility of the chosen HA gel with the mAb 
solution was assessed by visual inspection and turbidity measurements. These analytical 
methods were used to identify any precipitation phenomena or changes in color or clarity 
indicating physical instabilities of both components. Additionally, viscosity and injectability 
measurements were intended to provide information concerning the impact of the protein on 
the gel characteristics.  
3.2.1.1 Visual inspection and turbidity measurements of HA-mAb gel 
Visual inspection over a storage period of one month at 2-8 °C revealed no evidence of 
visible particle formation due to precipitation or phase separation. Turbidity measurements 
did not show any significant difference between the sum of the individual gel components 
and the HA formulation containing the mAb (figure 3-4). These results underline the absence 
of pronounced interactions between mAb and HA leading to particle formation >100 µm.  
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Figure 3-4 Turbidity contributions of the HA-mAb gel (1 %, 50 mg/mL) (A) and the sum of 
the individual components (B) after 1:5 dilution with mAb buffer. 
3.2.1.2 Rheometry and injectability of HA-mAb gel 
Rheometry did not reveal any significant differences between the viscosities of the placebo 
HA gel and the HA gel containing the mAb (HA gel 1 % 49.3 ± 7.3 Pa·s, HA-mAb gel 58.5 ± 
1.6 Pa·s at a shear rate of 1 s-1, figure 3-5). The impact of proteins on the viscosity of HA is 
controversially discussed in literature. More in general, Alfrey et al. argued that substances 
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that alter the solvent character may have any impact on the intrinsic viscosity of polymer 
solutions [141]. Balasz et al. reported about the absence of any impact of synovial proteins 
on the rheological properties of HA [135]. Contrary to that, the group of Fraser pointed out 
that proteins present in the SF are able to change the viscosity of HA [142]. Hence, the 
impact of proteins is hardly predictable and appears to be dependent on the HA 
characteristics (MW, concentration) as well as on the protein type and concentration.  
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Figure 3-5 Viscosity of HA placebo gel (1 %, square) and HA-mAb gel (1 %, 50 mg/mL, 
triangle) with increasing (filled) and decreasing (open) shear rate at 20 °C.  
Both HA placebo gel (1 %) and HA-mAb gel (1 %, 50 mg/mL) revealed excellent injectability 
through 23 G (Ø 0.6 mm) and 26 G (Ø 0.45 mm) syringe needles with maximal injection 
forces below 4 N (figure 3-6). The injection force slightly increased from 2.0 ± 0.2 N (HA 
placebo gel, 26 G) to 3.3 ± 0.1 N (HA-mAb gel, 26 G) in presence of mAb.  
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Figure 3-6 Injection force - plunger displacement diagram of injectability measurements of 
HA placebo gels (1 %, gray) and HA-mAb gels (1 %, 50 mg/mL, black) using 
26 G (thick line) and 23 G (thin line).  
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It has been described in literature that formulations that require injection forces ranging up to 
25 N in vivo are considered to be easy to inject [21]. As the experiment was performed by 
injection into air, a slight force increase in vivo is expected due to the limited physiological 
space and the higher resistance that needs to be overcome [21]. The use of a 23 G syringe 
needle aimed at an improvement of the injectability. This can be explained by the larger inner 
radius of the needle that influences the injectability according to the law of Hagen-Poiseuille 
with the power of 4. However, it has to be taken into consideration that the use of larger 
syringe needles is known to influence patient compliance due to injection pain [96]. With 
respect to potential in vivo animal studies, the use of thin needle sizes should always be 
aspired.  
3.2.2 Impact of HA on mAb conformational stability 
Besides the gel characteristics of the formulation, the maintenance of the mAb 
conformational stability is of major importance. The three-dimensional protein structure can 
be influenced by various factors such as formulation components, pH, ionic strength and/or 
the formulation preparation process [143]. In the following, the effect of HA on the mAb 
stability was assessed via DSC, second derivative UV and FTIR spectroscopy and HP-SEC.  
Tm in presence and absence of HA was studied with the help of DSC analysis. The pure 
protein solution, used as reference, showed one irreversible endothermic event at 69.9 ± 
0.1 °C. No difference in Tm value was identified after embedment into the HA gel, indicating 
that the thermal mAb stability remains untouched when adding HA. Matheus et al. [144] 
demonstrated with nano DSC measurements that an IgG1
 
mAb undergoes two endothermic 
events at ~73 °C and at ~80 °C. The first Tm value can be attributed to the unfolding of the 
Fab fragment whereas the second transition is related to the Fc fragment. In the present 
study, only one endothermic event was observed, due to the lower sensitivity of DSC 
measurements in crucibles compared to micro or nano DSC. Second derivative UV 
spectroscopy of the diluted HA-mAb gel revealed no peak shifts compared to the native mAb, 
indicating that the tertiary protein structure is not affected by the mAb embedment into the 
HA gel (figure 3-7 A). Analysis of the second derivative FTIR spectra demonstrated the 
absence of significant alterations in the characteristic IR bands between the wavenumbers of 
1720 and 1560 cm-1 due to the combination of the mAb with HA (figure 3-7 B). Hence, also 
the secondary protein structure is maintained.  
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Figure 3-7 Second derivative UV (A) and area normalized FTIR spectra (B) of diluted HA-
mAb gel (1 %, 50 mg/mL, black line) compared to native mAb solution 
(50 mg/mL, gray line). Artificial offset for clarity. 
No additional aggregate or fragment formation was observed by HP-SEC analysis. The 
monomer recovery after addition of HA was preserved (mAb standard 99.7 ± 0.03 %, mAb in 
HA gel 99.8 ± 0.02 %). Conformational protein structure analysis was completed after the 
result had been reached that the mAb bioactivity after incorporation into the HA gel was fully 
maintained (102 ± 3.5 %). 
3.3 Investigations on interactions between HA and mAb via surface 
plasmon resonance measurements 
As described in the introduction, HA presents a linear polysaccharide with polyelectrolyte 
properties due to the repeating D-glucuronic acid monomers. With an estimated acid 
dissociation constant (pKa) of 3, attributed to the carboxylic groups [145, 146], the polymer is 
negatively charged under physiological conditions [147]. At physiological pH, proteins bear 
positively charged residues ascribed to basic side chains of the amino acids lysine (pKa 
10.5), histidine (pKa 6.0) and arginine (pKa 12.5). The presence of these opposite charges 
enables electrostatic interactions between the polysaccharide and the protein. Interactions 
between HA and mAb could not be identified with the help of DSC, second derivative FTIR 
and UV measurements, analysis of turbidity, injectability, and viscosity as no alterations in 
either HA gel or mAb characteristics were detectable. These findings indicate that the 
potentially present interactions between HA and mAb are weak and for detection a highly 
sensitive method has to be used. Several studies have been reported which elucidate the 
non-specific interactions between HA and other macromolecules [137] and a few studies 
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investigated the occurrence of electrostatic complex formation between HA and e.g. BSA or 
lysozyme [148, 149]. In general, electrostatic interactions are dependent on the 
concentrations of the reaction partners, the ionic strength and pH of the surrounding medium, 
the charge density of the polyelectrolytes and the stereochemical accessibility of the charged 
moieties [147]. Macromolecular interactions can be identified by several methods. One 
approach uses the detection of precipitation phenomena by measuring the turbidity [147]. 
Another possibility is the application of chromatography where one of the complex partners is 
attached to a column resin and retention of the analyte is monitored [119]. Electrophoresis 
was successfully employed to elucidate the presence of electrostatic interactions as the 
mobility rate is affected if complex formation takes place [119]. Biomolecular interactions can 
be analyzed at high sensitivity using a quartz crystal microbalance. This method allows the 
detection of the mass increase per area upon binding of the analyte to the complex partner 
that is bonded on the chip surface. On account of the high sensitivity, the low required 
sample volumes and concentrations, surface plasmon resonance (SPR) was chosen as a 
method to gain insight into binding events between HA and mAb. This method was already 
successfully applied for analysis of interactions between heparin and complement proteins 
[150]. In brief, SPR allows the monitoring of weak interactions between two macromolecular 
components in real-time without labeling. The ligand is immobilized on a sensor chip and the 
binding partner is passed over the sensor surface by applying a continuous flow. Upon 
binding between ligand and partner, the refractive index on the sensor surface changes [150, 
151].  
Injection of the HA solution into the placebo cell led to a strong background signal of 80 RU 
induced by the refractive index difference between running buffer (10 mM phosphate, 
I=125 mM, pH 7.4) and HA solution (figure 3-8 A). In the sample cell with immobilized mAb, a 
signal response of 125 RU was detected (figure 3-8 B). Based on the resulting signal 
difference of 45 RU, a slight binding of HA to the mAb was concluded. The same signal 
response of 125 RU was identified by analysis of the immobilized human IgG upon injection 
of the HA solution (figure 3-8 C).  
Lowering the ionic strength of the running buffer to <1 mM in order to reduce shielding effects 
[147] led to an increase of the response to 140 RU with immobilized mAb (figure 3-8 D). 
Again, this result was verified by analysis of the immobilized human IgG where the same 
signal intensity was obtained (figure 3-8 E).  
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Figure 3-8 Sensorgrams upon injection of HA solutions (0.05 %) diluted with either 
10 mM phosphate buffer (pH 7.4, I=125 mM) (A-C) or 15 mM histidine buffer 
(pH 7.4, I<1 mM) (D, E) into cells with (A) CM3® chip without ligand 
immobilization (placebo), (B, D) immobilized mAb and (C, E) immobilized 
human IgG.  
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These results indicate that the ionic strength has a substantial influence on the interaction 
between HA and mAb as the response difference between mAb and placebo cell increased 
from 45 RU to 60 RU when the ionic strength was reduced from 125 mM to <1 mM. The 
presence of electrostatic interactions was underlined by analysis of the human IgG that 
revealed the same binding intensity to HA. Hence, the interaction between mAb and HA 
presents a non-specific charge-induced binding event. Even though mAb and human IgG 
have a different pI value (mAb: pI=8.25 vs. human IgG: pI=7.2), the difference of the 
molecule net charge is not expected to have a significant impact on the binding intensity to 
HA. Mathes et al. determined the protein net charge of an IgG1 (pI=8.33) as a function of the 
pH. Between pH 7 and 8 the protein net charge did not change considerably [152]. Taking 
into account that some IgG antibodies are known to occure in isoforms at a pI range of up to 
1.5 pH units [152], the overall net charge difference between mAb and human IgG is 
expected to be marginal. As shown by Yadav et al., the charge distribution within the 
molecule plays an important role in electrostatic interactions of proteins [153] and the regions 
responsible for electrostatic binding might be similar in charge despite slightly different 
overall molecule net charge. Overall, the interactions were only slightly pronounced, which 
can be attributed to comparibly low charge density of both interaction partners. Comper et al. 
reviewed that at physiological pH, carboxylic groups of polysaccharides interact less 
intensively with positively charged molecules than e.g. sulfate groups. Besides the type, also 
the charge density affects the interaction strength. The number of negatively charged groups 
per disaccharide can vary from one (HA) up to four (heparan sulphate) [147]. In this context, 
Gelman et al. demonstrated a higher interaction strength of heparan sulfate with the the 
cationic polypeptide poly-L-lysine compared to HA [154]. These examples clearly indicate 
that the extent of polysaccharide-protein interactions is dependent on various factors.  
3.4 In vitro release of mAb from HA gels 
The in vitro mAb release was tested for one week using a diffusion flow-through cell. In order 
to slow down dissolution and dilution of the HA gel, simulating the release from the synovial 
cavity, a separating 0.2 µm pore size membrane was used. It is known from literature that the 
synovial half-life of HA ranges from 10 to 16 hrs depending on the MW [155, 156].  
Similar to the results of Prisell [123], the mAb release was significantly reduced in presence 
of HA (figure 3-9). The control formulation revealed an intensive initial burst of 30 % within 
4 hrs that was not seen in the HA formulation. After 7 days, only 75 % were released from  
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Figure 3-9 Cumulative in vitro release of mAb from HA-mAb gel (1 %, 50 mg/mL, open 
square) compared to a HA-free control formulation (mAb solution 50 mg/mL, 
filled square). 
the HA formulation. However, the shape of both release curves showed high similarity. This 
leads to the presumption that the overall slower mAb release from the HA gel can be 
attributed to initial retardation of the mAb diffusion out of the gel induced by the dense gel 
structure. After day one, the initial retardation effect was diminished as the slope of the curve 
resembles that of the control formulation. This can be ascribed to dilution and dissolution 
effects of the gel induced by the continuous flow of the release medium that is pumped 
through the cell. Obviously, the interactions between HA and mAb, detected with the help of 
SPR measurements, have no impact on the mAb release from the gel. The dissolution of HA 
during the first day followed by adjustment of the mAb release rate to the reference agrees 
with the synovial half-life of HA known from literature. Assuming that mAb retention is related 
to the presence of HA, enhanced mAb release is expected upon dilution of the HA gel and 
clearance from the donor compartment. The detected initial retardation phenomenon, also 
known as macromolecular sieving or dynamic filtration effect, is described in literature as a 
typical property of polysaccharide gels [135, 137, 157, 158]. The mobility of molecules 
entrapped in a three-dimensional gel network built by overlapping HA chains is strongly 
reduced as soon as a certain concentration is exceeded. De Smedt et al. investigated the 
diffusion behavior of fluorescein isothiocyanate (FITC)-dextran in HA solutions of different 
concentrations via fluorescence recovery after photobleaching (FRAP). It was demonstrated 
that the diffusion coefficients were decreased with increasing HA concentration. Based on 
these results, they were able to calculate the average mesh size of the three-dimensional HA 
network [157]. From these findings, it can be concluded that the detected retardation effect is 
expected to be even more pronounced if a higher HA concentration would be used. This 
would lead to a higher density of the gel network. Taking into account that the present 
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formulation revealed an excellent injectability, as presented in section 3.2.1.2, a further 
increase in HA concentration appears feasible. The increase of the HA concentration up to 
3 % was shown to provide adequate injection force using 26 G syringe needles and could 
therefore be used for prolongation of the mAb release.  
3.5 In vivo mAb release from HA gels after IA application 
In order to gain some insight into the pharmacokinetic profile of the HA-mAb formulation and 
the physiological impact on the mAb release, an in vivo study with healthy rats was 
performed. Serum mAb concentrations in animals that were dosed with the HA-free mAb 
solution increased during the first 12 hrs until a maximum level was reached (figure 3-10 A). 
This level sustained up to 48 hrs. In contrast, HA-mAb gels initially revealed significantly 
lower serum levels at 2 and 4 hrs. After 12 hrs, a serum level similar to the HA-free 
formulation was reached that declined again after 48 hrs. Thus, overall lower serum levels 
were achieved with the HA gel. The increase in serum mAb concentration during the first 
12 hrs was accompanied by a decrease in SF mAb concentration (figure 3-10 B). Initially, 
high SF levels were detected in both sample and reference that decreased over time. Only 
after 4 hrs a significant difference in SF level between buffer and HA gel was detectable. 
After 48 hrs, the remaining mAb amount in SF was only 1.7 % of the initial concentration. 
The use of the SF / serum concentration ratio (SF / S ratio) of a drug is known to be a 
valuable tool to compare e.g. the permeability of the synovial membrane for proteins [159]. In 
the present study, this ratio was used as an indicator for the retention of the administered 
protein at the site of application: a high SF / S ratio reflects high mAb retention in the joint 
cavity. It can be concluded from the results that HA affects the mAb retention at the site of 
application at the beginning of the study only (figure 3-10 C). After 12 hrs, no difference 
between HA gel and HA-free formulation can be seen as the SF / S ratio of both formulations 
reaches the same level of approximately 3. These findings indicate that the mAb retention at 
the site of application due to the HA gel is only marginal. The study reflects well the findings 
of the in vitro study where significant slower mAb release rates were observed during the first 
12 hrs.  
Based on the results from the in vitro release study, a poor in vitro – in vivo correlation can 
be seen with respect to the duration of mAb release. While a continuous mAb release over 
7 days was observed in vitro, rapid mAb release from the gel during 48 hrs was identified in 
vivo. This could be attributed to the mechanical conditions present in the knee joint that were  
 
CHAPTER 3  77 
 
2 4 12 24 48
0
10
20
30
40
50
60
70
m
ea
n
 
se
ru
m
 
m
A
b 
co
n
ce
n
tr
at
io
n
[µg
/m
L]
time [hr]
A
    
2 4 12 24 48
0
100
200
300
500
1000
1500
2000
m
ea
n
 
sy
n
o
v
ia
l f
lu
id
 
m
A
b 
co
n
ce
n
tr
at
io
n
[µg
/m
L]
time [hr]
B
 
0 10 20 30 40 50
1
10
100
SF
 
/ S
 
co
n
ce
n
tr
at
io
n
 
ra
tio
time [hr]
C
 
Figure 3-10 Mean serum mAb concentrations (A), mean synovial fluid mAb concentrations 
(B) and ratio of SF and serum mAb concentration (SF / S) (C) at various time 
points in Lewis rats after IA administration of 50 µL of a HA-mAb formulation 
(1 %, 35.7 mg/mL, white) or a mAb solution (35.7 mg/mL, black).  
not simulated in the in vitro release model. As the animals were moving physiologically few 
minutes after injection, the formulations were presumably squeezed between the upper and 
lower knee compartment within the joint cavity. These mechanical conditions could have a 
tremendous impact on the release profile induced by an increase of the contact area 
between gel and surrounding SF. As animals can hardly be immobilized over a longer period 
of time, the exact impact of the mechanical conditions on mAb release is difficult to 
determine. Besides the mechanical influence, the synovial turnover of HA has to be taken 
into account. Brown et al. [155] reported that the synovial half-life of HA with a MW of 
>6.0 MDa in rabbits is only 13.2 hrs. Lower MW species with a MW of 90 Da revealed a 
similar half-life of approximately 10.2 hrs. Lindholm et al. studied the half-life of HA of 
different MW upon IA injection in carpal joints of horses. They reported about a half-life of 
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12.5 and 16 hrs for high and low MW, respectively [156]. Thus, the clearance of HA from the 
synovial space is only slightly influenced by the MW of the used HA species and is rather 
short [155]. However, Larsen et al. demonstrated that cross-linking of HA causes a 
significant prolongation of the residence time of IA administered HA. The mean half-life of 
cross-linked HA was prolonged to 8.8 ± 0.9 days [160]. The rapid clearance from the synovial 
space in general can be explained by the anatomical, fenestrated structure of the synovial 
membrane offering a trans-synovial diffusion in and out of the joint cavity [161]. This flux, 
however, is reported to be size-dependent. Molecules with a radius less than 250 nm were 
shown to exhibit a rapid diffusion in and out of the joint cavity. HA is described to have a 
radius of gyration of 28 – 260 nm, depending on the MW [139]. Also mAb with a radius of 
~5 nm is consequently rapidly cleared from the synovial space which was distinctly seen in 
the present in vivo study. Based on these facts it can be concluded that the molecular size of 
injected molecules plays a pivotal role in the synovial residence time. Consequently, the 
limited mAb retention at the site of application in the present in vivo study can be ascribed to 
both the mechanical conditions and the rapid clearance of the used HA type from the joint. In 
order to prolong the residence time of mAb upon IA injection, the use of a high MW cross-
linked HA species presents a promising approach as synovial clearance is expected to be 
reduced. 
3.6 Investigations on the interactions between sodium alginate and mAb 
Numerous polysaccharides such as HA, chondroitin sulphate and alginate possess 
negatively charged groups at a broad pH range. Depending on the type and number of these 
functional groups, the polyelectrolyte character is differently pronounced. HA with only one 
carboxylic group per disaccharide exhibits a lower negative charge density than alginate that 
possesses two carboxylic groups per disaccharide. As described in section 3.3, slight 
interactions between HA and mAb were identified with the help of SPR measurements. With 
increasing charge density of the polysaccharide the tendency to form complexes with 
positively charged proteins is reported to be enhanced [131]. As the interactions between HA 
and mAb did not affect the mAb release at an adequate level, the interactions between 
sodium alginate and mAb had to be studied. Alginate in solution can be cross-linked in 
presence of bivalent cations such as calcium, which results in gelation. The formation of 
insoluble complexes between alginate and proteins is described in literature [132]. 
Reversible mAb precipitation within the joint cavity presents a promising approach to prolong 
the residence time at the site of application due to reduced synovial clearance. As 
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precipitation phenomena in general occur as soon as the solubility is exceeded, dissolved 
and precipitated mAb exist in equilibrium. Upon injection into the joint cavity, dissolved mAb 
is expected to be continuously cleared which causes redissolution of precipitated mAb and 
thus generation of a sustained release system. In order to identify potentially relevant 
parameters and conditions at which insoluble mAb-alginate complexation occurs, mixtures of 
mAb with two different sodium alginate qualities (η(1 %, 25 °C) 4-12 mPa·s (low MW), η(1 %, 20 °C) 
350-550 mPa·s (high MW)), ratios (mAb:alginate ratio 5, 1 and 0.5 / 0.3 (high MW / low 
MW)), and calcium concentrations (0, 10, 50 and 150 mM) were prepared. It was known from 
preliminary experiments that mAb precipitates in presence of alginate when spray-dried 
powder is reconstituted with water. In order to generate dry particles in a high throughput 
setup, lyophilization was used instead of spray drying. Reconstitution of the dry cakes was 
performed with 10 mM histidine buffer at ionic strength of 10 mM at pH 5.5 and 7.4.  
3.6.1 Impact of mAb-alginate ratio on the precipitation efficiency prior to 
lyophilization 
After adding alginate to the mAb solution, samples immediately turned turbid (figure 3-11 A). 
Both low and high MW alginate samples revealed high turbidity values next to the detection 
limit of the instrument (3.5 AU). In order to quantify the dissolved mAb amount, samples were 
centrifuged for 30 min at 25,000 x g and the supernatant was analyzed. Overall high 
precipitation efficiencies above 70 % were observed. With increasing mAb-alginate ratio, the 
precipitation efficiency increased (figure 3-11 B).  
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Figure 3-11 Results of turbidity measurements (A) and determination of the mAb 
precipitation efficiency (B) of mAb-alginate mixtures prior to addition of calcium 
and lyophilization.  
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In order to study the reversibility of mAb precipitation and the impact on mAb conformational 
stability, the insoluble pellet of the sample with a mAb-alginate ratio of 1 after centrifugation 
was resuspended in either 500 µL histidine buffer (I=150 mM, pH 5.5) or water. It became 
apparent that the addition of histidine buffer induces a drastic reduction of the turbidity. This 
indicates that the precipitate partially redissolved (figure 3-12). However, the turbidity level of 
the placebo sample was not reached which underlines the fact that either a slight fraction of 
precipitated mAb remained or mAb partially irreversibly unfolded. The redissolved fraction 
was analyzed by HP-SEC. It was shown that the monomer content was preserved (mAb-high 
MW alginate 99.7 ± 0.03 %, mAb-low MW alginate 99.8 ± 0.01 %, mAb standard 99.7 %). 
These results demonstrate that mAb redissolution is not accompanied by formation of 
additional soluble aggregates of fragments. As the resuspension in water did not lead to any 
reduction in turbidity, it can be concluded that the ionic strength and/or the pH contribute to 
the effect of mAb precipitation in presence of alginate. 
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Figure 3-12 Turbidity measurements of mAb mixtures with low and high MW alginate after 
mixing, separation of the precipitate via centrifugation and resuspension in 
either histidine buffer (I=150 mM, pH 5.5) or water.  
Analysis of the second derivative FTIR spectra after resuspension in water revealed that the 
strong band at 1640 cm-1 was shifted to lower wavenumbers (figure 3-13). This signifies the 
presence of perturbations in the secondary protein structure. In contrast, upon resuspension 
in histidine buffer (I=150 mM, pH 5.5) no peak shifts were noticable and a high similarity to 
the control spectrum was seen. Based on these results it was concluded that mAb 
precipitation in presence of alginate is accompanied by conformational changes in the 
secondary protein structure. Due to the reversibility of these changes, mixtures of mAb and 
sodium alginate could be an interesting formulation approach. 
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Figure 3-13 Second derivative FTIR spectra of alginate-mAb pellets resuspended in either 
histidine buffer (I=150 mM, pH 5.5) or water. As reference, a native 
mAb solution was used.  
3.6.2 Impact of mAb-alginate ratio, MW of alginate, calcium concentration and pH 
of the reconstitution buffer on efficiency of mAb precipitation by alginate 
after lyophilization 
The conditions at which insoluble mAb-alginate complexes are formed were within the scope 
of the present study. After lyophilization and reconstitution of the samples with histidine 
buffer (10 mM, I=10 mM) at a pH of either 5.5 or 7.4, all samples turned turbid. In absence of 
calcium ions, complete mAb precipitation was observed. With increasing calcium 
concentration, the turbidity and precipitation efficiency of the samples decreased (figure 3-14 
and 3-15). The addition of calcium ions also induced gelation of alginate which can be 
ascribed to cross-linkage of the polysaccharide induced by ionic interactions. The gelation 
intensity was shown to correlate with the used calcium concentration. Based on these results 
it was concluded that mAb is replaced by the calcium ions from the charge-complex. As the 
calcium-alginate complex seems to have a higher solubility than the mAb-alginate complex, a 
turbidity decrease was observed. The protein-alginate interaction in the presence of calcium 
was also investigated by Zhao et al. [120]. They analyzed BSA-alginate complexes in 
conjunction with calcium ions. It was demonstrated that BSA can be replaced by calcium ions 
from the alginate complex due to a higher binding strength.  
Besides the calcium concentration, also the mAb-alginate ratio was identified to affect the 
mAb precipitation efficiency. This effect was clearly pronounced at low concentrations 
(10 mM) or in the absence of calcium. At these conditions, increased precipitation efficiency 
was observed when the mAb-alginate ratio was raised from 0.3/0.5 to 5. The effect can be 
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explained by presuming that charge-induced precipitation phenomena are favoured close to 
complete charge neutralization of the complex. At a low mAb-alginate ratio, the negative 
charges of the alginate molecules are not saturated. Induced by the unsaturated negative 
charges of the alginate molecules, the formation of insoluble mAb-alginate complexes is 
incomplete. With increasing mAb-alginate ratio, the number of mAb molecules per alginate 
molecule is raised. This causes saturation of the negative charges and therefore higher 
precipitation efficiency. Hence, in order to achieve complete complex precipitation, a molar 
excess of mAb needs to be provided. At higher calcium concentrations (>10 mM) the impact 
of the mAb-alginate ratio on mAb precipitation efficiency was not apparent. 
   
   
Figure 3-14 Exemplary pictures of samples 24 hrs after reconstitution with histidine buffer 
(I=10 mM) at pH 5.5 with a mAb-alginate ratio of 5 and calcium concentrations 
ranging from 10 to 150 mM.  
Overall slightly higher precipitation efficiencies were achieved at pH 5.5 compared to 7.4. At 
pH 5.5 and 7.4, sodium alginate (pKa1 3.4, pKa2 3.6) is calculated to be nearly completely 
dissociated with 99.0% and 99.9 % respectively. Similar to that, the degree of dissociation of 
the positively charged amino acids arginine (pKa 12.5) and lysine (pka 10.5) is estimated to 
be 99.9 % at both pH values. Histidine (pKa 6.0) is nearly completely undissociated (3.8 %) 
at pH 7.4 while exhibiting a degree of dissociation of 76 % at pH 5.5. Therefore, the observed 
higher precipitation efficiencies at pH 5.5 can be attributed to enhanced electrostatic 
interactions between mAb and alginate caused by a slightly higher positive net charge at pH 
5.5 compared to pH 7.4. 
high MW alginate 
calcium 10 mM 
high MW alginate 
calcium 50 mM 
high MW alginate 
calcium 150 mM 
low MW alginate 
calcium 10 mM 
low MW alginate 
calcium 50 mM 
low MW alginate 
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The MW of alginate had no significant influence on the mAb precipitation efficiency. Besides 
the impact of calcium concentration, pH and mAb-alginate ratio, also the ionic strength is 
reported to affect protein-alginate interaction. De Kruif et al. [131] reported about the 
dissociating effect of salts on the polyelectrolyte complex formation. With increasing salt 
concentration, the charges were shielded by the salt ions leading to reduction of electrostatic 
interactions. As shielding effects could contribute to the detected reduction of the 
precipitation efficiency at increasing calcium concentrations, the predominant mechanism of 
the mAb-alginate complex dissociation in the presence of calcium ions was to be 
investigated by replacing calcium chloride with sodium chloride.  
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Figure 3-15 MAb precipitation efficiency in dependence of the calcium concentration and 
the mAb-alginate ratio for low (A, B) and high MW alginate (C, D). Samples 
were lyophilized and reconstituted with 10 mM histidine buffer, pH of 5.5 (A, C) 
or 7.4 (B, D).  
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3.6.3 Impact of the salt concentration and type on the efficiency of mAb 
precipitation by alginate 
The influence of the salt concentration and type on the mAb precipitation efficiency in the 
presence of alginate was studied with the help of the replacement of calcium chloride with 
sodium chloride. Ionically cross-linkage of alginate is not described for sodium ions [162]. 
Thus, replacement of mAb from the alginate complex caused by binding competition with 
sodium ions is not expected. However, the impact of shielding effects on the mAb-alginate 
interaction should be detectable. For this purpose, mAb-alginate mixtures at a ratio of 5 and 
with low MW alginate were prepared. 
With increasing salt concentration the turbidity decreased significantly (figure 3-16). A slight 
turbidity at 150 mM NaCl persisted. As expected, no gelation of alginate was observed upon 
addition of NaCl. In absence of salt and in presence of 10 mM calcium chloride and sodium 
chloride the mAb was precipitated completely (figure 3-17). In the presence of 50 mM and 
150 mM NaCl the precipitation efficiency was strongly reduced to about 80 % and 10 % 
respectively. Thus under physiological conditions the mAb precipitation appears to be highly 
reversible. In the presence of calcium, the precipitation efficiency was reduced to 20 % 
already at 50 mM. The different impact of NaCl and CaCl2 concentration on mAb precipitation 
efficiency at 50 mM and 150 mM can be explained by the 3 times higher ionic strength in 
CaCl2 compared to NaCl at same molar concentration Consequently, 50 mM CaCl2 and 
150 mM NaCl, rendering the same ionic strength of 150 mM, show comparable precipitation 
efficiency. The slightly increased precipitation efficiency at 150 mM CaCl2 may be an artifact 
due to mAb entrapment in the stronger calcium alginate gel network prohibiting recovery in 
 
 
Figure 3-16 Visual appearance of samples containing mAb-low MW alginate mixtures in a 
ratio of 5 after addition of 10, 50 or 150 mM NaCl.  
NaCl 0 mM NaCl 10 mM NaCl 50 mM NaCl 150 mM placebo 
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Figure 3-17 MAb precipitation efficiency [%] from mAb-low MW alginate mixtures (ratio of 
5) after addition of different molar concentrations of CaCl2 (black) or NaCl 
(white).  
the supernatant. However, as the overall precipitation efficiency drastically decreased with 
increasing salt concentration, it can be concluded that this phenomenon is attributed to 
shielding effects instead of competitive effects between mAb and Ca2+ ions with alginate 
binding. 
3.6.4 Determination of the precipitation efficiency of mAb-alginate mixtures at 
physiological conditions 
The previous experiments had revealed that the mAb precipitation efficiency strongly 
depends on the ionic strength of the surrounding medium. In terms of an application in vivo, 
the impact of physiological conditions on the mAb precipitation is of major importance. 
Therefore, lyophilized mAb-alginate mixtures were reconstituted with physiological 
phosphate buffer (PBS 10 mM phosphate, 145 mM sodium chloride, pH 7.4). Besides the 
visual appearance and the turbidity 24 hrs after reconstitution, the mAb precipitation 
efficiency was determined.  
All samples almost completely dissolved independent of the mAb-alginate ratio with only a 
slight turbidity remaining compared to placebo samples (figure 3-18 A). Quantification of mAb 
in the supernatant after centrifugation revealed that more than 95 % of the mAb-alginate 
complexes redissociated (see figure 3-18 B). Thus, the stronger precipitation phenomena of 
mAb with alginate compared to HA that could potentially enhance the residence time of the 
mAb at the site of application, are expected to be less pronounced in vivo. Little information 
concerning the synovial half-life of sodium or calcium alginate can be found in literature.  
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Figure 3-18 Turbidity (A) and mAb precipitation efficiency (B) after reconstitution of mAb-
low and high MW alginate mixtures of varying ratios in PBS.  
However, the synovial clearance of the high MW alginate might be reduced compared to the 
used HA caused by the higher estimated average MW of alginate. The application of 
insoluble mAb-alginate complexes could be beneficial when incorporated into a solidifying or 
gel forming matrix based on e.g. PLGA, thermo-reversible polymer systems or thermally 
induced gelling systems. On account of the solid or semi-solid matrix, the influx of the 
surrounding medium is expected to be decelerated and therefore alginate-mAb complex 
dissociation and mAb release should be retarded. Besides this approach, mAb retention at 
the site of application could moreover be achieved by steric entrapment of the drug into an 
alginate gel cross-linked with calcium ions. Drug release from this system is reported to be 
governed by diffusion and polymer erosion [163]. Due to a slow disintegration of the gel 
network induced by loss of calcium ions, mAb release over a prolonged period of time can be 
achieved. As alginate solutions start gelation immediately after contact with calcium, the 
injectability of mAb containing calcium alginate systems is limited. Hence, a simultaneous 
injection of mAb-alginate solution and calcium chloride solution using a double barrel syringe 
could be applied, leading to in situ gelation of the alginate and entrapment of mAb [164].  
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4 SUMMARY AND CONCLUSION 
In this study the suitability of HA as carrier for local IA delivery of a therapeutic mAb was 
investigated. The focus was on the development of a HA-mAb formulation with high protein 
concentration, high gel viscosity but adequate injectability through thin syringe needles. 
Based on viscosity and injectability measurements, the HA material with a MW of 2 MDa at a 
concentration of 1 % revealed the most suitable gel characteristics. After incorporation of the 
mAb at a concentration of 50 mg/mL into the gel, no significant impact of mAb on the HA gel 
characteristics could be identified. The compatibility of HA with the incorporated mAb was 
assessed via various analytical methods. It was demonstrated that the secondary and tertiary 
protein structure as well as the protein unfolding temperature remained unchanged upon HA-
mAb formulation preparation. Moreover, the mAb monomer content and the bioactivity of the 
protein were shown to be preserved. Based on these promising results, the presence of HA-
mAb interactions that could contribute to mAb retention in the gel was analyzed with the help 
of SPR. The existence of weak interactions between HA and mAb was demonstrated 
employing a 10 mM phosphate buffer pH 7.4 with an ionic strength of 125 mM. The result 
was underlined by making use of a running buffer with reduced ionic strength where potential 
shielding effects induced by the buffer components were reduced. The binding signal 
increased with decreasing ionic strength, hence it was concluded that the observed HA-mAb 
binding is based on charge-charge interactions. In vitro release experiments revealed an 
overall significantly slower mAb release compared to a HA-free control formulation caused by 
restricted mobility and reduced diffusion rate of the molecules entrapped in the dense gel 
network. This effect occurred at the beginning of the experiment where dissolution of the gel 
by the release medium was less pronounced. Already after 24 hrs, the mAb release rates 
from buffer and HA gel became identical. Similar results were obtained upon IA 
administration of the HA-mAb formulation in rats. There, slightly lower mAb serum levels 
were achieved for the gel system compared to the HA-free mAb solution during the first 
12 hrs. Afterwards, no significant difference in mAb release from HA gels or buffer was 
identified which indicates that dilution and dissolution of the HA gel followed by synovial 
clearance of HA molecules strongly reduces mAb retention at the site of application. Based 
on the fact that the density of the gel network has been described to be dependent on the HA 
concentration, the mAb release could be further prolonged by increasing the HA 
concentration.  
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As the charge interactions between HA and mAb were apparently too weak to affect mAb 
release from the HA gel, combinations of sodium alginate that exhibits a higher charge 
density than HA, and mAb were studied. It was shown that alginate strongly interacts with 
mAb leading to complete mAb precipitation. The conditions at which mAb precipitation 
occurs were demonstrated as being slightly dependent on pH and mAb-alginate ratio. The 
presence of increasing concentrations of calcium ions induced gelation of alginate but 
simultaneously caused mAb redissolution. Increased ionic strength was shown to reduce the 
alginate-mAb precipitation considerably. At physiological conditions 96 % of mAb were 
dissolved. Hence, enhanced mAb retention at the site of application due to formation of 
alginate induced mAb precipitates is expected to be less effective.  
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CHAPTER 4 
DEVELOPMENT OF A PHOSPHOLIPID-BASED FORMU-
LATION FOR THE INTRA-ARTICULAR DELIVERY OF A 
THERAPEUTIC ANTIBODY 
1 INTRODUCTION 
For many years, the use of lipid-based systems for the delivery of proteins or peptides has 
been in the focus of numerous research groups. In addition to the development of solid lipid 
implants [70] or solid lipid nanoparticles [71], the use of lipid-based vesicular drug delivery 
systems for proteins or peptides offers a promising approach for generating prolonged 
therapeutic responses [165]. Such lipidic drug delivery systems are advantageous if drugs 
with short half-lives are administered or local drug retention at the injection site is desired. 
Vesicular drug delivery systems, such as liposomal formulations, have been intensively 
characterized with respect to vesicle size [166] and lamellarity [167], drug encapsulation 
efficiency [168] or stability during storage and upon administration in vivo [169]. Numerous 
studies have described experiments where liposomal formulations were applied to achieve 
the sustained release of proteins. The encapsulation of interleukine-2 into liposomes was 
shown to effectively prolong the half-life in comparison to free drug after intraveneous (IV) 
injection [170]. As reported by Stevenson et al., the encapsulation of insulin in phospholipid 
vesicles revealed prolonged plasma levels after subcutaneous (SC) administration in diabetic 
dogs, compared to free insulin [171]. Furthermore, drastically increased residence time of 
liposomal encapsulated 111indium-labeled desferrioxamine at the site of application was 
observed after SC administration which was not seen for the free molecule [172]. The 
enhanced retention effect at the SC injection site in general is reported to be highly 
pronounced for large vesicles and can be explained by a slower clearance via the lymphatic 
capillaries with increasing size [173]. Despite successful studies found in literature, the 
encapsulation of proteins into liposomes in general is challenging as oftentimes preparation 
methods are applied that might induce protein denaturation, comprising the use of organic 
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solvents or liposomal treatment by sonication, freeze-thaw stress, elevated heat or pressure 
[174]. As an alternative approach, Tian et al. proposed the entrapment of proteins into 
vesicular phospholipid gels [225]. These highly concentrated vesicular phospholipid 
dispersions are prepared by forced hydration of the phospholipids using a dual asymmetric 
centrifuge. This preparation method was shown to provide high protein stability and 
sustained release of the entrapped drug from the formulation [68]. As demonstrated by 
Brandl et al., vesicular phospholipid gels allow high drug encapsulation and present therefore 
an attractive alternative to liposomes where commonly low drug encapsulation efficiencies 
are obtained [175]. Another approach for vesicle preparation without the use of harsh 
processing methods was introduced by Nuernberg et al. who reported about the 
spontaneous formation of vesicles upon infusion of oil-bath preparations containing fatty oil, 
lipophilic detergent, active substance and phospholipids [176]. The size of the phospholipid 
vesicles in general can be mainly tailored by the preparation process: formulation preparation 
by e.g. dual asymmetric centrifuge or high pressure homogenization leads to small sized 
vesicles in the nm-range with narrow vesicle size distribution and low lamellarity [177, 178]. 
In comparison, spontaneously formed vesicles prepared by e.g. thin film hydration show high 
vesicle size distribution in the lower µm-range [179]. 
Due to the potential to prolong the drug residence time at the site of application and thus to 
reduce systemic exposure [180], lipid-based vesicular drug delivery systems present an 
attractive vehicle for the intra-articular (IA) administration of therapeutic drugs in the 
treatment of inflammatory joint diseases. This method was first introduced by Shaw et al. in 
1976 [33] who described the beneficial therapeutic effect of liposomally encapsulated 
corticosteroids. Bonanomi et al. studied the pharmacokinetic profile of dexamethasone 
palmitate-loaded liposomes after IA administration in rabbits and compared the synovial drug 
concentrations with that of microcrystalline triamcinolone acetonide, administered in non-
liposomal form. It turned out that after 6 hrs 36 % of the liposomal formulation was still 
present in the joint while 98 % of non-encapsulated drug had been cleared [35]. Similar 
results were obtained upon IA administration of liposomal lidocain in rabbits [37]. Also the 
residence time of liposomal iohexol was shown to be drastically prolonged after IA 
administration in sheep; while the liposomal drug revealed a synovial elimination half-life of 
138 hrs, non-encapsulated iohexol was completely cleared from the joint already 3 hrs after 
injection [39]. The extent of synovial retention was shown to increase with vesicle size [39]. 
Similarly, enlargement of the vesicle size from 160 nm to 750 nm led to an increased 
synovial retention of dexamethasone palmitate by a factor of 2.6 [35]. Williams et al. 
demonstrated that methotrexate-loaded liposomes with a size of 1.2 µm revealed higher 
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therapeutic efficacy than small-sized 100 nm variants [36]. Despite various successful 
studies that have shown the beneficial effect of the IA administration of liposomal drugs, only 
one liposomal formulation for IA administration, Lipotalon® containing dexamethasone-21-
palmitate for the treatment of rheumatic disorders, can be found on the German market 
[180].  
The aim of the study outlined in this chapter was the development of a phospholipid (PL)-
based drug delivery system for the IA administration of a therapeutic monoclonal antibody 
(mAb). Due to the limitations of IA injection with respect to frequency and volume, the 
formulation had to provide a high drug load. Moreover, both the formulation components and 
the formulation preparation process were to be highly protein-compatible. The scope of the 
study was limited to two different formulations. Firstly, a PL-mAb formulation, consisting of 
spray-dried mAb particles suspended within a non-aqueous PL solution was to be 
developed, which spontaneously transfers into a vesicular formulation upon contact with 
synovial fluid. This should lead to dissolution of the incorporated mAb particles and mAb 
entrapment in the vesicles. Alternatively, the spontaneous formation of the vesicles can be 
performed ex vivo by simply mixing a non-aqueous PL solution with a highly-concentrated 
mAb solution. After being administered into the joint cavity, both formulations were expected 
to provide prolonged residence time and thus sustained synovial mAb concentration with 
improved therapeutic effects. Both formulation approaches were based on knowledge from 
previous studies where the formation of large vesicles was demonstrated when they were 
spontaneously formed [179], and a high drug load and excellent protein stability was reported 
when using highly viscous phospholipid-based formulations [68, 175]. Besides the detailed 
characterization of the PL formulations, the compatibility with the mAb employed was to be 
assessed via a bundle of analytical methods. Additionally, the pharmacokinetic profile after 
IA administration was to be addressed with an in vivo study. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Monoclonal antibody (mAb) 
The mAb (IgG1) used for preparation of the vesicular phospholipid formulation was 
formulated at 70 mg/mL, pH 5.2 with sodium chloride (105.5 mM), monobasic sodium 
phosphate dihydrate (5.5 mM), dibasic sodium phosphate dihydrate (8.6 mM), sodium citrate 
(1.16 mM), citric acid monohydrate (6.19 mM), mannitol (65.9 mM) and polysorbate 80 
(0.1 %) and had a molecular weight (MW) of 148 kDa. MAb solution used for spray drying 
was formulated at a concentration of 100 mg/mL in trehalose (201.6 mM), histidine (15 mM) 
and polysorbate 80 (0.01 %) at pH 5.4. The bulk solutions were stored at -80 °C until use. 
Prior to use, protein solutions were filtered through an Acrodisc® 0.2 µm PVDF syringe filter 
(Pall, Dreieich, Germany). For an in vivo experiment, instead of the human mAb, the murine 
variant was used, which was formulated in histidine buffer (15 mM) at pH 6.0 and a 
concentration of 24.5 mg/mL. 
2.1.2 Phospholipids 
Table 4-1 lists all phospholipid (PL) components used throughout this chapter.  
Table 4-1 List of PL used in this work. 
Product name Composition Source 
1,2-dipalmitoyl-sn-glycero-3-
phosphate, sodium salt 
 Lipoid, Ludwigshafen, 
Germany 
1,2-dipalmitoyl-sn-glycero-3-
phospho-rac-glycerol, 
sodium salt 
 Lipoid, Ludwigshafen, 
Germany 
Phosal®50PG phosphatidylcholine 52.3 % 
lysophosphatidylcholine 0.9 % 
dissolved in propylene glycol 
PHOSPHOLIPID, Köln, 
Germany 
Phospholipon®90G phosphatidylcholine 97.3 % 
lysophosphatidylcholine 1.5 % 
PHOSPHOLIPID, Köln, 
Germany 
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2.1.3 Excipients, reagents and chemicals 
Table 4-2 lists the excipients, reagents and chemicals used throughout this chapter. All 
substances were of analytical grade. Ultrapure water for all buffers was used from a PureLab 
UV/UF system (Elga LabWater, Celle, Germany). 
Table 4-2 List of excipients, reagents and chemicals used in this chapter.  
Excipients, reagents, chemicals Source 
Alexa®Fluor488 Life Technologies, Darmstadt, Germany  
Citric acid monohydrate Carl Roth, Karlsruhe, Germany 
Cholesterol Synopharm, Barsbuettel, Germany 
Dibasic potassium phosphate AnalR Normapur, VWR international, 
Leuven, Belgium 
Dibasic sodium phosphate dihydrate Merck, Darmstadt, Germany 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt, Germany 
Ethanolamine Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
Ethylenediaminetetraacetic acid Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
Fetal calf serum Biochrom, Berlin, Germany 
Glycine Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
L-histidine Merck, Darmstadt, Germany 
N-2-hydroxyethylpiperazine-N-2-ethansulfonic acid Merck, Darmstadt, Germany 
N-methyl pyrrolidone (NMP) Fluka Chemie, Buchs, Switzerland 
Mannitol Riedel-de Haen, Seelze, Germany 
Monobasic sodium phosphate dihydrate Merck, Darmstadt, Germany 
N-ethyl-N9-(dimethylaminopropyl) Carbodiimide Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
N-hydroxy succinimide Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
Nile red Sigma-Aldrich Laborchemikalien, Seelze, 
Germany 
Octyl glycoside Carl Roth, Karlsruhe, Germany 
ortho-phosphoric acid Zentrale Versorgung LMU München, 
Germany 
Polyethylene glycol 300 (PEG 300) Sasol, Marl, Germany 
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Polysorbate 20 Merck, Darmstadt, Germany 
Polysorbate 80 Merck, Darmstadt, Germany 
Potassium chloride Caelo, Hilden, Germany 
Propylene glycol BASF, Ludwigshafen, Germany 
Sodium citrate Caelo, Hilden, Germany 
Sodium chloride AnalR Normapur, VWR international, 
Leuven, Belgium 
Sodium hydroxide, 1M Merck, Darmstadt, Germany 
Trehalose Merck, Darmstadt, Germany 
XenoLightTM CF680  Caliper Life Sciences, Hopkinton, USA 
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2.2 Methods 
2.2.1 Spray drying with the Mini Spray Dryer B-290 
Spray drying experiments were performed on a Mini Spray Dryer B-290 (Büchi Labortechnik, 
Flawil, Switzerland). This instrument comprised a heating system with inlet temperature (Tin) 
sensor for the drying air, a spray nozzle, a drying chamber with outlet temperature (Tout) 
sensor, a high efficiency cyclone for separation of the dried powder, a collection vessel and 
an aspirator with particle filter. For atomization of the spray drying solution, a two fluid nozzle 
(tip Ø 0.7 mm, cap Ø 1.5 mm) was used with compressed air from an in-house supply. The 
use of a LT Mini dehumidifier (Deltatherm, Much, Germany) ensured a constant low residual 
moisture within the system. Cooling water was circulated through a jacket around the nozzle. 
The Tin/Tout was 130 °C/64 °C, the aspirator flow rate was 38 m3/hr or 100 % and the 
atomizing air flow rate was 667 L/hr. The mAb spray drying solution was pumped with a 
liquid feed rate of 3 mL/min by means of an internal pump. All liquid samples were filtered 
through Acrodisc® 0.2 µm PVDF syringe filter prior to spray drying. After the process, the 
resulting powder was collected in glass vials, closed and stored in a desiccator at ambient 
atmosphere. The yield was calculated from the amount of powder recovered in the collection 
vessel in relation to the solid content of the used spray drying solution. 
2.2.2 Karl-Fischer analysis 
The residual moisture (RM) content of the spray-dried (sd) powder was determined by 
coulometric Karl-Fischer titration using an Aqua 40,00 titrator with headspace module 
(Analytik Jena, Jena, Germany). Therefore, 10-20 mg of the respective powder were 
accurately weighed into a 2 R glass vial, sealed with rubber stopper and heated up to 
100 °C. For determination of the RM content, the evaporated water was transferred into the 
titration solution. As reference, a standard with defined RM was used (apura® water standard 
oven 1 %, Merck, Darmstadt, Germany). 
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2.2.3 Formulation preparation 
2.2.3.1 Non-aqueous PL-mAb suspension 
This non-aqueous formulation was prepared by dispersing sd mAb powder, providing a final 
concentration of 50 mg/g mAb, in a 2:1 (w/w) mixture of Phosal®50PG and propylene glycol 
or a 60 % (w/w) Phospholipon®90G in PEG 300 solution (Phospholipon®90G was dissolved 
in PEG 300 at 80 °C), using a dual-syringe system consisting of two Luer-Lock syringes 
(VWR International, Ismaning, Germany) connected by a syringe adapter (Braun, 
Melsungen, Germany). 
2.2.3.2 Vesicular PL-mAb formulation 
Formulations were all prepared by emulsifying Phosal®50PG with mAb solution of 70 mg/mL 
(if not stated otherwise) (active) or mAb formulation buffer (placebo) by means of a dual-
syringe system, leading to a mAb content of 50 mg/g. The respective amounts of both 
components were filled into Luer-Lock syringes, the two syringes were connected by a 
syringe adapter and the content was carefully mixed by moving the syringe plungers. 
In a study to optimize the encapsulation efficiency the vesicular PL-mAb formulations were 
subjected to either: 
- 3 to 5 freeze-thaw cycles by repetitive sample freezing for 30 s in liquid nitrogen and 
subsequently thawing at 30 °C in a water bath for 4 min 
- treatment with a T 10 Ultra-Turrax® equipped with a S10N-5G dispersing tool (IKA®-
Werke, Staufen, Germany) for 15 s, 30 s or 45 s at 8000 rpm. All samples were kept on 
ice during mixing.  
Alternatively, formulation preparation was carried out in a Speed-MixerTM DAC 150 FVZ 
(Hauschild, Hamm, Germany) according to the method described by Tian et al. [68]. 
Formulation components were weighed into a 30 g polypropylene container and centrifuged 
at 3500 rpm and room temperature (RT) for 30 min or 60 min with steps of 1.5 min 
centrifugation followed by cooling on ice. 
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2.2.4 Buffer exchange and up-concentration of mAb solutions 
In order to obtain mAb concentrations >70 mg/mL, mAb solution at a concentration of 
100 mg/mL, formulated in trehalose (201.6 mM), histidine (15 mM) and polysorbate 80 
(0.01 %) at pH 5.4, was buffer exchanged against sodium chloride (105.5 mM), monobasic 
sodium phosphate dihydrate (5.5 mM), dibasic sodium phosphate dihydrate (8.6 mM), 
sodium citrate (1.16 mM), citric acid monohydrate (6.19 mM) and mannitol (65.9 mM). 
Therefore, a Vivaflow®50 tangential flow filtration cassette at a MW cutoff of 30 kDa (Satorius 
stedim, Göttingen, Germany) was used.  
2.2.5 Injectability 
The maximal injection force, required for injection of 0.4 mL of the formulation into air, was 
determined by means of a TA.XTplus texture analyzer (Stable Micro Systems, Surrey, UK) at 
RT. This value was defined as the highest force measured before the plunger reached the 
end of the syringe after having overcome the plunger-stopper breakloose force. Therefore, 
1 mL Luer-Lock syringes connected to 26 G syringe needles (Terumo Europe, Leuven, 
Belgium) were clamped in a tripod underneath the punching tool of the instrument. The 
crosshead velocity was set to 1 mm/s, a representative velocity for the manual syringe 
delivery [96]. After 20 s, the measurement stopped automatically. 
2.2.6 Rheometry 
The rheological properties of the formulations were studied on a plate-cone rheometer 
(Physica MCR 100, Anton Paar, Ostfildern, Germany) with in- and decreasing shear rate (10-
100 s-1, 100-10 s-1) at a gap position of 0.042 mm using a cone with a diameter of 50 mm and 
an angle of 1 °. Analysis was performed at 25 °C using 600 mg of the respective formulation. 
2.2.7 Dynamic light scattering (DLS) 
DLS measurements were performed on a Zetasizer Nano ZS (Malvern, Herrenberg, 
Germany) at 25 °C using 0.5 mL cuvettes (Brand, Wertheim, Germany). Formulations were 
diluted with PBS by factor 100 and analyzed in triplicate. 
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2.2.8 Cryo-transmission electron microscopy (Cryo-TEM) 
Cryo-TEM analysis was performed on a LEO 912 OMEGA electron microscope (Zeiss, 
Oberkochen, Germany). Prior to analysis, samples were diluted with PBS to a lipid 
concentration of 5-10 mM. Approximately 7 µL were plotted on a copper grid (Quantifoil S7/2 
100 x 400 mesh, Quantifoil Micro Tools, Jena, Germany). Excess sample volume was 
removed from the copper grid by means of a filter paper. The sample-loaded grid was 
immediately shock-frozen by immersing it into liquid ethane using a CryoBox (Carl Zeiss, 
Oberkochen, Germany) cooled with liquid nitrogen. The sample grid was transferred into the 
TEM by means of a pre-cooled cryogenic sample holder (626-DH, Gatan, Warrendale, USA). 
Images were recorded in vacuum atmosphere at -175 °C and 120 kV with a 6,300-12,500-
fold magnification in underfocus mode and processed with the iTEM software (Olympus, 
Muenster, Germany). 
2.2.9 UV spectroscopy (OD 280, second derivative, absorbance at 350 nm) 
Protein concentrations were determined photometrically on an Agilent 8453 UV-Vis 
spectrometer (Agilent Technologies Deutschland, Böblingen, Germany) equipped with a 
Peltier temperature controller (Agilent Technologies Deutschland, Böblingen, Germany) at 
λ=280 nm and 25 °C in quartz UV cuvettes with a path length of 1 cm. An extinction 
coefficient of either 1.39 mL·mg-1·cm-1 (mAb) or 1.40 mL·mg-1·cm-1 (murine mAb) was 
applied. Samples were diluted to a concentration ranging from 0.1 to 0.7 mg/mL prior to 
analysis. Corresponding blank spectra were subtracted from the protein spectra. Second 
derivative protein spectra were calculated between 240 and 350 nm by means of the 
ChemStation software. Determination of turbidity of protein or vesicle containing samples 
was performed with a UV plate reader (FLUOstar Omega, BMG LABTECH, Ortenberg, 
Germany) in 96-well plates (Nunc®, Sigma-Aldrich Laborchemikalien, Seelze, Germany) and 
a filling volume of 300 µL. 
2.2.10 Fourier transform infrared spectroscopy (FTIR) 
FTIR spectra were recorded with the Tensor 27 FTIR spectrometer (Bruker Optics, Ettlingen, 
Germany) using a Bio-ATR unit (attenuated total reflection) connected to a thermostat at 
20 °C (DC30-K20, Thermo Haake, Dreieich, Germany). Corresponding blank spectra were 
subtracted from the protein spectra. After a 120-scan measurement, the second derivative 
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spectrum was generated with the help of the spectrometer software (OPUS, Bruker Optics, 
Ettlingen, Germany). For investigation of changes in secondary protein structure, the vector 
normalized second derivative spectra between the wavenumbers of 1720 and 1580 cm-1 
were compared with the spectra of the native, untreated protein. 
2.2.11 High performance size exclusion chromatography (HP-SEC) 
Size exclusion chromatography was used for quantification of soluble aggregates, monomer 
and fragments of the mAb. The measurement was performed on a HPLC 1100 
chromatograph (Agilent Technologies Deutschland, Böblingen, Germany) using a 
Superose® 6 10/300 GL column (GE Healthcare, Uppsala, Sweden) with UV detection at 214 
and 280 nm. The mobile phase consisted of 0.15 M sodium chloride in 0.02 M sodium 
phosphate, adjusted to pH 7.5 with ortho-phosphoric acid. The flow rate was 0.5 mL/min. 
Samples were diluted with mobile phase to a target concentration of 1 mg/mL and 
centrifuged for 10 min at 12,000 rpm (Sigma 1-15, Sigma Laborzentrifugen, Osterode am 
Harz, Germany) in order to remove insoluble aggregates. Chromatograms were integrated 
manually by means of the ChemStation software Rev. B.02.01 (Agilent Technologies 
Deutschland, Böblingen, Germany). For quantification, the area under the curve was used. 
Protein concentrations were calculated based on a calibration curve.   
2.2.12 Fluorimetry 
Protein concentrations below 0.1 mg/mL were determined with a Varian Carry Eclipse 
fluorimeter (Varian, Darmstadt, Germany). Solutions were measured at 20 °C in 0.5 mL 
cuvettes (Brand, Wertheim, Germany). Excitation occurred at a wavelength of 280 nm with 
an excitation slit of 5 nm. The emission spectrum was recorded from 280 nm to 600 nm. For 
protein quantification a calibration curve, ranging from 0.002 to 0.1 mg/mL at the emission 
maximum at 334 nm, was used. 
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2.2.13 MAb extraction from PL formulations 
2.2.13.1 Extraction by using a detergent 
For further analysis, mAb was extracted from the lipid matrices by solubilization of the lipids 
in 100 mM octyl glycoside (OG) solution. The volume ratio of matrix to detergent solution was 
adapted to provide a clear micellar solution. 
2.2.13.2 Extraction by centrifugation 
MAb extraction without use of detergents was performed by centrifugation of the vesicular 
PL-mAb formulations for 1 hr at 186,000 x g (OptimaTM TLX Ultracentrifuge, Beckman 
Coulter, Krefeld, Germany) at 20 °C. For mAb analysis the clear lower aqueous phase was 
used. 
2.2.14 MAb bioassay 
The biological activity of mAb after extraction from the vesicular PL formulation was 
assessed by a cell based bioassay performed at Abbott, Ludwigshafen, Germany according 
to the Abbott standard protocol. This assay is based on the determination of cell viability 
upon neutralization of cytotoxic recombinant human TNF (rhTNF) by mAb. Mouse L-929 cells 
were incubated with defined amounts of rhTNF and various concentrations of mAb. After 
incubation for 48 hrs at 37 °C the survived cells were stained with crystal violet and their 
color intensity was determined photometrically at 620 nm. The bioactivity [%] was then 
calculated in comparison to a reference. MAb samples, extracted by centrifugation from 
vesicular PL formulations, were diluted to a mAb concentration of 1 mg/mL with formulation 
buffer. As reference, a mAb solution at same concentration was used. 
2.2.15 Determination of the encapsulation efficiency (EE) 
For determination of the EE, vesicular PL-mAb samples were diluted with PBS to a mAb 
concentration of 1 mg/mL (c0) and 850 µL of the diluted samples were centrifuged for 40 min 
at 2739 x g and 20 °C (Sigma 4K15, Sigma Laborzentrifugen, Osterode am Harz, Germany) 
using Vivaspin®2 centrifugation tubes (Satorius stedim, Göttingen, Germany) with a MW 
cutoff of 1 MDa. As reference, a non-encapsulated active sample with same mAb 
concentration was used and treated equally. MAb concentrations in the first elution fraction of 
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PL-mAb formulation (cactive) and reference (creference) were determined by UV spectroscopy. 
The EE [%] was calculated based on equation (1): 
(1) ( )
reference
active
c
c
EE
⋅
−=
%100%100[%]   
For quantification of the liposomally encapsulated mAb, samples were centrifuged as 
described before. After centrifugation, the eluted volume was replaced by PBS and this 
centrifugation/washing procedure was performed another 5 times. The absence of mAb in 
the elution fraction was confirmed fluorimetrically (see section 2.2.12). Thereafter, the 
purified vesicles were admixed with OG solution (100 mM) in a 1.37:1 ratio in order to 
solubilize the lipids and to release encapsulated mAb. MAb was quantified by fluorimetry. 
The EE [%] was calculated based on equation (2): 
(2) 
0
%100[%]
c
c
EE liposomal
⋅
=  
2.2.16 Separation of non-encapsulated mAb from loaded vesicles 
For purification of mAb loaded PL vesicles from non-encapsulated mAb, vesicular PL-mAb 
formulations were diluted with PBS to a mAb concentration of 1 mg/mL and subsequently 
transferred into Vivaspin®2 centrifugation tubes with a MW cutoff of 1 MDa. Samples were 
centrifuged for 40 min at 2739 x g and 20 °C (Sigma 4K15, Sigma Laborzentrifugen, 
Osterode am Harz, Germany) and the eluted volume was replaced by PBS. The washing 
procedure was repeated until the complete absence of mAb in the elution fraction was 
achieved. The elution fraction was checked for presence of mAb by determination of the 
intrinsic fluorescence (see section 2.2.12).  
2.2.17 Labeling of mAb with AlexaFluor®488 
MAb bulk solution (70 mg/mL) was dialyzed against 10 mM PBS using Vivaspin®6 
centrifugation tubes (Satorius stedim, Goettingen, Germany) with a MW cutoff of 30,000 Da. 
After dialysis, the protein concentration was adjusted with PBS to 2 mg/mL. For covalent 
binding of the fluorescent dye to the protein, 1 mL of the mAb solution was admixed with 
0.1 mL bicarbonate solution (1 M). To the protein solution, 4 µL of AlexaFluor®488, 
formulated in DMSO at a concentration of 10 mg/mL, were added. The sample was 
incubated for 1 hr at room temperature on a horizontal shaker at 350 rpm (Titramax 101, 
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Heidolph, Schwabach, Germany) under exclusion from light. After incubation, the sample 
was transferred into a Vivaspin® centrifugation tube with a MW cutoff of 30,000 Da and 
washed with at least the 10-fold volume of PBS for separation of the free fluorescent dye. 
The elution fractions were checked for absence of free dye via UV spectroscopy at 494 nm. 
The molar protein concentration [IgG] and the degree of labeling after purification were 
determined according to equations (3) and (4) [181]: 
(3) [ ] ( )[ ]
000,203
11.0494280 factordilutionAAIgG ⋅⋅−=  
 
(4) [ ]IgG
factordilutionAlabelingofDegree
⋅
⋅
=
000,71
494
 
2.2.18 Labeling of mAb with XenoLightTM CF680 
MAb bulk solution (70 mg/mL) was dialyzed against 10 mM PBS using Vivaspin®6 
centrifugation tubes with a MW cutoff of 30,000 Da. After dialysis, the protein concentration 
was diluted with PBS to 1 mg/mL. For pH adjustment of the protein solution, 1 mL of the mAb 
solution was admixed with 0.1 mL bicarbonate solution (1 M). Preparation of the near-
infrared dye stock solution was performed by dissolution of 0.1 µmole XenoLightTM CF680 in 
25 µL anhydrous DMSO. For covalent binding of the dye to the protein, 12 µL dye stock 
solution were added to the mAb solution and the mixture was incubated for 1 hr at room 
temperature under exclusion of light on a horizontal shaker. Unconjugated dye was removed 
by ultrafiltration using NanoSep membrane filtration vials provided by the supplier and using 
PBS. Labeled protein concentration after separation of the free dye [IgG] [mg/mL] and 
degree of labeling were determined according to equations (5) and (6) [182]:  
(5) [ ] ( )[ ]
39.1
09.0681280 factordilutionAAIgG ⋅⋅−=
 
 
(6) [ ]IgG
factordilutionAlabelingofDegree
⋅
⋅⋅
=
000,210
000,148681
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2.2.19 Staining of PL vesicles with nile red 
PL vesicles were stained with nile red for fluorescence microscopy. Therefore, 1 µL of a 
1 mg/mL nile red solution in acetone was spiked to the PL vesicles prior to microscopy 
analysis. 
2.2.20 Fluorescence microscopy 
Visualization of stained PL vesicles loaded with fluorescence-labeled mAb (F-mAb) was 
carried out on a Biozero BZ-8100E fluorescence microscope (Keyence Deutschland, 
Frankfurt, Germany) combined with the BZ-Analyzer software (Keyence Deutschland, 
Frankfurt, Germany). 
2.2.21 Surface plasmon resonance (SPR) measurements 
SPR measurements were performed in order to investigate the impact of the labeling 
procedure on mAb binding affinity to its target. The study was carried out at the Abbott 
Bioresearch Center, USA using a BICORE T100 instrument (GE Healthcare, Uppsala, 
Sweden) in combination with Biaevaluation® Software. Goat anti-huIgG-FC antibody was 
immobilized on a carboxy methylated (CM5®) research chip following the standard 
immobilization procedures described by Biacore Life Science. The sensor chip surfaces of 
sample and reference cells were first activated by a 6-min injection of a solution containing 
0.4 M N-ethyl-N9-(dimethylaminopropyl) carbodiimide and 0.1 M N-hydroxy-succinimide. 
After goat anti-huIgG-FC antibody immobilization in the sample cell via amine linkage of 
lysine residues, residual activated carboxymethyl groups of both sample and reference cell 
were deactivated with ethanolamine. The running buffer contained 0.01 M HEPES, 0.15 M 
sodium chloride, 0.003 M EDTA and 0.05 % Polysorbate 20 at pH 7.4. F-mAb samples were 
diluted with running buffer to a concentration of 0.2 µg/mL. Capturing by the immobilized anti-
huIgG-FC antibody occurred at a flow rate of 5 µL/min within 30 s. Afterwards, TNFα-
solutions in a concentration range of 25-0.39 nM were carried through the cell at a flow rate 
of 50 µL/min. As reference, non-labeled mAb was used at same concentrations. Surface 
regeneration was performed with 50 µL of 0.01 M glycine solution at pH 1.5 with a flow rate 
of 100 µL/min. Samples were measured in duplicate. Determination of the dissociation 
constant KD was carried out with the help of the instrument software.  
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2.2.22 In vivo experiments 
In vivo studies were performed at the Abbott Bioresearch Center in Worcester, USA in order 
to assess the pharmacokinetic profile of PL-mAb formulations upon IA injection. The studies 
were carried out with healthy male Lewis rats weighing approximately 275 – 300 g at the 
start of the study.  
In a first study, the vesicular PL-mAb formulation was analyzed. Instead of the human mAb, 
the murine variant was used. As the murine mAb was formulated in histidine buffer (15 mM) 
at a concentration of 24.5 mg/mL, the solution was buffer exchanged against mAb 
formulation buffer and up-concentrated to 50 mg/mL using Vivaspin® centrifugation tubes 
with a MW cutoff of 30 kDa (Satorius stedim, Göttingen, Germany). Prior to injection, animals 
were anaesthetized in an anesthesia chamber using isoflurane (5 %) and oxygen. Once the 
rat was completely anesthetized, the right knee was shaved. Animals were dosed IA with 
50 µL of the formulation (mAb content 35.7 mg/g) via injection through the patella into the 
knee joint using a 26 G needle. As reference a murine mAb solution at same concentration 
was used. The study was performed during 48 hrs. At predefined time points (2 hrs, 4 hrs, 
12 hrs, 24 hrs and 48 hrs) animals were sacrificed in an anaesthesia chamber using CO2. 
Synovial fluid (SF) samples were obtained from each animal via synovial wash. Therefore, a 
small volume of PBS was injected into the joint cavity and subsequently removed. Moreover, 
blood samples were taken at each time point. Both, SF and blood samples were analyzed in 
regard to mAb concentration via ELISA according to the Abbott standard protocol.  
In a second study, the pharmacokinetic profile of mAb-loaded PL vesicles separated from 
non-encapsulated mAb was investigated. This study was carried out with the human mAb. 
The mAb concentration in the PL vesicles was 1 mg/mL. As reference, empty PL vesicles 
with spiked mAb as well as a mAb solution at same concentration were analyzed. The study 
was performed during 10 d. At predefined time points (1 hr, 4 hrs, 1 d, 3 d, 7 d, 10 d) blood 
samples were collected from the tail nick of the animals and stored at -80 °C until analysis. At 
day 10, animals were sacrificed in an anesthesia chamber using CO2 and SF was removed 
by synovial wash. Blood and SF samples were analyzed in regard to mAb concentration. 
In order to study the fate of the mAb-loaded vesicles after IA administration, the 
encapsulated mAb was labeled with a near-infrared dye according to 2.2.18 prior to mAb 
encapsulation and separation of non-encapsulated protein. The study was carried out with 
the human mAb at a mAb concentration in the PL vesicles of 1 mg/mL. Three days after 
injection of 50 µL of the formulation into the right hind leg, the animals (n=2) were sacrificed 
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and the full animal body prior to and after laparotomy were examined using a FluobeamTM 
700 fluorescence imaging system (excitation wavelength 680 nm, emission wavelength 
>700 nm, Fluoptics, Cambridge, USA).  
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3 RESULTS AND DISCUSSION 
3.1 Non-aqueous PL-mAb suspension 
3.1.1 Pre-screening experiments 
3.1.1.1 MAb stability in Phosal®50PG-mAb formulation and propylene glycol 
After preparation of the non-aqueous PL-mAb suspension based on Phosal®50PG 
(phosphatidylcholine 52.3 %, lysophosphatidylcholine 0.9 %, dissolved in propylene glycol) 
and a mAb content of 50 mg/g added as sd powder, the analysis of the protein conformation 
was in the focus of the study. In situ vesicle formation upon contact with SF was simulated by 
injection of the formulation into PBS at a 1:2 (w/w) ratio using a 26 G needle. After 
dissolution of the sd mAb and entrapment into the vesicles, mAb was intended to be 
extracted for analytical purpose via centrifugation for 1 hr at 186,000 x g. In contrast to the 
placebo sample, it was not possible to separate the lipid structures from the aqueous phase. 
Alternatively 100 mM OG solution was added to the samples for solubilization of the lipid 
phase. Compared to the placebo sample, addition of the detergent did not render a clear 
solution but a white precipitate remained. The precipitated sample was characterized by 
second derivative FTIR spectroscopy. Furthermore, the supernatant after centrifugation was 
subjected to second derivative UV spectroscopy and mAb quantification in order to 
determine the extend of mAb precipitation. 
Compared to the spectrum of the native mAb solution, drastical changes in the amide I 
spectral region of the second derivative FTIR spectrum and thus in the secondary protein 
structure were seen for the precipitate (figure 4-1 A). The native mAb spectrum showed the 
characteristic predominant bands at 1638 cm-1 and 1688 cm-1 and a weak band at 1612 cm-1 
which can be attributed to intramolecular β-sheet structures [183, 184]. The spectrum of the 
precipitated mAb exhibited a band intensity increase at 1615 cm-1. The strong band at 
1638 cm-1 was shifted to 1625 cm-1 with a decrease in intensity which can be assigned to the 
formation of intermolecular β-sheet elements and thus protein aggregation [185]. An 
additional band at 1650 cm-1 was found which is indicative for the presence of non-ordered 
structures. The peak at 1680 cm-1 as well as the slight shift from 1688 cm-1 to higher 
wavenumbers can be ascribed to the formation of turns [144, 184]. Determination of the mAb 
concentration in the supernatant liquid revealed that most of the protein had been 
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precipitated as only 8.2 % of the mAb was recovered. Alterations in band position were also 
found in the second derivative UV spectrum compared to the native mAb reference (figure 4-
1 B): a slight shift to lower wavelength was observed for the bands at 284 nm and 275 nm. 
These changes in the tertiary protein structure can be ascribed to alterations in the 
microenvironment of the aromatic amino acids tyrosine and tryptophane [102, 103] causing 
an enhanced propensity to aggregation. 
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Figure 4-1 Second derivative FTIR (A) and UV (B) spectra of mAb from PL-mAb 
suspension after vesicle formation in PBS and addition of OG solution (thick 
line) compared to native mAb solution (thin line).  
This observed protein instability might be attributed to the destabilizing effect of the 
employed organic solvent propylene glycol or to incompatibilities with the phospholipid 
component used for formulation preparation and the lamellar structure formation. From 
previous studies, the denaturing impact of various organic solvents on proteins in aqueous 
solution is well-known [186, 187]. Water-miscible organic solvents mainly destabilize proteins 
by direct binding via hydrophobic interactions or indirectly via perturbation of the hydration 
shell which causes aggregation. The extent of destabilization depends on the degree of 
protein hydration and concentration of the organic solvent [188] but also on the fact whether 
the protein is in dissolved or dried state. Griebenow et al. demonstrated that the secondary 
structure of lysozyme was maintained when the protein was suspended in pure organic 
solvent but changed when dissolved in organic solvent-water mixtures. This behavior was 
explained by the fact that the protein conformation is restricted in anhydrous environment. In 
presence of only low amounts of water, the protein mobility increases which may cause 
aggregation [189]. Additionally, the formation of hydrophilic-hydrophobic interfaces, as 
observed when e.g. using poorly water-miscible organic solvents or lipidic components, 
might also contribute to protein instabilities in aqueous solutions. As surface-active 
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molecules, proteins tend to aggregate on such interfaces. In a study of Morlock et al. it was 
demonstrated that erythropoietin mainly formed aggregates during the first emulsification 
step of encapsulation into PLGA microparticles using a double-emulsion technique [84]. In 
another study, the stability of lysozyme in aqueous solution upon emulsification with 
methylene chloride was investigated and it was shown that 20 to 35 % of the protein non-
covalently aggregated at the water-organic solvent interface [190]. In conclusion, the type 
and the concentration of the organic solvent employed, as well as whether the protein is in 
dissolved or in a dried state influence protein stability in general. 
In order to investigate the potential role of propylene glycol in mAb denaturation, sd mAb 
particles were suspended at 50 mg/g in propylene glycol and admixed with PBS in a ratio of 
1:2 (w/w). Directly after mixing a strong turbidity occurred. Similar to foregoing experiments, 
FTIR measurements revealed alterations in the second derivative spectrum (figure 4-2 A). 
The predominant band at 1638 cm-1 was shifted to lower wavenumbers with shoulder 
formation at 1640 cm-1 and decrease in intensity which is indicative for the presence of 
intermolecular β-sheet structures. A slight band shift at 1688 cm-1 to higher wavenumbers 
was found which can be assigned to the formation of turns. More than 99 % of the initial 
protein content was precipitated as determined via UV analysis of the supernatant liquid after 
centrifugation. HP-SEC analysis of the supernatant revealed a decline in monomer recovery 
from 99.5 % to 96 % with drastical increase in soluble aggregate formation in comparison to 
the native mAb. No structural changes in the second derivative UV spectrum of the 
remaining mAb in solution were identified (figure 4-2 B).  
These results underpin the suspicion that propylene glycol induces mAb aggregation in 
aqueous environment. As it is known from literature that solvent-induced protein instabilities 
might be dependent on the concentration of the organic solvent [188], the impact of the 
propylene glycol concentration on the mAb stability was examined in a further step. To this 
end differently concentrated propylene glycol/water mixtures were added in equal volumes to 
a 50 mg/mL mAb solution, leading to a mAb concentration of 25 mg/mL and propylene glycol 
concentrations of 20 to 50 % in the sample. MAb stability was assessed via second 
derivative FTIR and UV spectroscopy and HP-SEC. 
After the addition of the propylene glycol/water mixtures to the mAb solution, all samples 
remained clear without evidence of visible particle formation. No alterantions in the second 
derivative FTIR and UV spectra were identified in comparison to the native mAb spectrum 
(figure 4-3 A and B). HP-SEC analysis did not show additional aggregates or fragments. 
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Figure 4-2 Second derivative FTIR (A) and UV spectra (B, concentration normalized, 
artificial offset for clarity) of mAb suspension in propylene glycol at 50 mg/g 
mixed with PBS in a 1:2 ratio (w/w) (thick line) compared to native mAb 
solution (thin line).  
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Figure 4-3 Second derivative FTIR (A) and UV spectra (B, artificial offset for clarity) of 
mAb in different propylene glycol (PG)/water mixtures in comparison to the 
spectrum of the native mAb solution. 
Thus propylene glycol up to 50 % does not result in mAb instability. In contrast, during 
dissolution of the sd mAb particles suspended in propylene glycol or Phosal®50PG, the mAb 
initially faces high propylene glycol concentrations which lead to mAb aggregation. 
3.1.1.2 Screening of mAb-compatible organic solvents for PL  
As a consequence of the destabilizing effect of propylene glycol and thus Phosal®50PG on 
mAb, the non-aqueous PL solution for preparation of the PL-mAb suspension had to be 
modified. Therefore, different organic solvents were tested with respect to mAb 
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conformational stability and suitability as solvent for the PL component. Based on Strickley 
[99], who reviewed organic solvents commonly used for parenteral formulations, PEG 300, 
DMSO, and NMP were selected. Spray-dried mAb was dispersed in the solvents at 
50 mg/mg and subsequently admixed with PBS for redissolution.  
After mixing the suspensions with PBS in a 1:2 (w/w) ratio only PEG 300 rendered a clear 
solution, whereas the use of DMSO and NMP induced strong mAb precipitation. FTIR and 
UV spectroscopy confirmed a high compatibility of mAb with PEG 300 as no changes in 
tertiary and secondary protein structure were detected (figure 4-4). Furthermore, 
Phospholipon®90G, the PL component of Phosal®50PG, showed a maximal solubility of 60 % 
(w/w) in PEG 300. Hence, this solution was used for further experiments. 
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Figure 4-4 Second derivative FTIR (A) and UV spectra (B, artificial offset for clarity) of 
mAb suspension in PEG 300 mixed with PBS (thick line) compared to the 
spectrum of native mAb solution (thin line).  
3.1.1.3 MAb stability in Phospholipon®90G-PEG 300 formulation 
The stability of sd mAb suspended at a concentration of 50 mg/g in the 60 % 
Phospholipon®90G / 40 % PEG 300 solution was studied after injection into PBS in a 1:2 
(w/w) ratio and vesicle formation. Similar to the placebo formulation it was possible to 
separate the lipidic from the aqueous phase by centrifugation for 1 hr at 186,000 x g. No 
changes in tertiary and secondary structure of the protein in the aqueous phase were 
identified by second derivative FTIR and UV spectroscopy (figure 4-5). HP-SEC analysis 
revealed a monomer recovery of 99.2 ± 0.04 %. Based on these results, it was concluded 
that the Phospholipon®90G-PEG 300 solution can be used for preparation of the PL-mAb 
suspension. 
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Figure 4-5 Second derivative FTIR (A) and UV spectra (B, artificial offset for clarity) of sd 
mAb suspended in the 60 % Phospholipon®90G / 40 % PEG 300 solution after 
injection into PBS for vesicle formation, mAb dissolution and centrifugation for 
1 hr at 186,000 x g (thick line). Comparison with the spectrum of native mAb 
solution (thin line). 
3.1.2 Cryo-TEM analysis of PL-mAb suspension after vesicle formation in PBS 
Cryo-TEM analysis of the vesicular structures formed after injection of the PL-mAb 
formulation (sd mAb suspended at 50 mg/g in a solution of 60 % Phospholipon®90G in 
PEG 300) into PBS in a 1:2 (w/w) ratio and carefully manual shaking revealed a broad 
vesicle size distribution ranging from ~100 to 1000 nm with presence of multilamellar (MLVs), 
bilamellar (BLVs) and unilamellar vesicles (ULVs) of round or oval shape (figure 4-6). 
  
Figure 4-6 Cryo-TEM images of PL-mAb suspension composed of sd mAb (50 mg/g) in a 
60 % Phospholipon 90G / 40 % PEG 300 solution after vesicle formation in 
PBS. For microscopy analysis, vesicular samples were further diluted in a 1:25 
ratio.  
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Brandl et al. also demonstrated that semi-solid PL dispersions which were manually shaken 
upon dilution yielded both large MLVs and small ULVs [191]. With respect to IA retention, the 
formation of large MLVs is of advantage, since clearance from the synovial cavity is known to 
be reduced for large vesicles. In a study with healthy rabbits Bonanomi et al. showed that 
increasing the vesicle diameter from 160 nm to 750 nm led to a prolongation of IA vesicle 
retention by a factor of 2.6 [35]. Besides the increase in IA retention, the amount of 
encapsulated drug is described to be elevated with increasing vesicle diameter [191]. 
3.1.3 Determination of the mAb EE after vesicle formation of the PL-mAb 
suspension 
For determination of the EE, the PL-mAb suspension composed of 50 mg/g sd mAb 
suspended in a solution of 60 % Phospholipon®90G in PEG 300 was injected into PBS in a 
1:2 (w/w) ratio in order to allow mAb dissolution and vesicle formation. No significant 
encapsulation was detected as at the end of the washing procedure mAb was eluted with a 
recovery of 102.5 ± 7.3 % (figure 4-7). This result was underlined by fluorescence 
measurements after the addition of OG to the purified vesicles rendering an EE of 
2.5 ± 0.5 %. 
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Figure 4-7 Elution profile of mAb after injection of the PL-mAb suspension (50 mg/g sd 
mAb in a solution of 60 % Phospholipon®90G in PEG 300) into PBS in a 1:2 
ratio for vesicle formation and further dilution to a mAb concentration of 
1 mg/mL (filled square) in comparison to empty vesicles with spiked, 
extravesicular mAb at same concentration (opened square).  
Marrink et al. simulated the association of dipalmitoylphosphatidylcholine into vesicles [192]. 
They reported that vesicle formation takes place within nanoseconds with formation of 
intermediate structures such as bicelles and cup-like vesicles. In contrast, dissolution of the 
sd mAb particles in water was determined to occur within 3.2 ± 0.1 min. Hence, the low 
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observed EE can be explained by the time differences between vesicle formation and 
dissolution of sd particles. Since non-encapsulated drug is rapidly cleared from the synovial 
space, a high EE is mandatory for achieving prolonged drug retention. Thus, the use of mAb 
suspended in a PL concentrate was not further pursued. 
3.2 Vesicular PL-mAb formulation 
The application of preformed mAb containing vesicles using a highly-concentrated mAb 
solution presents an attractive alternative. The development and characterization of such a 
formulation was the focus of the following part of this work. 
3.2.1 MAb stability in vesicular PL-mAb formulation 
As shown in preliminary experiments (section 3.1.1.1), propylene glycol up to 50 % has no 
destabilizing effect on mAb. In the following section, the suitability of Phosal®50PG 
(phosphatidylcholine 52.3 %, lysophosphatidylcholine 0.9 %, dissolved in propylene glycol) 
for the preparation of a vesicular PL-mAb formulation using a highly-concentrated mAb 
solution was investigated. Therefore, Phosal®50PG was admixed with a 70 mg/mL mAb 
solution and emulsified using a dual-syringe system leading to a vesicular PL-mAb 
formulation with a mAb content of 50 mg/g. MAb extraction from the formulation was 
performed both via centrifugation for 1 hr at 186,000 x g as well as by the addition of an OG 
solution for solubilization of the lipid matrix. Similar to the placebo sample, phase separation 
was achieved for the PL-mAb formulation by centrifugation. The addition of OG led to a clear 
micellar solution without evidence of visible particle formation or signs of turbidity. The mAb-
containing aqueous phase obtained by centrifugation was analyzed by second derivative 
FTIR and UV spectroscopy, HP-SEC and determination of the mAb bioactivity. 
Second derivative FTIR and UV spectroscopy did not show structural changes compared to 
the native mAb (figure 4-8). HP-SEC analysis revealed that the monomer content was 
preserved (99.7 ± 0.03 %) and the extracted mAb did not show a change in bioactivity 
(104 ± 17.1 % vs. 112 % mAb standard). The high mAb compatibility of Phosal®50PG can be 
explained by the low total propylene glycol concentration of 11.8 % in the sample after 
addition of the mAb solution, as shown in section 3.1.1.1. Additionally, it was concluded that 
the presence of vesicular interfaces, formed by the phospholipid component, does not lead to 
any instability of the surface-active protein molecules. 
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Figure 4-8 Second derivative FTIR (A) and UV spectra (B, artificial offset for clarity) of 
mAb after extraction from the vesicular PL-mAb formulation (Phosal®50PG 
and mAb solution (70 mg/mL) emulsified using a dual-syringe system leading 
to a mAb concentration of 50 mg/g) by centrifugation for 1 hr at 186,000 x g 
(thick line) compared to the spectrum of native mAb solution (thin line). 
3.2.2 Characterization of vesicular PL-mAb formulation 
3.2.2.1 Rheometry and injectability 
Rheometry of the vesicular PL-mAb formulation (Phosal®50PG and mAb solution (70 mg/mL) 
emulsified using a dual-syringe system leading to a mAb concentration of 50 mg/g) did not 
reveal any significant differences between placebo and mAb-containing vesicular PL 
formulation (0.48 ± 0.02 Pa·s (active) vs. 0.39 ± 0.03 Pa·s (placebo) at 10 s-1) (figure 4-9), 
indicating that the viscosity is not affected by the addition of mAb or any PL-mAb 
interactions. Both formulations showed a pronounced shear thinning behavior and should 
enable easy injectability.  
Determination of the maximal injection force revealed that the vesicular PL-mAb formulation 
can in fact easily be handled. Low maximal injection forces were required (3.2 ± 1.2 N) that 
did not differ significantly from injection force values determined for the placebo formulation. 
Hence it was concluded that the presence of mAb had no impact on injectability. 
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Figure 4-9 Viscosity of vesicular PL-mAb formulation (Phosal®50PG and mAb solution 
(70 mg/mL) emulsified using a dual-syringe system leading to a mAb 
concentration of 50 mg/g, filled symbol) and vesicular PL-placebo formulation 
(opened symbol) with increasing (square) and decreasing (triangle) shear rate. 
3.2.2.2 Cryo-TEM and DLS analysis 
Cryo-TEM analysis of the vesicular PL-mAb formulation revealed a broad size distribution 
ranging from ~100 nm to 800 nm with the presence of MLVs, BLVs and ULVs (figure 4-10). 
These results are comparable to the vesicular structure resulting from PL-mAb suspensions 
(section 3.1.2).  
  
Figure 4-10 Cryo-TEM images of vesicular PL-mAb formulation (Phosal®50PG and mAb 
solution (70 mg/mL) emulsified using a dual-syringe system leading to a mAb 
concentration of 50 mg/g) after 1:20 dilution with PBS (lipid concentration 
10 mM). 
The broad vesicle size distribution was underpinned by a high polydispersity index of 
0.4 ± 0.1 (placebo) and 0.5 ± 0.04 (active) in DLS measurements. Placebo and mAb 
containing vesicles showed comparable average vesicle size (411.2 ± 57.3 nm (placebo) and 
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520.4 ± 28.6 nm (active)). Hence, due to the presence of large vesicles it might be possible 
to encapsulate higher amounts of protein and a reduced clearance from the synovial cavity is 
expected compared to small sized vesicles.  
3.2.2.3 Determination of mAb EE 
Determination of the EE in the first elution fraction after Vivaspin® centrifugation, as 
described in section 2.2.15, revealed that 15.9 ± 1.0 % of the mAb were encapsulated. This 
result was confirmed by quantification of encapsulated mAb after vesicle purification and 
solubilization of the lipids rendering an EE of 14.2 ± 2.0 %.  
Many publications describe the encapsulation of proteins or peptides in liposomes. Apart 
from the drug to be encapsulated, the method of preparing the liposomes determines the 
vesicle size and thereby the EE value. Colletier et al. encapsulated acetylcholinesterase in 
200 nm sized liposomes using the film hydration method and achieved an EE of less than 
10 %. With increasing number of additional freeze-thaw cycles, the EE was elevated to 
~25 % under preservation of the enzyme activity [193]. Zhao et al. incorporated recombinant 
human growth hormone into preformed placebo phosphatidylcholine/cholesterol liposomes 
using a freeze-thaw technique. Depending on the number of freeze-thaw cycles and the 
incubation time after each freeze-thaw cycle, EE values ranging from 40-80 % were 
achieved. Liposomes had a mean size of 1.7-2.5 µm. Even though this preparation technique 
was considered as mild, no information concerning the protein stability after liposome 
preparation are provided and thus protein instabilities that might contribute to the 
determination of a high EE value should be taken into account [194]. Xu et al. analyzed the 
EE of the enzyme superoxide dismutase in ULVs with a size between 150 and 180 nm. 
Depending on the number of applied freeze-thaw cycles, an EE between 34 % and 50 % was 
achieved while maintaining of the enzyme activity [195]. Taking into consideration that the 
vesicular PL-mAb formulation was prepared under avoidance of harsh volatile organic 
solvents or critical freeze-thaw cylces by using a simple emulsification technique, an EE of 
15 % can be regarded as an adequate value. 
3.2.3 In vivo experiments with the vesicular PL-mAb formulation 
In order to study the pharmacokinetic profile of the vesicular PL-mAb formulation 
(Phosal®50PG and mAb solution emulsified using a dual-syringe system) upon IA 
administration in vivo, an animal study was performed at the Abbott Bioresearch Center. This 
study was carried out with the murine mAb variant and the mAb concentration in the PL 
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formulation was reduced to 35.7 mg/g. Compared to the PL-free reference group (murine 
mAb solution), a slightly lower mAb absorption rate into the systemic circulation was seen 
upon application of the vesicular PL-mAb formulation (figure 4-11). This difference was most 
pronounced after 4 and 12 hrs. Thereafter, no or only slight differences between both 
formulations were observed. The increase in mAb serum concentration occurred 
concomitantly to a decrease in the SF mAb concentration. However, only at the 4 hr time 
point did a significant difference between PL-mAb formulation and mAb solution become 
apparent in SF.  
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Figure 4-11 Mean serum mAb concentrations (A) and mean SF mAb concentrations (B) in 
Lewis rats after IA administration of the vesicular PL-mAb formulation 
(Phosal®50PG and murine mAb solution (50 mg/mL) emulsified using a dual-
syringe system leading to a murine mAb concentration of 35.7 mg/g, white) or 
a murine mAb solution (35.7 mg/mL, black). 
Various studies can be found in literature demonstrating the prolonged residence time of 
drug-loaded PL vesicles within the joint cavity [38, 39, 41]. However, these studies were 
performed with drug-loaded vesicles after separation of non-encapsulated drug. This makes 
direct comparison with the results of the present study difficult, as the vesicular PL-mAb 
formulation tested contained both encapsulated and non-encapsulated drug. Obviously, 
retention of non-encapsulated mAb due to a potential steric entrapment within the PL matrix 
was not achieved. One reason for the observed low drug retention within the joint cavity 
could be the EE value of 15 % which might be too low for detection of a retardation effect in 
comparison to the PL-free mAb solution, as non-encapsulated mAb is rapidly cleared from 
the synovial cavity. After the observation period of 48 hrs, the effect of the vesicularly 
encapsulated mAb could not become evident. In order to increase the percentage of drug 
retained at the site of application, an increase in EE and/or separation of non-encapsulated 
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mAb would be beneficial. Furthermore, insufficient SF stability of mAb-loaded vesicles could 
be another reason for the low synovial retention. In this case, mAb release from the vesicles 
would be facilitated causing rapid clearance from the joint cavity. Alternatively, vesicular 
binding to e.g. the joint cartilage or migration into the surrounding tissue under preservation 
of the vesicular structure could also be hypothesized. This would initially lead to a lack of 
mAb recovery in both serum and SF. Therefore, knowledge about the fate of the mAb-loaded 
vesicles presents an important aspect. 
3.2.4 Approaches to increase the EE of the vesicular PL-mAb formulation 
A major drawback of vesicular PL-based delivery systems is the limited EE [191]. The 
various attempts towards increasing the EE can be classified into two overall groups: 
formulation- and preparation-related approaches [195]. Formulation-related approaches 
comprise the increase of the lipid content [191, 195], the addition of cholesterol [168, 195] 
and the change of the lipid composition [195]. The increase of the lipid content is reported to 
improve the EE of drugs due to the enlargement of the membrane area, leading to an 
augmentation of the vesicle number per unit volume. Thus, the encapsulation volume and 
amount of encapsulated drug is enhanced [191]. Xu et al. found out that the EE of the 
enzyme superoxide dismutase changed from 26.5 % to 51.9 % when the lipid content was 
raised by a factor of three [195]. The addition of cholesterol is known to increase the packing 
density of lipid vesicles causing a reduction of the membrane permeability [168, 169]. 
Cagdas et al. demonstrated that the hydrophilic protein cytochrome C could only be 
encapsulated when cholesterol was present in the membrane [168]. The change of the lipid 
composition, for instance by the addition of anionic lipids might lead to an increase of the EE 
of positively charged drugs induced by electrostatic interactions. Preparation-related 
approaches include the application of a freezing step after vesicle formation followed by 
thawing [195] as well as the use of homogenization methods such as ultra-turrax® treatment 
[196] or DAC [177]. The positive effect of vesicle freezing and thawing can be mainly 
explained by the reversible physical disruption of the vesicle membrane due to ice crystal 
formation, and the presence of an osmotic gradient between vesicle exterior and interior, 
leading to augmentation of intravesicular drug concentration. The required number of freeze-
thaw cycles to reach a concentration equilibrium mainly depends on the lamellarity of the 
vesicle and on the diffusion coefficient of the drug to be encapsulated [195]. Laloy et al. 
introduced a simple liposome preparation method where dispersions of lipids in aqueous 
bovine hemoglobin solution were emulsified by means of an ultra-turrax®. The high shear 
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forces during mixing induce the reordering of the vesicle membrane. In this study, liposomes 
with an EE of 24 % were generated. However, no information concerning the protein stability 
were provided [196]. Liposome preparation using a DAC was reported to yield small sized 
liposomes with high EE values due to the efficient homogenization based on oppositely 
vectored rotating movements. Massing et al. employed this method to prepare calcein 
containing vesicular phosphospholipid gels showing EE values up to 56 % upon dilution 
[177]. The suitability of the aforementioned approaches in generating high mAb entrapment 
was subsequently investigated and is described in the following section. 
3.2.4.1 Increase of lipid content 
In a first effort to improve the EE, formulations with lipid contents ranging from 152 mg/g to 
355 mg/g were prepared with the dual-syringe system. To keep the total mAb concentration 
in the formulation at a constant 50 mg/g, the lipid content was increased by using mAb 
solutions at concentrations ranging from 70 mg/mL (PL content 152 mg/g) to 150 mg/mL (PL 
content 355 mg/g) (table 4-3). A further increase of the lipid content was not possible as the 
viscosity of the formulation drastically increased and homogeneous mixing could not be 
achieved. By changing the PL content from 152 mg/g to 236 mg/g, the EE was raised by a 
factor of 2 from 15.9 ± 1.0 % to 31.5 ± 4.4 % (figure 4-12 A). A further increase of the lipid 
content did not further augment the EE. Vesicle size and size distribution decreased with 
increasing PL content from 520 ± 28 nm (PdI 0.5 ± 0.02) at 152 mg/g to 210 ± 6 nm (PdI 
0.2 ± 0.02) at 355 mg/g (figure 4-12 B).  
Table 4-3 Formulation compositions used for improvement of the EE by increasing the 
lipid content. 
Mixing ratio 
Phosal®50PG:mAb solution  
(w/w) 
Concentration  
mAb solution  
[mg/mL] 
Resulting PL content  
[mg/g] 
1:2.5 70 152 
1:1.25 90 236 
1:0.63 130 327 
1:0.5 150 355 
The limited increase of the EE with plateau formation was also reported by Xu et al. [195]. 
Similar observations were made by Shew et al. who investigated the EE of both alkaline 
phosphatase and hemoglobin at various lipid contents. They explained the limited increase of 
the EE by presuming that with raising lipid content mainly MLVs instead of ULVs are formed 
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which leads to plateau formation with respect to the captured volume [197]. The DLS 
measurements (figure 4-12 B) revealed that with increasing lipid content, vesicle size and 
size distribution were reduced. However, from these data it is not possible to draw 
conclusions concerning lamellarity of the vesicles. Since with increasing lipid content the 
number of vesicles is supposed to be raised, a direct correlation between results of EE 
determination and DLS measurements cannot be found. The decline in vesicle size with 
increasing lipid content can be explained by the viscosity increase of the formulation leading 
to vesicle deformation and smaller sizes during formulation preparation. With respect to IA 
administration it should be noticed that a high vesicle size is preferred as clearance from the 
synovial space is reportedly thereby reduced. Therefore, for several reasons, the use of PL 
contents above 236 mg/g offers no advantage. Due to the possibility to raise the EE by the 
factor of 2 when increasing the lipid content from 152 mg/g to 236 mg/g, this approach is 
highly beneficial with regards to the reduction of the free drug amount.  
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Figure 4-12 EE (A) and DLS results (B) of PL-mAb formulations composed of 
Phosal®50PG and mAb solutions at concentrations ranging from 70 mg/mL to 
150 mg/mL, prepared with the dual-syringe system, leading to PL contents 
ranging from 152 mg/g to 355 mg/g and a mAb content of 50 mg/g.  
3.2.4.2 Addition of cholesterol 
In a second approach, cholesterol was dissolved in Phosal®50PG at 40 °C at molar 
cholesterol:PL concentrations of 1:9, 2:8 and 2.5:7.5 (corresponding cholesterol 
concentration in Phosal®50PG: 3 %, 6.5 % and 8.4 %) prior to formulation preparation. 
Higher amounts of cholesterol could not be added as solubility was exceeded. All 
formulations were prepared with a PL content of 236 mg/g. Therefore, the mAb solution at a 
concentration of 90 mg/mL was employed. The addition of small amounts of cholesterol (ratio 
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1:9) significantly elevated the EE from 31.5 ± 4.4 % to 43.4 ± 2.2 % (figure 4-13 A). A further 
increase of the cholesterol content (ratio 2.5:7.5) induced a reduction of the EE to 23.4 ± 
1.1 %. The vesicles were slightly smaller compared to a cholesterol-free formulation with the 
same lipid content (figure 4-13 B) and the size distribution was not affected by addition of 
cholesterol. 
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Figure 4-13 EE (A) and DLS results (B) of PL-cholesterol-mAb formulations, composed of 
cholesterol dissolved in Phosal®50PG, emulsified with mAb solution 
(90 mg/mL) by using a dual-syringe system, leading to a mAb concentration of 
50 mg/g and a PL content of 236 mg/g.  
In general, cholesterol is incorporated into the PL bilayer via interactions between the 3β-OH 
group and the hydrophilic part of the PL molecules as well as between the sterol backbone 
and the PL fatty acid chains [198]. Cholesterol incorporation into the bilayer leads to 
enhanced liposomal membrane rigidity, higher physical stability of the vesicles and reduced 
membrane permeability due to a higher packing density of the membrane forming molecules 
[168, 199]. The observed EE increase upon addition of small amounts of cholesterol is in 
good accordance with published research [200]. The concentration dependent increase and 
decrease of the EE was also seen by Shimizu et al. [201]. They found that the addition of 
small amounts of cholesterol led to a noticeable increase of the EE of an antibody into egg 
lecithin/cholesterol liposomes, but a further increase of cholesterol reduced the efficiency 
drastically. However, while Shimizu et al. observed a reduction of EE at a molar 
cholesterol:lipid ratio of 1:2, these changes were already observed at a cholesterol:PL ratio 
of 2:8 in the present study. Ramana et al. demonstrated that the EE of nevirapine increased 
significantly at a cholesterol:PL ratio of 1:9. A further increase in cholesterol led to a slight 
reduction of the EE [202]. Similar results were also found by Deniz et al. who reported that 
the entrapment of the hydrophobic drug celecoxib in liposomes decreased with increasing 
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cholesterol content. This was explained by the competition between the drug molecule and 
cholesterol for incorporation in the PL membrane [203], a phenomenon which should not play 
a role for mAb loading of vesicles. On the other hand, as the hydrophobicity of the bilayer is 
expected to be elevated at increased cholesterol concentrations, it is likely that potential 
protein-PL interactions are reduced, leading to the observed decline in EE. Taking into 
account that the increase of the EE with the addition of small amounts of cholesterol was 
accompanied by a decrease of the vesicle size, the addition of cholesterol is not expected to 
provide a benefit compared to the cholesterol-free formulation with respect to prolongation of 
the IA residence time of the vesicles. 
3.2.4.3 Addition of negatively-charged lipids 
Another potential approach to increase the EE is the addition of negatively-charged lipids. 
Such lipids are commonly used for the preparation of liposomes as they can result in higher 
zetapotential, thus reduce aggregation and fusion tendencies and can provide better 
liposome stability during storage. Moreover, the uptake of negatively-charged liposomes by 
mononuclear phagocytes is reported to be enhanced [204], which is an advantage when 
passive targeting is envisaged. Commonly used lipids are phosphatidylglycerol, phosphatidic 
acid and phosphatidylserin that are negatively charged at physiological pH. The addition of 
negatively-charged lipids moreover offers the possibility to increase the EE of positively 
charged drugs via electrostatic interactions. As the present mAb has a positive net charge at 
physiological pH, a charge-induced increase of the EE could be hypothesized. Therefore, 
phosphatidylglycerol and phosphatic acid were intended to be dissolved in Phosal®50PG. 
However, as these lipids proved to be insoluble in the PL solution, even at elevated 
temperature, this approach was not further investigated. 
3.2.4.4 Freeze-thaw treatment 
The application of freeze-thaw cycles to vesicular drug-containing formulations is a common 
preparation step to achieve high drug encapsulation and can be explained by different 
theories. As demonstrated by Mayer et al., reduced solute concentrations were found inside 
the vesicle core upon dispersion of egg phosphatidylcholine in aqueous buffer causing an 
osmotic gradient between vesicle exterior and interior. The application of repetitive freezing 
and thawing balance out the solute gradient leading to increased EE [205]. Another 
explanation is that during freezing, ice crystals form across the liposome and this water 
removal from the hydrated bilayer via phase separation causes breakage of the membrane 
[206]. On thawing, ice crystals are transformed into water channels that allow drug diffusion 
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along the concentration gradient from the surrounding medium into the vesicular core before 
the vesicles are reformed [195, 207]. Freezing is commonly performed by sample immersion 
into liquid nitrogen (ca. -200 °C) [207] until complete solidification is achieved. This freezing 
technique results in the formation of heterogeneous small ice crystals by directional 
solidification as a consequence of a low degree of supercooling and thus fast freezing rate 
[208]. The beneficial effect of this technique on the drug EE, however, might be accompanied 
by protein instabilities as repetitive freezing and thawing may induce protein denaturation 
induced by the formation of a large liquid-ice interface or the concentration increase upon ice 
formation [208, 209]. Several studies can be found in literature in which protein-loaded 
liposomes were subjected to repetitive freeze-thaw cycles for improvement of the EE under 
maintenance of protein stability. It was shown that e.g. the enzyme activity of superoxide 
dismutase encapsulated in lipid vesicles was preserved after two freeze-thaw cycles [195]. 
Encapsulation of rhG-CSF by application of 5 freeze-thaw cycles did not lead to changes in 
protein structure [69]. At first, to study the impact of repetitive freeze-thaw cycles on mAb 
stability, a 2 mg/mL mAb solution, containing sodium chloride (105.5 mM), monobasic 
sodium phosphate dihydrate (5.5 mM), dibasic sodium phosphate dihydrate (8.6 mM), 
sodium citrate (1.16 mM), citric acid monohydrate (6.19 mM) and mannitol (65.9 mM), was 
subjected to 2, 4, 6 and 8 freeze-thaw cycles by immersion into liquid nitrogen and 
subsequent thawing at 30 °C in a water bath. Samples were analyzed by HP-SEC and 
turbidity measurement at 350 nm.  
The application of up to 6 freeze-thaw cycles had no impact on the HP-SEC monomer 
recovery. Additional aggregates (0.2 %) were detectable after 8 freeze-thaw cycles (figure 4-
14 A). No increase in turbidity which could indicate formation of larger protein aggregates 
compared to the native mAb solution was identified (figure 4-14 B) and also visual 
appearance did not change.  
In order to investigate the impact of repetitive freeze-thaw cycles on the mAb EE, the 
vesicular PL-mAb formulation at PL content of 236 mg/g (Phosal®50PG and mAb solution 
(90 mg/mL) emulsified by using a dual-syringe system, leading to a mAb concentration of 
50 mg/g) was subjected to 3 and 5 freeze-thaw cycles. As illustrated in figure 4-15 A, the 
encapsulated amount of mAb was not increased by the freeze-thaw cycles. Furthermore, 
neither vesicle size nor vesicle size distribution was affected by the freeze-thaw treatment 
(figure 4-15 B).  
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Figure 4-14 Impact of repetitive freeze-thaw (FT) cycles on HP-SEC recovery (A) and 
turbidity at 350 nm (B) of a 2 mg/mL mAb solution.  
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Figure 4-15 EE (A) and DLS results (B) of PL-mAb formulation (Phosal®50PG and mAb 
solution (90 mg/mL) emulsified by using a dual-syringe system, leading to a 
mAb concentration of 50 mg/g) after 0, 3 or 5 freeze-thaw (FT) cycles. 
Ice crystal formation during freezing, which causes disruption of the PL bilayer, is described 
to be influenced by various factors such as cooling rate and type of excipients employed 
[210]. A fast cooling rate of >20 °C/min is reported to induce complete intra-liposomal ice 
formation leading to expansion of the intra-vesicular aqueous phase and thus to membrane 
disruption [207]. The presence of cryoprotectants such as trehalose or surcrose prevents the 
PL bilayer from ice crystal damage via water replacement and thus contributes to liposome 
stabilization during freezing [211]. In addition, these excipients build a vitrified matrix in which 
the liposomes are embedded on freezing [212]. The use of organic solvents such as ethylene 
glycol, propylene glycol and glycerol was reported to improve the liposomal retention of 
calcein upon freeze-drying and subsequent rehydration in the presence of 
cycloinulohexaose. This phenomenon was explained by the ability of the additives to interact 
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with the lipid molecules via hydrogen bonding. These interactions lead to membrane 
stabilization and maintenance of a certain distance of the vesicles which prevents fusion and 
aggregation [213]. The present vesicular PL-mAb formulation contains propylene glycol as 
PL solvent in Phosal®50PG. Based on the aforementioned study the presence of propylene 
glycol could be one reason for the missing increase of the EE following the repetitive freeze-
thaw cycles. Mannitol, contained in the mAb solution used for formulation preparation, is a 
common bulking agent in freeze-drying due to its ability to form a crystalline matrix. However, 
depending on the applied cooling rate, amorphous mannitol can also be found. Cavatur et al. 
analyzed the morphology of mannitol in relation to the cooling rate via X-ray diffractometry. 
They were able to show that a rapid cooling rate inhibited mannitol crystallization whereas 
slow cooling rates led to crystalline matrices [214]. As the sample immersion into liquid 
nitrogen is leading to a rapid cooling rate [208], the initial formation of amorphous mannitol 
could be speculated that leads to membrane stabilization via water replacement and 
embedment of the vesicles into the vitrified matrix. However, the mannitol concentration in 
the sample was only 1 % and thus the impact of amorphous mannitol on the vesicle 
stabilization might be of minor importance. The presence of extravesicular mAb could also 
contribute to vesicle stabilization by embedment into the amorphous protein matrix formed 
upon freezing. As the concentration of free mAb in the sample was 3.5 %, the non-
encapsulated mAb could be hypothesized as predominant reason for to the missing increase 
of the mAb EE. Based on these considerations, the application of freeze-thaw cycles for 
improvement of the EE has limited applicability for the present formulation. However, from 
the present results it can be also concluded that the vesicular PL-mAb formulation offers the 
possibility to freeze the formulation for storage or shipping purpose without loss of mAb EE 
or mAb stability.  
3.2.4.5 Ultra-turrax® treatment 
The impact of ultra-turrax® emulsification on the EE of mAb was studied with the vesicular 
PL-mAb formulation at a PL content of 236 mg/g, prepared by emulsification of Phosal®50PG 
with mAb solution (90 mg/mL) by means of a dual-syringe system. As it is known that shear 
stress may induce protein aggregation [215], the impact of different mixing times on mAb 
stability was assessed first. A 2 mg/mL mAb solution was subjected to ultra-turrax® 
homogenization for 15, 30 or 45 s at 8000 rpm and analyzed via HP-SEC and turbidity 
measurement at 350 nm.  
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Ultra-turrax® treatment of up to 45 s had no impact on HP-SEC monomer recovery but an 
increase in turbidity was observed (figure 4-16). On account of the unchanged HP-SEC data, 
the slight increase in turbidity could be ascribed to the presence of insoluble aggregates 
formed. However, the general impact of this additional preparation step on the mAb EE was 
studied by ultra-turrax® treatment of the PL-mAb formulation for 45 s. The EE of the PL-mAb 
formulation (30.7 ± 4.4 % ultra-turrax® vs. 31.5 ± 4.4 % untreated) as well as its vesicle size 
and size distribution (330.0 ± 14.3 nm, 0.4 ± 0.01 (ultra-turrax®) vs. 326.5 ± 6.1 nm, 0.4 ± 
0.05 (untreated)) were unchanged. Based on these results it was concluded that the shear 
forces induced by the instrument were insufficient to induce opening and reformation of the 
vesicles which might contribute to an increase of EE. Moreover, it was demonstrated that the 
present formulation provides a high mechanical stability which is of advantage if samples are 
intended to be shipped.  
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Figure 4-16 Impact of ultra-turrax® emulsification at 8000 rpm for 15, 30 and 45 s on HP-
SEC recovery (A) and turbidity at 350 nm (B) of a 2 mg/mL mAb solution. 
3.2.4.6 Formulation preparation using the dual asymmetric centrifuge 
The DAC as alternative preparation method was evaluated with respect to increasing the EE 
of the PL-mAb formulation with lipid contents of 236 mg/g and 355 mg/g. Compared to the 
preparation by dual-syringe system, the use of the DAC for 30 min did not lead to a 
significant increase in EE (figure 4-17 A). Similar to previous results (section 3.2.4.1) an 
increase of the lipid content from 236 mg/g to 355 mg/g had no impact on the EE. The 
change in total centrifugation time induced an increase in EE from 38.7 ± 5.6 % (30 min) to 
53.3 ± 5.4 % (60 min). The formation of small sized vesicles with narrow size distribution was 
observed in samples prepared via DAC (figure 4-17 B). At a higher lipid content, the 
polydispersity index was further reduced, which corroborates results from literature [177].  
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The results demonstrate that increased EE values are obtained by extended centrifugation 
time which can be explained by the enhanced homogenization of the formulation and thus 
increased exposure of the vesicles to shear forces. Since the prolonged centrifugation time 
had no impact on the vesicle size, it can be concluded that the elevated entrapment 
efficiency is induced by continuous reformation of the vesicles under maintenance of the 
size. Apparently, the shear forces in the DAC are much higher than upon mixing within the 
dual-syringe system as the vesicle size and size distribution of formulations prepared by 
syringe-mixing were significantly higher compared to the DAC method. At higher lipid 
content, size distribution was further reduced using the DAC. 
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Figure 4-17 EE (A) and DLS results (B) of PL-mAb formulations at lipid contents of 236 or 
355 mg/g (Phosal®50PG emulsified with mAb solution at 90 mg/mL or 
150 mg/mL) after formulation preparation with the DAC in comparison to the 
dual-syringe system. If not stated otherwise, a total centrifugation time of 
30 min was applied. 
Above results showed that the EE of mAb can be increased by raising the lipid content, by 
application of freeze-thaw cycles and by use of homogenization methods such as ultra-
turrax® and DAC. The overall increase achieved was only up to a maximum of approximately 
30 %. In contrast to this, EE values of up to 40 % were achieved after the addition of small 
amounts of cholesterol to the formulation. The application of a DAC centrifugation time of 
60 min led to the highest EE value of 53.3 ± 5.4 %. Most of these approaches resulted in 
vesicle sizes smaller than 300 µm. Bearing in mind that small vesicles are rapidly cleared 
from the synovial space, the increase in EE might not lead to prolonged drug retention at the 
site of application. Furthermore, even with an EE of 53 %, the percentage of free mAb is still 
high, which makes the assessment of pharmacokinetic differences to IA injected liposomal-
free mAb difficult. Therefore, despite of the achievements in EE, the separation of non-
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encapsulated mAb from mAb containing vesicles presents an attractive approach in order to 
study the pharmacokinetic profile of the present formulation in vivo. 
3.2.5 Short time stability study of PL-mAb vesicles after separation of non-
encapsulated mAb in PBS 
Leakage of encapsulated drugs out of PL vesicles presents a frequently observed 
phenomenon. The extent of leakage is described to be dependent on the lamellarity of the 
vesicle, the molecular size of the entrapped molecule [191] and the membrane composition 
[216]. The physical stability of the mAb-containing vesicles was studied using a PL-mAb 
formulation with PL content of 236 mg/g prepared with the dual-syringe system. Non-
encapsulated mAb was separated from the vesicles using Vivaspin®2 centrifugation tubes. 
The purified PL-mAb vesicles were stored for 7 d at 2-8 °C and subsequently again 
centrifuged for 40 min at 2739 x g and 20 °C in Vivaspin®2 centrifugation tubes. The elution 
fractions were fluorimetrically analyzed with regards to the released mAb. As reference the 
elution fractions of the last purification step prior to storage were employed. After storage for 
one week, the fluorescence intensity of the elution fractions was insignificantly higher than 
before storage (figure 4-18). Based on these results it was concluded that mAb is retained by 
the vesicle membrane and is not released under the given conditions. This is in good 
accordance with literature, where it was reported that the PL membrane permeability is very 
low when high MW drugs are encapsulated [169]. 
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Figure 4-18 Intrinsic fluorescence intensity of elution fractions before and after storage of 
purified mAb containing PL vesicles in PBS (2-8 °C, 7 d) in comparison to 
placebo and PBS.  
Additionally, the mAb stability in the purified vesicles was studied. Therefore, samples stored 
for 1 d, 7 d and 14 d at 2-8 °C were subjected to one freeze-thaw cycle in order to release 
encapsulated mAb. The application of detergents for release of encapsulated mAb was not 
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applied as the HP-SEC analysis of mAb in presence of lipid-containing micelles was intended 
to be avoided. Vesicles were separated from released mAb by centrifugation for 1 hr at 
186,000 x g and 20 °C. The supernatant was subjected to HP-SEC analysis. The monomer 
recovery slightly decreased during the observation period from 98.7 ± 0.03 at day 1 to 97.1 ± 
0.9 % at day 14 (figure 4-19) which might be ascribed to the exposure of the encapsulated 
mAb to the lipid membrane of the vesicles. 
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Figure 4-19 HP-SEC monomer recovery of mAb upon encapsulation into PL vesicles, 
vesicle separation from non-encapsulated mAb, storage at 2-8 °C and mAb 
release induced by one freeze-thaw (FT) cycle in comparison to a PL vesicle-
free mAb solution with and without FT treatment.  
3.2.6 Fluorescence microscopy of fluorescence-labeled PL-mAb vesicles 
In order to visualize the encapsulation of mAb into the PL vesicles, both mAb and PL 
vesicles were labeled with a fluorescent dye and analyzed by using a fluorescence 
microscope. After labeling of mAb with AlexaFluor®488, HP-SEC analysis confirmed that the 
labeling process did not induce mAb aggregation (mAb standard 99.3 % vs. F-mAb 98.8 %). 
SPR measurements confirmed that the labeling procedure did not affect the binding affinity of 
mAb to its antigen as reflected by an unchanged dissociation constant KD (mAb standard  
7.7 x 10-11 ± 6.4 x 10-12 mol/L vs. F-mAb 6.7 x 10-11 ± 4.8 x 10-12 mol/L). For the PL-mAb 
formulation preparation at PL content of 236 mg/g a 1:10 F-mAb to non-labeled mAb mixture, 
up-concentrated to 90 mg/mL, was used. Fluorescence microscopy analysis was performed 
after dilution to a mAb concentration of 1 mg/mL. Observation under bright-field mode 
revealed the vesicles varying in size (figure 4-20 A). Due to the limited resolution of the 
microscope, only vesicles of the upper size range were detectable. Observation upon 
excitation at 480 nm for visualization of F-mAb showed bright shining spots of green color  
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Figure 4-20 Fluorescence microscopy images of F-mAb-loaded PL vesicles, stained with 
nile red. (A) bright-field mode for visualization of PL vesicles (exposure time 
1/70 s) (B) excitation at 480 nm for F-mAb visualization (exposure time 1.8 s), 
(C) excitation at 560 nm for visualization of PL vesicles (exposure time 1/13 s), 
(D) overlay of (B) and (C).  
 
 
Figure 4-21 Fluorescence microscopy images of empty PL vesicles, stained with nile red 
and spiked F-mAb. (A) bright-field mode (exposure time 1/70 s), (B) excitation 
at 480 nm (exposure time 1.8 s), (C) excitation at 560 nm (exposure time 
1/13 s). 
(figure 4-20 B) indicating vesicularly entrapped protein. Extravesicular F-mAb was not 
detectable. On excitation at 560 nm, nile red-stained PL vesicles were identified by red 
A B 
C D 
A B 
C 
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fluorescence (figure 4-20 C). Overlay of the images of green and red fluorescence 
observation mode proved that the F-mAb was associated with the PL vesicles (figure 4-20 
D). 
In order to investigate whether the green fluorescence is ascribed to F-mAb adsorption on 
the outer PL membrane or encapsulation in the inner PL vesicle core, empty vesicles were 
prepared, spiked with a F-mAb/mAb solution at 1 mg/mL and incubated for 1 day at 2-8 °C. 
Fluorescence microscopy revealed that only the nile red-stained PL vesicles were 
detectable. Observation in green fluorescence mode revealed a dark background (figure 4-
21). Overlay of 4-21 B and C led to a dark image and is therefore not depicted. Hence, the 
green spots detected in figure 4-20 B are ascribed to F-mAb encapsulated in PL vesicles. 
3.2.7 Short time stability study of PL-mAb vesicles in serum 
Not only stability of the vesicles ex vivo is critical, but also increased permeability of drug-
loaded PL vesicles in the presence of serum has been widely reported in literature. Allen et 
al. demonstrated that the in vitro efflux of calcein from small ULVs was raised with increasing 
serum concentrations present in the incubation medium [217]. Scherphof et al. postulated 
that the enhanced permeability of 125I-labeled albumin from liposomes in the presence of 
plasma can be ascribed to a transfer of phosphatidylcholine to high-density lipoproteins 
which leads to disintegration of the vesicles [218]. Another study reported that the 
complement system plays an important role in the destabilization of liposomes [219]. 
Investigations of the impact of BSA on the stability of methotrexate-loaded liposomes 
revealed enhanced leakage with increasing BSA concentrations present in the surrounding 
medium [220]. Also upon incubation of drug-loaded liposomes in SF, obtained from patients 
suffering from rheumatoid arthritis, a remarkable release of entrapped 125I-lactoferrin from PL 
vesicles was identified [38]. These studies demonstrate that vesicle stability in body fluids 
presents an important parameter for the prediction of the drug delivery upon in vivo 
application. For stability analysis of PL-mAb vesicles in body fluids, the PL-mAb formulation 
at a lipid content of 236 mg/g was prepared using a 1:10 F-mAb/mAb solution. After dilution 
of the formulation to a mAb concentration of 1 mg/mL, non-encapsulated F-mAb/mAb was 
separated from the F-mAb/mAb-loaded vesicles. Purified vesicles were incubated in fetal calf 
serum (FCS) and stored at 37 °C for 4 days. 
Fluorescence microscopy images of F-mAb/mAb-loaded vesicles incubated in PBS showed 
no changes during the observation period. In contrast, incubation in FCS led to strong 
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agglomeration of the vesicles that did not change upon incubation for 4 days (figure 4-22). As 
the detected agglomerates showed strong fluorescence intensity, it was hypothesized that at 
least a majority of the mAb content was retained inside the vesicular structures. Analysis of 
 
 
 
 
 
Figure 4-22 Fluorescence microscopy images of PL-F-mAb/mAb-vesicles directly after 
incubation in FCS (A-C) and after 4 days stored at 37 °C in FCS (D-F). A,D: 
excitation at 480 nm; B,E: bright-field mode; C,F: overlay of fluorescence 
image and bright-field image.  
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the released F-mAb amount at day 0 and day 4 on incubation in PBS underlined the results 
outlined in section 3.2.5 that the mAb-loaded vesicles show a high stability over time, even at 
37 °C (figure 4-23). Vesicles incubated in FCS were initially stable but released 18.9 ± 2.6 % 
of the content during 4 days of incubation at 37 °C. 
PBS t=0 PBS t=4 d FCS t=0 FCS t=4 d
0
5
10
15
20
25
re
le
as
e
d 
m
Ab
 
[%
]
 
Figure 4-23 Percentage of mAb released from PL-mAb vesicles upon incubation in PBS 
(reference) and FCS for 0 and 4 days at 37 °C.  
Aggregation of PL vesicles in the presence of serum is described in literature to occur as a 
consequence of serum protein adsorption on the vesicle membrane [221] and presumably 
serum albumin leads to gap formation in the lipid membrane followed by phase separation 
[222]. This agglomerate formation may even be advantageous for IA application as synovial 
clearance is known to be decelerated with increasing vesicle size. In the present study, 80 % 
of encapsulated mAb were retained by the vesicle membrane after 4 days, which can be 
seen as an adequate release rate for the intended purpose. In order to improve vesicle 
stability, potentially cholesterol could be incorporated into the lipid bilayer [223].  
3.2.8 In vivo mAb release from PL-mAb vesicles after separation of non-
encapsulated mAb 
As described in section 3.2.3, prolonged synovial mAb retention after IA application of the 
initial vesicular PL-mAb formulation in comparison to a PL-free mAb solution was not seen. It 
was hypothesized that the low EE of only 15 % was the reason for the similar 
pharmacokinetic profiles as the high amount of free mAb was rapidly cleared from the 
synovial space. Thus, an effect of mAb encapsulation on synovial mAb retention could not be 
identified during the observation period of 48 hrs. Consequently, the non-encapsulated 
portion was separated from the mAb-loaded vesicles and the mAb recovery in serum upon IA 
administration was investigated during 10 days. Besides the purified PL-mAb vesicles, empty 
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vesicles with spiked mAb and a mAb solution of the same concentration were used as 
controls. 
Mean serum mAb concentrations after IA administration of the PL-mAb vesicles were 
drastically lower compared to the references (figure 4-24). After 4 hrs, the mean mAb serum 
concentration of the vesicle formulation was only 6 % of the concentration of both controls. 
All formulations reached the cmax after one day. Animals, dosed with mAb solution and empty 
vesicles with spiked mAb, revealed maximal mAb serum concentrations of 1.4 ± 0.3 µg/mL 
and 1.6 ± 0.2 µg/mL respectively. The cmax after dosing with PL-mAb vesicles was only 0.2 ± 
0.03 µg/mL. After one day, mean serum mAb concentrations of all groups slightly decreased. 
Both references revealed highly similar pharmacokinetic profiles. After 10 days, SF of all 
animals was analyzed with respect to the remaining mAb concentration. All sample 
concentrations were found to be below the lower limit of quantification and therefore no 
relevant information concerning the remaining mAb could be obtained (data not shown).  
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Figure 4-24 Mean serum mAb concentrations after IA administration of PL-mAb vesicles 
separated from non-encapsulated mAb (white) in comparison to mAb solution 
(black) and empty vesicles with spiked mAb (striped).  
The observed lower mean serum mAb concentrations upon application of the PL-mAb 
vesicles compared to the references show that mAb encapsulation drastically reduced the 
systemic exposure which is in good accordance with the literature [35, 37]. The fact that no 
vesicles were detectable in SF at the end of the study might be due to vesicle migration into 
the surrounding tissue. Similar observations were reported by Edwards et al. who identified 
extra-articular liposome distribution after IA administration of iohexol-loaded liposomes in 
sheep [39]. Another possible explanation could be that the vesicles were adsorbed to the 
articular cartilage surface and thus were not removable by synovial wash. Moreover, vesicle 
clearance from the synovial space and subsequent accumulation in the liver could also be 
hypothesized. Until day one, increased mAb concentrations were found in the systemic 
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circulation which can be ascribed to mAb release from the PL vesicles and underlines the 
findings of section 3.2.7 where it was shown that vesicle stability in serum is limited. In order 
to gain insight into the potential fate of the mAb-loaded vesicles following IA administration, 
an additional experiment with near infrared fluorescent dye-labeled mAb incorporated into 
vesicles was performed in rats and the fluorescence intensity of the knee joint and of the 
gastrointestinal tract was studied using a near infrared fluorescence camera. This experiment 
was performed in collaboration with the Preformulation Group (Dr. Michael Siedler, Dr. 
Vishwesh A Patil) and the Pharmacology Department (Dr. Bradford McRae, Grace Lynch) at 
the Abbott Bioresearch Center. Three days after IA injection, high fluorescence intensity of 
the knee joint was detectable (figure 4-25 A) indicating that at least the labeled protein was 
still present at the site of injection. From previous studies it is known that free mAb is rapidly 
cleared from the synovial cavity (section 3.2.3). Hence, the fluorescence intensity in the right 
joint after 3 days can be ascribed to the presence of mAb-loaded vesicles that are retained at 
the site of injection. Protein accumulation at the injection site due to formation of large protein 
aggregates is not expected based on foregoing experiments showing the excellent 
formulation stability. Moreover, also the control formulation in the aforementioned in vivo 
study containing empty vesicles with spiked mAb showed a rapid mAb release from the joint 
without evidence of protein aggregation. After 3 days, no fluorescence intensity was found in 
the liver (figure 4-25 B) which demonstrates that the mAb-loaded vesicles are not cleared  
 
 
Figure 4-25 Fluorescence images of right joint (A, arrow 1) and gastrointestinal tract after 
laparotomy (B) 3 days after IA administration of near infrared fluorescent dye-
labeled mAb encapsulated in PL vesicles in rats. Arrow 2, dashed boundary: 
liver; arrow 3: stomach; arrow 4: intestine, arrow 5, dashed boundary: forceps. 
The experiment was performed in collaboration with the Preformulation group 
(Dr. Michael Siedler, Dr. Vishwesh A Patil) and the Pharmacology Department 
(Dr. Bradford McRae and Grace Lynch) at the Abbott Bioresearch Center. 
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from the joint as such. In literature it is described that liposomes that enter into the systemic 
circulation are commonly phagocytosed by the reticuloendothelial system which is mainly 
located in liver and spleen [224]. The high fluorescence intensity observed in figure 4-25 B 
can be ascribed to the auto-fluorescence of the stomach and intestine content and is not 
attributed to the mAb-vesicles.  
The above findings indicate that IA injected mAb-loaded vesicles show a high residence time 
at the site of injection. Based on the fact that at the end of the previous study residual mAb 
was undetectable in the SF, it can be presumed that vesicle adsorption to the articular 
cartilage takes place which would be beneficial for the intended purpose. In order to 
substantiate this presumption, histological cross-sections of the joint would provide a detailed 
understanding concerning the synovial behavior of the mAb-loaded vesicles. Additionally, the 
efficacy of IA application of mAb-loaded vesicles in reducing arthritic disorder would provide 
important information. The overall promising results outlined above underline the importance 
of mAb entrapment in vesicles for the prolongation of the synovial mAb residence time. 
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4 SUMMARY AND CONCLUSIONS 
The aim of this chapter was the development of a biocompatible PL-based vesicular mAb 
formulation for IA administration. This formulation was intended to provide prolonged 
synovial residence time and thus therapeutic action at the site of injection. Within this scope, 
two different formulations were developed and characterized and their suitability for the 
intended purpose was evaluated. In a first approach, sd mAb was suspended at a 
concentration of 50 mg/g in a non-aqueous PL solution containing propylene glycol as 
organic solvent. Upon contact with body fluid, sd mAb was to be dissolved and subsequently 
entrapped within in situ formed PL vesicles. For assessment of the mAb stability after 
incorporation in the PL solution and the subsequent vesicle formation in contact with the 
aqueous medium, mAb was extracted from the PL matrix. It was shown that insoluble 
aggregates were formed and that both secondary and tertiary protein structure were 
drastically altered. The detected protein instabilities were identified to be induced by the 
organic solvent (propylene glycol) that was used to dissolve the PL component. The 
destabilizing influence of propylene glycol was shown to occur only at high organic solvent 
concentrations. Analysis of mAb in the presence of 50 % propylene glycol/water mixtures did 
not lead to any precipitation and no alteration in secondary and tertiary protein structure were 
detectable. In order to exclude the destabilizing effect of propylene glycol, the formulation 
was modified with respect to the organic solvent. PEG 300 was identified to show excellent 
mAb compatibility and solubility properties for the PL component. After suspension of sd 
mAb particles in the PL-PEG 300 solution, injection into PBS and subsequent extraction of 
mAb, the conformational mAb stability was maintained. Cryo-TEM analysis revealed a broad 
vesicle size distribution ranging from ~100 nm to 1000 nm with the presence of ULVs, BLVs 
and MLVs. By analysis of the EE it became evident that the complete mAb amount was 
present outside of the vesicles. Apparently, vesicle formation occurred more rapidly than 
dissolution of the sd mAb particles causing the formation of empty vesicles that were 
surrounded by a highly-concentrated mAb solution. As non-encapsulated mAb was reported 
to be rapidly cleared from the synovial space, the use of this approach appeared unsuitable 
for the intended purpose.  
In a second approach, the vesicular PL-mAb formulation was prepared ex vivo by mixing a 
highly-concentrated mAb solution with a non-aqueous PL solution consisting of 50 % PL 
dissolved in propylene glycol. Analysis of mAb stability after incorporation into the vesicular 
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PL matrix and subsequent extraction revealed excellent mAb stability as assessed by various 
analytical methods. Moreover, the mAb bioactivity was shown to be maintained. The 
formulation exhibited shear thinning behavior that enabled easy injection through thin syringe 
needles. The maximal injection forces using 26 G syringe needles did not exceed 4 N and 
did not differ significantly from the placebo formulation. These results indicated that the 
physical formulation characteristics were not altered by the presence of mAb. Cryo-TEM 
analysis revealed a broad vesicle size distribution ranging from ~100 nm to 800 nm with the 
presence of ULVs, BLVs and MLVs. These findings were consistent with DLS measurements 
where a mean vesicle size of 520.4 ± 28.6 nm with a polydispersity index of 0.5 ± 0.04 was 
detected. By analysis of the EE it became apparent that ~15 % of mAb were entrapped in the 
vesicles. The encapsulation of mAb in the vesicles was confirmed by fluorescence 
microscopy analysis after labeling of both mAb and PL vesicles. In order to gain an insight 
into the pharmacokinetic profile of the formulation upon IA administration, an in vivo study 
with healthy Lewis rats was performed. The mean serum and SF mAb concentration levels of 
the vesicular PL-mAb formulation were compared to a PL-free mAb solution as reference. An 
initially slightly lower mAb absorption rate into the systemic circulation was observed for the 
PL formulation during the first 12 hrs. At later time points no or only marginal differences 
between PL formulation and reference were observed. This indicates that the EE of 15 % 
was too low to detect differences compared to the reference. In order to increase the EE, the 
lipid content of the formulation was modified. It was shown that the EE was raised from 
15.9 ± 1.0 % to 31.5 ± 4.4 % when increasing the lipid content from 152 mg/g to 236 mg/g. A 
further increase of the lipid content did not affect the EE. The addition of cholesterol in a 
molar ratio of 1:9 (cholesterol:PL) at a lipid content of 236 mg/g increased the EE up to 
43.4 ± 2.2 %. A further increase of the cholesterol content, however, led to a decrease in the 
EE. The application of 5 freeze-thaw cycles as well as the formulation homogenization by 
means of an ultra-turrax® had no impact on the EE. Formulation preparation by means of a 
DAC significantly increased the EE up to 53.3 ± 5.4 % at a centrifugation time of 60 min. All 
modifications led to a decrease of vesicle size. In order to keep the preparation of the dosage 
system as convenient as possible, the formulation preparation by means of a dual-syringe 
system was maintained and an increased lipid content of 236 mg/g was chosen for further 
experiments, providing an EE of 31.5 ± 4.4 % and a mean vesicle size of ~300 nm. To study 
the physical stability of the PL-mAb vesicles in phosphate buffer, the non-encapsulated mAb 
amount was removed from the vesicles. While the encapsulated mAb remained completely 
entrapped during one week of storage at 2-8 °C, a marginal decrease of HP-SEC monomer 
recovery to 98.7 ± 0.03 % at day 1 and 97.1 ± 0.9 % at day 14 was observed. For 
assessment of the vesicle stability upon contact with body fluid, fluorescence-labeled mAb 
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containing PL vesicles, separated from non-encapsulated mAb, were incubated in FCS and 
stored for 4 days at 37 °C. Fluorescence microscopy images demonstrated that the vesicles 
formed large agglomerates in the presence of FCS while no changes were observed in 
phosphate buffer. After 4 days, 18.9 ± 2.6 % of the encapsulated mAb were released 
indicating that FCS did slightly affect the vesicle stability. In order to study the 
pharmacokinetic profile of PL-mAb vesicles in the absence of non-encapsulated drug, an in 
vivo study was performed on healthy rats. Analysis of the mean serum mAb concentrations 
upon IA administration during an observation period of 10 days revealed significantly lower 
serum levels in comparison to a mAb solution and placebo vesicles with non-encapsulated 
mAb as references. Due to the fact that at the end of the study residual mAb could not be 
recovered in the SF, an additional study was performed that was intended to provide 
information concerning the fate of the vesicles in vivo. Near infrared fluorescent dye-labeled 
mAb was encapsulated into the PL vesicles and 3 days after IA injection the rat was 
examined using a near infrared fluorescence camera. It was shown that the PL-mAb vesicles 
remained at the site of injection and no mAb-related fluorescence intensity was observed in 
liver. Based on these results it was presumed that PL-mAb vesicles that remain at the 
injection site adsorb to the cartilage surface and are therefore not removable by synovial 
wash. The results lead to the conclusion that this vesicular drug delivery system is a highly 
potent formulation for the sustained IA delivery of mAb and subsequent efficacy studies 
should be envisaged.   
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CHAPTER 5 
SUMMARY OF THE THESIS 
The objective of the present thesis was the development of sustained release formulations 
for the IA delivery of a therapeutic mAb. In Chapter 1 the reader is introduced to the IA route 
of application and the respective literature is reviewed with regards to the current status of IA 
drug delivery strategies. Within this scope, it became apparent that despite numerous 
promising studies published in literature the application of IA drug delivery systems to 
therapeutic proteins was not investigated in detail up to now. Based on the unique 
physiological conditions prevailing in the joint and the current knowledge concerning the IA 
route of application, the requirements on the mAb-containing depot formulation to be 
developed were defined. This comprised the injectability through small size syringe needles 
that are commonly applied for IA injection. Moreover, an adequate viscosity after injection 
had to be provided in order to permit entire joint mobility. On account of the limited injection 
frequency, the restricted injection volume and the rapid clearance of drugs from the synovial 
space, a high drug load and a prolonged residence time at the injection site were envisaged. 
The preservation of the mAb stability after incorporation into the formulation and after release 
was of utmost importance. Furthermore, a high physiological compatibility of the formulation 
components was aspired. 
The focus of Chapter 2 lay on the development of an in situ forming PLGA formulation for the 
IA delivery of the mAb. This concept encompassed the dispersion of the sd mAb in a non-
aqueous PLGA solution. After contact with SF the PLGA formulation was intended to 
precipitate, leading to a solidified matrix and entrapment of the mAb. Release of mAb was 
meant to occur simultaneously to polymer degradation over a prolonged period of time. For 
formulation preparation, the polymer was dissolved in PEG 300 and triacetin. As no mAb 
instabilities were detected with the help of various analytical methods, these solvents were 
identified as protein-compatible. Excellent conformational mAb stability was demonstrated 
after extraction from the non-aqueous PLGA formulation. Analysis of the protein stability after 
release, performed with the murine mAb variant, revealed a slight decrease in HP-SEC 
monomer recovery, but preserved binding affinity to the target. In vitro mAb release 
experiments pointed out that the mAb release can be tailored by the amount of the 
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hydrophobic solvent triacetin used. With increasing amounts of triacetin employed, the initial 
burst was reduced and therefore higher amounts of mAb were entrapped in the solidifying 
matrix. The observed in vitro release characteristics could however not be confirmed in vivo. 
This was ascribed to the distinct mechanical impact on mAb release induced by the 
movement of the animals which leads to rapid mAb release. Modification of the in vitro 
release model enabled simulation of the physiological conditions prevailing in the joint. 
However, a promising formulation composition that might provide a high mAb entrapment 
rate after injection could not be identified with the help of a formulation screening. In addition, 
considerable protein aggregate formation became apparent after application of the modified 
in vitro release model. Based on these results, it was concluded that the in situ forming 
PLGA formulation has limited applicability for the IA delivery of mAb.  
In Chapter 3, the suitablity of polysaccharides as carrier for the local IA delivery of mAb was 
investigated. The main focus was on the development of a HA-mAb gel with high protein 
concentration, high gel viscosity but adequate injectability through thin syringe needles. The 
HA material with a MW of 2 MDa at a concentration of 1 % provided the most suitable gel 
characteristics. Excellent compatibility with the incorporated mAb at a concentration of 
50 mg/mL was shown using a variety of analytical methods. SPR measurements 
demonstrated the presence of slight interactions between HA and mAb. However, a distinct 
impact of these interactions on both the in vitro and in vivo mAb release from the HA gel 
could not be observed. Overall, a significantly slower in vitro mAb release from the gel 
compared to the HA-free mAb solution was identified during the first day. This was ascribed 
to the initially dense gel network causing a restricted mobility and a reduced diffusion rate of 
mAb. After day one, the mAb release rates from buffer and HA gel became identical. In vivo 
experiments in rats revealed comparable results as slightly lower mAb serum levels were 
achieved for the gel system compared to the HA-free mAb solution during the first 12 hrs 
only. This was explained by the continuous dissolution and dilution of the HA gel followed by 
synovial clearance of the HA molecules, leading to enhanced mAb release. An additional aim 
of this chapter was to evaluate if the use of polysaccharides with a higher charge density 
than HA might lead to more pronounced mAb retention at the site of application. Within this 
scope, sodium alginate was employed to study the conditions at which insoluble charge 
complexes with mAb are formed. It was demonstrated that complex formation between mAb 
and alginate depends on the pH and the mAb-alginate ratio. The presence of increasing 
concentrations of calcium ions induced gelation of alginate but simultaneously caused mAb 
redissolution via shielding effects. At physiological conditions 96 % of mAb were dissolved. 
Based on these results, it was concluded that enhanced mAb retention in the synovial cavity, 
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induced by HA at a concentration of 1 % or by using sodium alginate, was expected to be 
less effective.  
The development of PL-based formulations for the IA delivery of mAb is outlined in 
Chapter 4. In a first approach, an in situ forming PL-mAb formulation was to be developed. 
This formulation consisted of sd mAb particles suspended in a non-aqueous PL solution. 
Upon contact with SF, sd mAb was to be dissolved and subsequently entrapped within the in 
situ formed PL vesicles. After detailed protein analysis upon extraction from the formulation, 
the vesicular structure was characterized with the help of cryo-TEM analysis. The presence 
of mainly MLVs in the size range of ~100 nm to 1 µm became apparent. Analysis of the EE 
elucidated that vesicle formation occurred more rapidly than dissolution of the sd mAb 
particles. This caused the formation of empty vesicles that were surrounded by a highly-
concentrated mAb solution. As non-encapsulated mAb is reported to be rapidly cleared from 
the synovial cavity, the use of this formulation appeared unsuitable for the intended purpose. 
In a second approach, the vesicular PL-mAb formulation was prepared ex vivo by mixing a 
highly-concentrated mAb solution with a non-aqueous PL solution using a dual-syringe 
system. Excellent mAb stability and preserved bioactivity were proven with the help of 
several analytical methods. Moreover, adequate injectability and a broad vesicle size 
distribution were demonstrated. Analysis of the EE revealed that 15 % of the mAb were 
vesicularly encapsulated. However, results of an in vivo study demonstrated that a higher EE 
needed to be achieved in order to realize the beneficial effect of drug encapsulation in 
vesicles. Several attempts were made to increase the EE. This included the increase of the 
lipid content, the addition of cholesterol, the application of freeze-thaw cycles as well as the 
use of preparation methods such as ultra-turrax® homogenization or dual asymmetric 
centrifugation. As these approaches did not lead to EE values higher than 53 %, non-
encapsulated mAb was separated from the drug-loaded vesicles for further experiments. The 
purified vesicles provided a high physical stability in phosphate buffer. After incubation in 
FCS, distinct vesicle agglomeration was identified, accompanied by mAb release (18 % 
during 4 days). In vivo administration of the mAb-loaded vesicles induced drastically lower 
serum mAb levels compared to the reference. Vesicle visualization in the animal after IA 
administration of near infrared fluorescent dye-labeled mAb-vesicles after 3 days using a 
near infrared fluorescence camera revealed that the vesicles remained at the application site 
and accumulation in the liver could not be detected. These promising results led to the 
conclusion that this vesicular drug delivery system presents a highly potent formulation for 
the sustained IA delivery of mAb. 
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LIST OF ABBREVIATIONS 
 
A    absorbance 
ATR    attenuated total reflection 
AUC    area under the curve 
BLV    bilamellar vesicle 
BSA    bovine serum albumin 
Cryo-TEM   cryo-transmission electron microscopy 
DAC    dual asymmetric centrifuge 
DLS    dynamic light scattering 
DMARD   disease-modifying anti-rheumatic drug 
DMSO    dimethylsulfoxide 
DSC    differential scanning calorimetry 
EA    ethyl acetate 
EE    encapsulation efficiency 
ELISA    enzyme-linked immunosorbent assay 
FCS    fetal calf serum 
FDA    Food and Drug Administration 
FITC    fluorescein isothiocyanate 
F-mAb    fluorescence-labeled monoclonal antibody 
FT    freeze-thaw 
FTIR    Fourier transform infrared spectroscopy 
GH    growth hormone 
GRAS    generally recognized as safe 
HA    hyaluronic acid 
HEC    hydroxyethyl cellulose 
HP-IEC   high performance ion exchange chromatography 
160 LIST OF ABBREVIATIONS 
 
HPLC    high performance liquid chromatography 
HP-SEC   high performance size exclusion chromatography 
I    ionic strength 
IA    intra-articular 
IgG1    immunoglobulin 1 
Ile    isoleucine 
IV    intravenous 
KD    dissociation constant 
mAb    monoclonal antibody 
MLV    multilamellar vesicle 
mu    murine 
MW    molecular weight 
NMP    N-methyl-2-pyrrolidone 
OA    osteoarthritis 
OG    octyl glycoside 
PBS    phosphate buffered saline 
PdI    polydispersity index 
PEG    polyethylene glycol 
PG    propylene glycol 
Phe    phenylalanine 
pI    isoelectric point 
pKa    acid dissociation constant 
PL    phospholipid 
PLA    polylactide 
PLGA    poly(lactide-co-glycolide) 
P/T    PEG 300/triacetin 
PVDF    polyvinylidene difluoride 
RA    rheumatoid arthritis 
rhG-CSF   recombinant human granulocyte colony stimulating factor 
rhTNF    recombinant human tumor necrosis factor 
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RM    residual moisture 
RT    room temperature 
SC    subcutaneous 
sd    spray-dried 
SEM    scanning electron microscopy 
SF    synovial fluid 
SPIONs   superparamagnetic iron oxide nanoparticles 
SPR    surface plasmon resonance 
TGF-β    transforming growth factor-β 
Tin/Tout    spray drying inlet/outlet temperature 
Tm    melting temperature 
TNF    tumor necrosis factor 
Trp    tryptophane 
Tyr    tyrosine 
ULV    unilamellar vesicle 
UV    ultraviolet 
vs.     versus 
w/w    weight per weight 
 
 
 
 
